

CURRICULUM VITAE

Revised: July 2018

1. Name: **Walter A. Orenstein, MD, DSc (Hon)**
2. Office Address: Emory Vaccine Center Telephone: 404-712-2466 Fax: 404-712-2557
Emory University
Mailstop: 1370/004/1AD
1462 Clifton Rd., Room 446, Dental Bldg
Atlanta, GA 30322
3. E-mail Address: worenst@emory.edu
4. Citizenship: United States
5. Current Titles and Affiliations:
 1. Primary appointments:
7/01/11 – Present Professor of Medicine – Infectious Diseases, Emory University
 2. Joint and secondary appointments:
7/01/11 – Present Professor – Hubert Department of Global Health, Rollins School of Public Health
7/01/11 – Present Professor – Pediatrics, Infectious Diseases
6/01/13 – Present Professor - Epidemiology
 3. Administrative appointments:
7/01/11 – Present Director, Emory Program for Vaccine Policy and Development
7/01/11 – Present Associate Director, Emory Vaccine Center
 4. Affiliate Professor
4/20/10 – Present Department of Global Health, University of Washington, Seattle, WA
6. Previous Academic and Professional Appointments
 - 3/15/04 – 10/6/08 Professor of Medicine – Infectious Diseases, Emory University School of Medicine
 - 3/15/04 – 10/6/08 Professor – Hubert Department of Global Health, Rollins School of Public Health, Emory University
 - 3/15/04 – 10/6/08 Professor – Pediatrics, Infectious Diseases, Emory University School of Medicine
 - 10/7/08 – 7/1/11 Deputy Director for Immunization Programs, Vaccine Delivery Team, Global Health Program, Bill and Melinda Gates Foundation

7. Previous Administrative and/or Clinical Appointments:
 - a. Clinical appointments:
 - 4/1/1985 – 8/31/92 Clinical Associate Professor, Department of Community Health, Emory University School of Medicine
 - 9/1/1992 – 5/31/94 Clinical Associate Professor, Community Health and Rollins School of Public Health, Emory University
 - 6/1/1994 – 3/15/04 Adjunct Clinical Professor, Department of International Health, Rollins School of Public Health, Emory University
 - 6/3/2004 – 10/6/08 Director, Strategic Planning – The Hope Clinic, Emory University
 - 6/1/2004 – 10/6/08 Courtesy, Emory Healthcare (Consultant)
 - a. Other administrative appointments:
 - 3/15/04 – 10/6/08 Director, Emory Program for Vaccine Policy and Development
 - 3/15/04 – 10/6/08 Associate Director, Emory Vaccine Center
 - 3/15/04 – 4/19/07 Associate Director of the Southeastern Center for Emerging Biological Threats
 - 4/19/07 – 10/6/08 Executive Director of the Southeastern Center for Emerging Biological Threats
8. Licensures/Boards:
 - Licensure: Georgia Issued: 12/6/1976
9. Specialty Boards:
 - The American Board of Pediatrics February 1980
10. Education:
 - Bronx High School of Science, The Bronx, New York 1961-1964
 - City College of New York, New York, New York, BS 1964-1968
 - Albert Einstein College of Medicine, The Bronx, New York, MD 1968-1972
11. Postgraduate Training:
 - Internship: Pediatrics, University of California, San Francisco, California, 1972-1973
 - Residency: Pediatrics, University of California, San Francisco, California, 1973-1974
 - Pediatrics, Children’s Hospital of Los Angeles, University of Southern California, Los Angeles, California, 1977-1978

Fellowship: Infectious Diseases, Los Angeles County, University of Southern California Medical School, 1978-1980

Residency: Preventive Medicine, Centers for Disease Control, 1980-1982

12. Military or Government Service:

July 1974 – June 1976 EIS Officer, Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia.

July 1976 – June 1977 and
June 1980 – March 1982 Medical Epidemiologist, Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia.

March 1982 – June 1985 Chief, Surveillance and Investigations Section, Surveillance, Investigations, and Research Branch, Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia.

July 1985 – March 1988 Chief, Surveillance, Investigations, and Research Branch, Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia.

March 1988 – May 1993 Director, Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta, Georgia.

May 1993 – April 2004 Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia.

January 1, 1995 Rear Admiral (LH), Assistant Surgeon General, United States Public Health Service.

October 1, 1997 –
April 30, 2004 Rear Admiral (UH), Assistant Surgeon General, United States Public Health Service.

13. Committee Memberships

a. National and International:

American Academy of Pediatrics

Member, Committee on Infectious Diseases, July 1, 2008 – July 2014

Centers for Disease Control and Prevention (CDC)

- Liaison Member, National Vaccine Advisory Committee, 1988 – 2004
- Liaison member, Committee on Infectious Diseases, American Academy of Pediatrics, 1989 – 2004
- Liaison Member, Advisory Commission on Childhood Vaccines, 1989 – 1994
- Member, 317 Coalition for Vaccine Finance, April 2006 – October 2008
- External Review Panel Member, National Immunization Survey and Other Assessment Platforms, April 27, 2007
- Member, CDC Foundation's Atlanta Advocacy Council, February 2008
- Member, Advisory Committee on Immunization Practices (ACIP) Working Group on General Recommendations, 2011 – present
- Member, Immunization Services Division Director Search Committee, Centers for Disease Control and Prevention (CDC), January 2012 – June 2012
- Chair, Global Health Chronicles, Polio Project, David J. Sencer CDC Museum, October 2015 - present
- Member, Search Committee for Director, National Center for Immunization and Respiratory Diseases (NCIRD), August 2015 – March 2016
- Member, Advisory Committee on Immunization Practices (ACIP) Working Group on Cholera, August 2015 - present

Corporation(s)

- Data Safety Monitoring Board Representative – DynPort - Counter – Terrorism Vaccine Program, November 2004 – July 2008

Foundations

- Every Child by Two (ECBT)
 - Board Member, July 2006 – Present
- Bill & Melinda Gates Foundation
 - Peer Reviewer, Grand Challenges in Global Health Childhood Vaccines, August 2004
 - Reviewer, Records for Life Awards, January 2014
- Task Force for Global Health
 - Member, Polio Antivirals Initiative (PAI), December 2012 – January 2014
 - Chair, PAI – January 2014 – present

Infectious Disease Society of America (IDSA)

- Immunization Working Group for Vaccine Finance Reform – September 2006 – October 2008
- Immunization Panel, Pediatric Infectious Disease Representative (PIDS) – November 2006 to October 2007
- Member, IDWeek Program Committee, 2014 – 2016

Institutions of Higher Learning

- Center for Vaccine Ethics and Policy, NYU
 - Member, Advisory Board, June 2012 – December 2017
- The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, Ebola Team B Member, November 2015 – March 2016

National Academy of Medicine (formerly: National Academies of Science, Institute of Medicine (NAS/IOM))

Reviewer, Performance Measurement – Accelerating Improvement. Committee on Redesigning Health Insurance Performance Measures, Payment, and Performance Improvement Programs, Board on Health Care Services, October 2005. Print of report December 2005 from The National Academies Press

Member, October 2007

Reviewer, Draft Report of “A National Strategy for the Elimination of Hepatitis B and C” from the Health and Medicine Division of the National Academies of Science, Engineering, and Medicine, January 2017

National Foundation for Infectious Diseases (NFID)

Board of Directors, May 2005 – Present

Member, Scientific Program Committee on Annual Conference on Vaccine Research (ACVR), January 2008 – October 2008

Secretary, Board of Directors, June 2010 – June 2012

Vice President, Board of Directors, June 2012 – June 2014

Member, Scientific Program Committee, Clinical Vaccinology Course (CVC), June 2012 - present

President-Elect, Board of Directors, June 2014 – June 2016

Chair, Awards Committee, June 2015 - present

Member, Scientific Program Committee on Annual Conference on Vaccine Research (ACVR), July 2016 – present

Liaison, CDC Office of Infectious Diseases, Board of Scientific Counselors, July 2016 – present

President, Board of Directors, July 1, 2016 – June 30, 2018

National Institutes of Health (NIH)

Liaison member, NIAID-supported HIV Vaccine Trials Network (HVTN) External Advisory Board – 2003 – 2008

External Epidemiology Advisory Panel –National Institute of Allergy and Infectious Diseases, Office of the Director, Bethesda, MD, October 17, 2005

Member, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Biodefense Advisory Group through the Obstetric and Pediatric Pharmacology Branch, May 2008 – August 2008

National Vaccine Program Office / National Vaccine Advisory Committee (NVAC)

Member, NVAC Finance Working Group, February 2007 – October 2008

Member, Vaccine Economics Evaluation Project Steering Committee (VEEPS), June 2007 – October 2008

Member, February 2011 – February 2012

Chair, NVAC, February 2012 – July 2016

Organization(s)

American Academy of Arts and Science

Member, Public Trust in Vaccines, April 2012 – 2014

Partnership for Prevention

Representative, National Commission on Prevention Priorities, 2003

GE2P2 Global Foundation, Center for Vaccine Ethics and Policy (CVEP)
 Senior Fellow, January 2018 - present

GAVI Alliance
 Member, Advance Market Commitments (AMC) Independent Assessment
 Committee (IAC), December 2007 – October 2008

Hilleman Laboratories
 Member, Strategic Advisory Group (SAG), September 2013 – present

Immunization Action Coalition (IAC)
 Liaison, Advisory Board, 2008 - present

PATH (Program for Appropriate Technology in Health)
 Member, Scientific Advisory Board, PATH Vaccine Solutions, August
 2012 – October 2017

Pan American Health Organization (PAHO)
 Member and Rapporteur - Technical Advisory Group (TAG) on Vaccines
 and Immunization - 1997 - 2004

Pediatric Infectious Diseases Society (PIDS)
 Chairman, Publications Committee, 1996 – 1997
 Secretary/Treasurer, 2003 – 2005
 Fellow, 2014

Sabin Vaccine Institute
 Board of Directors, 2004 – October 2008
 Member, International Association of Immunization Managers (IAIM),
 September 2012 – present

Wellcome Trust – CIDRAP Ebola Vaccine Team B
 Member, November 2014 – October 2017
 co-Chair, Workgroup #6, Vaccination Strategy

World Health Organization (WHO)
 Member and Rapporteur, Global Advisory Group, Expanded Programme
 on Immunization, 1991-1993
 Chairman - Technical Consultative Group on the Global Eradication of
 Poliomyelitis, 1996 – 2004
 Member, Quantitative Immunization and Vaccines Related Research
 Advisory Committee (QUIVER), October 2006 to October 2008,
 extended October 2010
 Member, SAGE (Strategic Advisory Group of Experts) Working Group on
 Polio Vaccine, September 2008 – present
 Member, Ad Hoc Expert, Hib Vaccination Schedules, October 3– 4, 2012
 Member, SAGE (Strategic Advisory Group of Experts) Working Group on
 non-specific effects of vaccines, January 2013 – December 2014
 Member, Technical Advisory Group on Maternal Immunization for
 WHO/PATH, March 2014 – December 2016
 Chair, Midterm Review of Global Measles 2020 plan, WHO/M&RI,
 January 2016 – November 2017
 Member, SAGE (Strategic Advisory Group of Experts) Working Group on

Measles and Rubella, January 2017 – present
Member, Advisory Committee on Immunization and Vaccines-related
Implementation Research (IVIR-AC), March 2018 – present
Member, IVIR-AC Measles Working Group, May 2018 – present

b. Regional and State:

Georgia Pandemic Influenza Coordinating Committee – August 2006 – October 2008

Georgia Pandemic Influenza Subcommittee on Antivirals – October 2006 – October 2008

c. Institutional:

Member, Pediatric Infectious Disease Search Committee - 2004

Member, Vaccine Dinner Club Advisory Committee – September 2004 – October 2008

Co-Chair, Emory Pandemic Influenza Task Force – October 2005 – October 2007

Co-Chair, Emory Pandemic Influenza Task Force Retreat – January 14, 2006

Member, Infectious Disease Research Retreat, 2005, 2006

Member, Global Health Brainstorming Committee for Strategic Plan, 2006

Member, Creation of Science and Religion Center, Schinazi Chair in Bioethics, Planning Committee, July 2006

Member, Search Committee, Schinazi Chair for Jewish Bioethics, July 2007 – August 2008

2007 Faculty Award for Outstanding Research Citation Award Nominee, June 2007

Executive Committee Member, Center for Global Vaccines (Emory ICGEB), August 2007 – October 2008

Member, Emory Fusion Group, Emory Office of Critical Event Preparedness and Response (CEPAR), February 2008 – October 2008

Member, CFAR Internal Scientific Group, March 2008 – October 2008

Ad hoc Committee Member, Emory Healthcare Influenza Initiative, March-April, 2008

Ad hoc Reviewer, Emory University Research Committee Application, February 2015

Member, Emory Antibiotic Resistance Center, February 2015 – present

Member, Search Committee for William H. Foege Chair in Global Health, Emory University, February 2015 – June 2016

14. Consultantships:

Centers for Disease Control and Prevention (CDC)

Member, Medical Advisory Board, Centers for Disease Control, October 1981 - September 1984

Review Panel, Emerging Infections Programs External Review – Centers for Disease Control and Prevention, Atlanta, February 16-17, 2006

Corporation(s)

Member, Global Health 2035: Mission Grand Convergence (Scientific Exchange) Meeting, GlaxoSmithKline (GSK), Palio Series, Siena Italy, July 17-19, 2015

Co-Chair, Working Group, Top 5 vaccine attributes for developed countries

Member, Emerging infectious diseases: Planning a sustainable future – the role of biologics (Scientific Exchange) Meeting, Palio Series, GlaxoSmithKline (GSK), Rockville Maryland, July 7-8, 2016

Chair, Working Group, Safety & regulatory considerations

Member, Prioritizing vaccines to fight antimicrobial resistance (Scientific Exchange) Meeting, Palio Series, GlaxoSmithKline (GSK), Brussels Belgium, July 5-7, 2017

Chair, Working Group, Regulatory actions needed to accelerate AMR vaccines

Member, Sustainable Global Health (Scientific Exchange) Meeting, Palio Series, GlaxoSmithKline (GSK), Siena Italy, July 4-7, 2018

Foundation(s)

Consultant, Bill & Melinda Gates Foundation, Polio Eradication, Measles Elimination, & Routine Immunizations, October 2011 – present

Member, Surveillance Advisory Group, Bill & Melinda Gates Foundation, September 2015 – 2017

Scientific Advisor, Pertussis Infant Burden of Diseases Mini-Symposium, Bill & Melinda Gates Foundation, Emory University, Atlanta, Georgia, February 23, 2016

Member, Immunization Schedule Optimization Meeting, Bill & Melinda Gates Foundation, London, UK, June 2018

Institutions of Higher Learning

Member, National Professional Advisory Group, Rochester Center for Adolescent Immunization Research (RCAIR), Grant PI – Peter G. Szilagyi, Professor of Pediatrics, University of Rochester Medical Center – 2004-2007

Consultant, Evaluation of Parents Claiming Exemption to School Entry Immunization Requirements, CDC Grant PI – Daniel Salmon, Johns Hopkins, Baltimore – September 30, 2004 – September 30, 2006

Member, National Stakeholder Committee for Parent Preferences in Immunizing Children (PPIC) study, PCORI Pilot project PI – Tracy Lieu, Harvard, Cambridge – November 2012 – November 2015

Advisor, Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE), Bill & Melinda Gates Foundation Award to the University of Virginia Health System, September 2011 – August 2016

National Institutes of Health

Co-Chair, External Advisory Panel on the Scientific Agenda of HIV Vaccine Trials Network (HVTN), Bethesda, Maryland, September 13-14, 2004

National Vaccine Program Office / National Vaccine Advisory Committee (NVAC) Consultant, February 2005 – October 2008

Consultant, Revision of National Vaccine Plan, April 2007 – October 2008

Organization(s)

Pan American Health Association (PAHO)

Short term Consultant, Expanded Programme on Immunization, Measles Control, Sao Paulo, Brazil and Buenos Aires, Argentina, January 1985

Short Term Consultant, Expanded Programme on Immunization, Polio eradication and measles control, Lima, Peru, Buenos Aires, Argentina, January 1988 - February 1988

Short Term Consultant, Expanded Programme on Immunization, Technical Advisory Group Meeting, November 1988

World Health Organization

Short Term Consultant, Smallpox Eradication Program, Uttar Pradesh, India, December 1974 - April 1975

Short Term Consultant, European Region, Investigation of Poliomyelitis, Israel, October 1988

Temporary Advisor, Polio Research Committee (PRC) Meeting, Geneva, Switzerland, May 6-7, 2014

Temporary Advisor, Accelerating Progress towards Measles and Rubella Control and Elimination Meeting, Geneva, June 24-26, 2016

Peer-Reviewer, WHO IVB – Immunological Basis for Immunization – Polio Module, March-April, 2018

15. Editorships and Editorial Boards:

American Journal of Preventive Medicine
Editorial Board, 2004-2015

Epidemiologic Reviews
Co-Editor, 2006

Health Affairs Journal
Co-Guest Editor, May/June 2005 Vaccine Issue, Volume 24, Number 3

Clinical and Vaccine Immunology
Editorial Board Member, October 2005 – October 2008

Clinical and Diagnostic Laboratory Immunology

Editorial Board Member, January 2006 – December 2008
Current Topics in Microbiology & Immunology: Vaccines for Pandemic Influenza
 Co-Editor, Springer-Verlag Berlin Heidelberg, Germany, 2009
 Infectious Diseases in Children
 Liaison member, Editorial Board, 2002 – 2004
 Member, 2004 – present
 Infectious Diseases News
 Member, Editorial Board, 2009 – 2016
 Journal of Pediatric Infectious Diseases
 Editorial Board Member, 2011 – present
 National Network for Immunization Information
 Editorial Board Member, 2004 – 2014
 Nature Partner Journals (npj)
 npj Vaccines, Editorial Board Member, 2016 – present
 Pediatric Infectious Disease Journal
 Editor, Centers for Disease Control Section, January 1987 – 2001
 Vaccine Journal
 Member – International Editorial Board - 2000 – 2008
 Member, Council of 100, *Vaccine*, Elsevier, January 2013 – April 2017
 Associate Editor, May 2017 - present
Plotkin's Vaccines (as of 7e, previously Vaccines)
 Co-Editor, 5th edition, Elsevier, 2008
 Co-Editor, 6th edition, Elsevier, 2013
 Co-Editor, 7th edition, Elsevier, 2018

16. Manuscript Reviewer: (from 1980 – present)

Ad hoc Reviewer:

<i>The American Journal of Epidemiology</i>	<i>Global Public Health</i>
<i>American Journal of Preventative Medicine</i>	<i>Health Affairs</i>
<i>Annals of Internal Medicine</i>	<i>Human Vaccines & Immunotherapeutics</i>
<i>BioMed Central</i>	<i>Infection Control & Hospital Epidemiology</i>
<i>BioMed Central Infectious Diseases</i>	<i>Indian Pediatrics</i>
<i>BioMed Central Medicine</i>	<i>International Journal of Epidemiology</i>
<i>Clinical Infectious Diseases</i>	<i>International Journal of Health Governance</i>
<i>Emerging Infectious Diseases</i>	<i>International Journal of Preventative Medicine</i>
<i>Epidemiology</i>	<i>JAMA Pediatrics</i>
<i>Expert Review of Vaccines</i>	<i>Journal of the American Medical Association</i>
<i>Frontiers in Public Health Services Research</i>	
<i>Global Health: Science & Practices</i>	
<i>Global Health Communication</i>	

Journal of Infectious Diseases
Journal of Pediatrics
Journal of Public Health Policy
Lancet
Lancet Fast Track
Lancet Global Health
Lancet Infectious Diseases
The Medical Letter
Trials in Vaccinology

New England Journal of Medicine
Pediatrics
Pediatric Infectious Diseases Journal
Pediatric Research
PLOS Biology
PLOS ONE
Risk Analysis
Vaccine

American Academy of Pediatrics

2004 Red Book Chapter/Manuscript Reviewer, 27th Edition
2006 Red Book Chapter/Manuscript Reviewer, 28th Edition
2009 Red Book Chapter/Manuscript Reviewer, 29th Edition
2012 Red Book Chapter/Manuscript Reviewer, 30th Edition
2015 Red Book Chapter/Manuscript Reviewer, 31st Edition

17. Honors and Awards:

Phi Beta Kappa

Alpha Omega Alpha

Centers for Disease Control and Prevention (CDC)

National Center for Immunization and Respiratory Diseases (NCIRD)

Creation of the Walter Orenstein Lifetime Scientific Achievement Award

The awardee is the NCIRD nominee for the CDC Shepard Lifetime Achievement Award (2015)

Foundation(s)

Healthy Mothers, Healthy Babies, Special Recognition Award, 1996

Every Child by Two, Immunization Partners Award, 1996

National Academy of Medicine (formerly named, Institute of Medicine)

Elected Member, September 2006, inducted October 7, 2007

Institutions of Higher Learning

Alpha Omega Alpha Distinguished Visiting Professor, the University of Tennessee, Memphis, TN, March 20, 1996

Honorary Doctor of Science, Wake Forest University, May 15, 2006

2006 Townsend Harris Medal, City College of New York, October 26, 2006

The 2008 Pfizer Visiting Professorship in Infectious Diseases, at Stony Brook University, September 2008

Keynote Speaker and Guest of Honor, 2015 Class Day graduation ceremony of

The Sophie Davis School of Biomedical Education City College of New York, Friday, May 29, 2015

Organization(s)

Excellence in Public Health Award, Association of State and Territorial Health Officials, 1994

1995 World Health Day Award, the American Association for World Health,
 April 1995

American Academy of Pediatrics Excellence in Public Service Award, 2003

Phillip R. Horne Award, National Immunization Conference, May 2004

Rotary International Award, May 2004

Georgia Chapter of the American Academy of Pediatrics – Outstanding
 Achievement Award 2004 – October 2004

The Dr. Charles Mérieux Award, 2007 Recipient, presented by the National
 Foundation for Infectious Diseases, Washington DC, April 30, 2007

Ronald McDonald House Charities Award of Excellence, Chicago, Illinois,
 October 2011

British Medical Association, 19th Annual Medical Book and Patient Information
 Awards, Highly commended for *Vaccines 6th edition*, awarded in Public
 Health category for both Expert Consult – Online and Print, 2013

Pediatric Infectious Diseases Society

Pediatric Infectious Diseases Society, Distinguished Service Award, 2001

Special Article: Walter A. Orenstein, MD – A Tribute from Grateful Pediatric &
 Public Health Communities – *Pediatr Infect Dis* 2004; 23(9):803-805

Stanley A. Plotkin Lecture in Vaccinology Awards, May 1, 2006

U.S. Public Health Service Awards

Individual Awards:

Commendation Medal, United States Public Health Service, June 1984

Meritorious Service Medal, United States Public Health Service, May 1988

Jeryl Lynn Hilleman Lecture, National Immunization Conference, CDC
 Foundation, May 2004

Charles C. Shepard Lifetime Scientific Achievement Award, CDC, June 2004

Special Recognition Award, 5th Immunization Registry Conference, presented by
 the CDC/NIP on October 18, 2004

Certificate of Outstanding Service, as Chair, National Vaccine Advisory
 Committee (NVAC) February 2011 to July 1, 2016 on June 7, 2016

Group Awards:

Unit Commendation Medal, December 1990

Unit Commendation Medal, April 1992

Outstanding Unit Citation, January 1993

Unit Commendation Medal, February 1993

Unit Commendation Medal, June 1997

Unit Commendation Medal, October 2000

U.S. Department of Health and Human Services

Surgeon General's Exemplary Service Medal, July 1992

The Distinguished Service Medal, Public Health Service, September 20, 2004

The Outstanding Unit Citation, Public Health Service, September 20, 2004

The Outstanding Unit Citation, Public Health Service, January 7, 2005

The Outstanding Unit Citation, Public Health Service, September 8, 2005

The Outstanding Unit Citation, Public Health Service for exemplary performance of duty, awarded December 12, 2006
The Outstanding Unit Citation, Public Health Service for the 2003-2004 Influenza Response, awarded January 2007
Certificate of Outstanding Service, as Chair, National Vaccine Advisory Committee (NVAC) February 2011 to July 1, 2016 on June 7, 2016

18. Society Memberships:

Fellow, American Academy of Pediatrics, 1980
Fellow, Infectious Diseases Society of America, 1990
Member, American Public Health Association, 1980
Member, American Epidemiological Society, 1995
Member, Society for Epidemiologic Research, 1985
Fellow, Pediatric Infectious Diseases Society, 1988
Member, Council of the Pediatric Infectious Diseases Society, 1993 - 1996
Member, the American Pediatric Society, 1995
Member, American College of Preventive Medicine, 1985
Member, Institute of Medicine of the National Academies, October 1, 2006
Fellow, American Association for the Advancement of Science, 2018

19. Organization of National or International Conferences:

a. Administrative positions:

Orenstein WA. Organizing Committee. 2nd Workshop on Strengthening the Supply of Vaccines in the US. Wyndham City Center, Washington, DC, January 24-25, 2005.

Orenstein WA, Strikas R, Schwartz B, Abramson J, Uyeki T. Organizing Committee. Universal Vaccination Against Influenza – are we ready? Crowne Plaza Hotel, Atlanta, GA, October 24-25, 2005.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course, Atlanta, GA, November 3-5, 2006.

Orenstein WA. Member of the Organizing Committee. AAP/AMA Immunization Summit, Chicago, IL, January 3, 2007.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course, Bethesda, MD, November 9-11, 2007.

Orenstein WA, Member of the Organizing Committee. Representative for NFID and PIDS. CDC International Conference on Emerging Infectious Diseases (ICEID) 2008 Scientific Program Committee, Atlanta, March 2008.

Orenstein WA, Member of the Organizing Committee. National Foundation for Infectious Diseases Eleventh Annual Conference on Vaccine Research, Bethesda, MD, May 5-8, 2008.

Compans RW, **Orenstein WA**, Altman JD, Jacob J, Tompkins SM, Steinhauer D. Organizing Committee for the Immunobiology and Pathogenesis of Influenza Infection Conference for IPIRC, Atlanta, GA, June 1-3, 2008.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2008.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2009.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2010.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2011, held in Atlanta, Georgia and Miami, Florida.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2012, held in Chicago, Illinois and Baltimore, Maryland.

Orenstein WA. Organizing Committee. Charting New Frontiers in Immunizations Across the Aging Continuum. National Adult Vaccination Program, the Gerontological Society of America, Washington, DC, April 25-27, 2012.

Orenstein WA. Organizing Committee. Institute of Medicine (IOM) Interest Group (IG) 02 on Global Health, Infectious Diseases, and Microbiology, IOM Annual October Meeting 2012. Appointment from December 2011 to October 31, 2012.

Orenstein WA, Farley MM, Rehm S, Novick L. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2013, held in Chicago, Illinois and Baltimore.

Orenstein WA. Organizing Committee. Institute of Medicine (IOM) Interest Group (IG) 02 on Global Health, Infectious Diseases, and Microbiology, IOM Annual October Meeting 2013. Appointment from December 2012 to October 31, 2013.

Orenstein WA, Farley MM, Rehm S, Dalton M. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2014, held in Seattle and Houston, 2014.

Orenstein WA, Member of the Organizing Committee. National Foundation for Infectious Diseases Eleventh Annual Conference on Vaccine Research, Bethesda, MD, April 28-30, 2014.

Orenstein WA. Organizing Committee, IDWeek 2014, Philadelphia, PA, October 8-12, 2014.

Orenstein WA. Group Leader of Poster Discussion Round on Adult and Pediatric Vaccines, IDWeek 2014, Philadelphia, PA, October 8-12, 2014.

Orenstein WA, Farley MM, Rehm S, Dalton M. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course for 2015, held in Denver and Bethesda, 2015.

Orenstein WA. Member, Organizing Committee (AAP Representative), ICEID 2015, Atlanta, GA August 24-26, 2015.

Orenstein WA. Organizing Committee, IDWeek 2015, San Diego, CA, October 7-11, 2015.

Orenstein WA, Farley MM, Rehm S, Dalton M. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course, Phoenix, AZ, March 18-20, 2016.

Orenstein WA. Organizing Committee, IDWeek 2016, New Orleans, LA, October 26-30, 2016.

Orenstein WA, Farley MM, Mulligan M, Pickering L, Dalton M. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course, Phoenix, AZ, March 18-20, 2016.

Orenstein WA, Member of the Organizing Committee. National Foundation for Infectious Diseases Thirteenth Annual Conference on Vaccine Research, Bethesda, MD, April 23-26 2017.

Orenstein WA, Farley MM, Mulligan M, Pickering L, Dalton M. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course, Chicago, IL, March 10-12, 2017.

Orenstein WA. Organizing Committee, Annual CEIRS Network Meeting, Atlanta, GA, July 16-19, 2017.

Orenstein WA. Member of Organizing Committee with CDC, 1918 Pandemic Flu Symposium: 100 years of Influenza Pandemics and Practice, 1918-2018. Atlanta, GA, May 7, 2018. Program available: <https://www.youtube.com/watch?v=tAiZjScSA7k>

Orenstein WA, Farley MM, Mulligan M, Pickering L, Dalton M. Organizing Committee. National Foundation for Infectious Diseases Clinical Vaccinology Course, Bethesda, MD, November 9-10, 2018.

b. Sessions as chair:

Orenstein WA. Chairperson, Expert Review of Estimated Levels and Trends of Measles Mortality: 1999-2003. World Health Organization – Immunization, Vaccines and Biologicals – Vaccine Assessment and Monitoring. Atlanta, Georgia, January 12-13, 2005.

Orenstein WA. Chairperson, Expert Review of *Hemophilus influenzae* type B (Hib) and Pneumococcal Disease Burden Estimates. World Health Organization – Immunization, Vaccines and Biologicals – Vaccine Assessment and Monitoring. Baltimore, MD, June 21-23, 2005.

Orenstein WA. Chairperson, External Review of Burden of Disease Attributable to Rotavirus. World Health Organization, Geneva, Switzerland, November 30-December 1, 2005.

Orenstein WA. Chairperson, CDC External Peer Review of Grants IP07-001, IP07-008, IP07-013. Centers for Disease Control and Prevention, Atlanta, GA, June 15, 2007

Orenstein WA. Chairperson, Commission on the Future of Vaccines in Latin America (COFVAL), Instituto CARSO de la Salud, A.C., Mexico City, Mexico, November 28-30, 2007 and August 7-8, 2008.

Orenstein WA. Chair, Session 19 – Adult Immunizations, IDWeek 2014, Philadelphia, PA, October 8-12, 2014.

Orenstein WA. coChair, Symposium 109 – Hot Issues in Vaccine Policy, IDWeek 2015, San Diego, CA, October 7-11, 2015.

Orenstein WA. coChair, Symposium 193 – Global Immunizations, IDWeek 2015, San Diego, CA, October 7-11, 2015.

Orenstein WA. Chair, Midterm Review of Global Measles and Rubella Strategic Plan 2012-2020, Working Group meeting, Atlanta, GA, January 12-14, 2016.

Orenstein WA. Chair, Midterm Review of Global Measles and Rubella Strategic Plan 2012-2020, Working Group meeting, Atlanta, GA, May 24-26, 2016.

Orenstein WA. coChair, Symposium 22 – A Three-for: Protecting Mother, Fetus, and Infant with Immunization, IDWeek 2016, New Orleans, LA, October 20-30, 2016.

Orenstein WA. coChair, Symposium 126 – Incentivizing Vaccine Innovation, IDWeek 2016, New Orleans, LA, October 20-30, 2016.

Orenstein WA. coChair, Symposium 201 – New Vaccines/New Challenges, IDWeek 2016, New Orleans, LA, October 20-30, 2016.

20. Research Focus:

Improving the control, elimination, and eradication of vaccine-preventable diseases through trials of promising vaccine candidates, development of the critical database needed to formulate sound immunization policies, health services research to evaluate the best means of implementing immunization recommendations, and determining barriers to successful immunization delivery.

21. Grant Administration (Project Officer) at the Bill and Melinda Gates Foundation:

Imperial College. London, 2009, \$499,478.

Title: project to support public confidence in immunization programs.

Description: to develop a global surveillance system to identify and track rumors/misinformation related to immunization, with a particular focus on GAVI-eligible

SEEDR, 2009, \$450,866.

Title: reengineering (reverse) cold chain for vaccine and specimen transport.

Description: to apply selected technologies to improve the carriers and cold boxes used in Vaccine-preventable disease programs, and to transport biological specimens for diagnostic and surveillance purposes.

The Task Force for Global Health, Inc., 2009, \$500,000.

Title: interventions to support African leadership on measles.

Description: grant supports the Task Force for Global Health, former U.S. President Jimmy Carter and other statesmen to generate awareness and momentum amongst Heads of State in Africa to assume a leadership role in preventing a projected resurgence of measles deaths on the continent, and to lead Africa's decision and action on a regional goal to eliminate measles.

Centers for Disease Control Foundation, 2010, \$20M
Title: improving disease control by strengthening surveillance and response:
Demonstration Project in Central Africa.
Description: to strengthen surveillance response in Central Africa.

Johns Hopkins University, 2009, \$1.3M
Title: estimating the Burden of Serious Pneumococcal and meningococcal disease in older children and adults globally.
Description: to estimate the burden of serious pneumococcal and meningococcal disease in older children and adults globally.

World Health Organization, 2009, \$1.5M
Title: Measles-Economic Analysis
Description: to assess the feasibility and appropriateness of global measles eradication.

World Health Organization, 2009, 1.1M
Title: Vaccine Safety
Description: development of a global blueprint for building and sustaining vaccine safety capacity.

United Nations Foundation, 2009. \$7M
Title: Measles Initiative
Description: to reduce measles mortality.

The Rotary Foundation, 2009-2012, \$100M
Title: PolioPlus
Description: to support global polio eradication activities through the Rotary Foundation's PolioPlus program

World Health Organization, 2009, \$93M
Title: Intensification of the Global Polio Eradication Initiative
Description: to intensify the Global Polio Eradication Initiative

UNICEF Headquarters, 2009, \$39.5M
Title: the critical leap: Enhanced communication and vaccine supply, and operational support for the final stage of polio eradication.
Description: to support polio eradication through enhanced communication, vaccine supply, and operational support.

World Vision, 2009, \$334,500
Title: strengthening CORE Group Polio Project Impact

Description: to support the CORE group in their global polio eradication efforts by bridging implementation gaps, improving performance monitoring/management, and building capacity.

The Task Force for Global Health, Inc, 2010, \$21M

Title: Poliovirus Antivirals Initiative: Proof of Concept

Description: to support the Polio Antivirals Initiative

International Bank for Reconstruction and Development, 2009, \$39.4M

Title: Polio Eradication

Description: to support the World Bank's efforts towards Polio eradication in developing countries.

23. Grant Support:

ACTIVE

Bill & Melinda Gates Foundation

02/06/2014 – 12/31/2019

OPP1092014

PI: Saad Omer

Efficacy and Immunogenicity of Tdap Immunization of Pregnant Women for Preventing Pertussis in Early Infancy

Role: Co-Investigator

NIH/NIAD/DMID (Contract)

04/01/2014 – 03/31/2021

HHSN272201400004C

PI: Walter Orenstein

Emory / UGA CEIRS

NIAID Centers of Excellence for Influenza Research and Surveillance (contract)

The goals of the center are to determine the molecular, ecologic and/or environmental factors that influence the evolution, emergence, transmission and pathogenicity of influenza viruses, including studies on animal influenza viruses with pandemic potential; and to characterize the immune response to influenza vaccination to improve understanding of the immune correlates of protection and cross-protection.

NIH

11/05/2014 – 10/31/2019

1R01-AI10482-01A1

PI: Saad Omer

A study to develop and evaluate an intervention to improve vaccination coverage for pregnant women and their children.

Role: Co-Investigator

Task for Global Health (CDC prime)

09/30/2017 – 11/29/2018

Subcontract

Emory PI: Orenstein

GVAP 2.0

Continued assistance in determining reasons for the global community being unable to meet the midterm milestones for the Global Vaccine Action Plan (GVAP) utilizing country based surveys. Data to be used in the planning for the final GVAP report and insight for planning

for the next edition of the plan.

PENDING

N/A

INACTIVE

Task for Global Health
Subcontract
GVAP Coalition

01/01/2017 – 09/29/2017
Emory PI: Orenstein

Assist in determining the reasons for the global community being unable to meet the midterm milestones for the Global Vaccine Action Plan (GVAP).

Task Force for Global Health (Gates Foundation)
Subcontract

06/01/2013 – 12/31/2017
Emory PI: Orenstein

IPV Introduction Support to the Immunization Management Group (IMG) of the World Health Organization (WHO)

The IMG-ST (Task Force/Emory) will serve as the Secretariat to the IMG with the purpose of implementation of IPV use around the globe by 2015.

NIH
1R01-AI110474-01

03/01/2014 – 02/26/2017
PI: Michael Haber

Study Designs for Estimating the Effectiveness of Vaccination Against Influenza
The study will look at evaluating bias and precision of observational study designs, develop new study designs and utilize a stochastic agent-based simulation model to achieve these goals

Role: Co-Investigator

NIH Fogarty International Center
AGA KHAN UNIVERSITY (Anita Ziadi)
Global Infectious Disease Research Training Program

01/01/2013 – 12/31/2016
PI: Walter A. Orenstein

Description: Train pre- & post-doctoral fellows in Pakistan.

WHO Reference: 2013/3153525-0
Contract

05/01/2013-04/30/2015
PI: Murali Kaja

Immune Mechanisms of Long-term Immunity Induced by IPV
To test the duration of immunity and the number of doses needed to achieve and sustain immunity induced by IPV.

Role: Co-Investigator

NIH HHSN266200700006C
NIH/NIAID/DMID (old PI: Richard Compans)

03/30/07 - 03/31/14
PI: Walter A. Orenstein

NIAID Centers of Excellence for Influenza Research and Surveillance (contract)
The goals of the Influenza Pathogenesis and Immunology Research Center (IPIRC) are to determine the molecular, ecologic and/or environmental factors that influence the evolution,

emergence, transmission and pathogenicity of influenza viruses, including studies on animal influenza viruses with pandemic potential; and to characterize the immune response to influenza vaccination to improve understanding of the immune correlates of protection and cross-protection.

Role: Principal Investigator

200-2002-00732

10/01/2010 - 09/30/2012

Kaiser Foundation Health Plan of Georgia, Inc.

PI: Saad B. Omer

Vaccine Safety Datalink (VSD)

Centers for Disease Control and Prevention/America's Health Insurance Plans

Description: The purpose of this project is to conduct surveillance and follow-up studies of H1N1 vaccine safety in a large and diverse population and other related vaccine safety issues.

Role: Co-investigator

1 P20 RR020735-01

09/28/04-7/31/09

3PM

National Center for Research Resources

\$1,182,207 (no cost extension granted)

PI: Walter A. Orenstein (as of 6/06)

Previous PI: David S. Stephens, MD

Exploratory Center for Vaccinology Research

The major goals of the application are to develop a comprehensive program to better integrate new quantitative methodologies into Vaccinology and to engage multidisciplinary science in solving significant and complex problems in vaccine development, safety and adverse events, production and supply, acceptance and use.

1 U19 AI61728-01

9/2/04 - 8/31/09

2.34PM

NIH/NIAID

\$4,133,290

PI: Mark Feinberg, MD (Orenstein Co-Investigator)

Optimizing the Immunogenicity of MVA-Based AIDS Vaccine

To work with MVA based AIDS vaccines making them more immunogenic, develop vaccine regimens that are simpler but more potent with a rapid developmental timeline following human volunteers into Phase I clinical trials.

1 U19 057266

9/30/03 - 3/31/08

NIH/NIAID

\$1,061,826 CoreB

0.60PM

PI: Rafi Ahmed, PhD (Orenstein Co-Investigator)

Vaccine induced immunity in the young and aged – there is a clinical core (Core B)

The major goal of this core is to facilitate the design of translation research studies.

Assuring that all collaborating Center investigators a highly interactive and effect bridge is established between basic and clinical research activities with a focus that studies are conducted according to the highest standards and regulations for safe and ethical human subject research.

Novartis

03/01/07-09/30/08

1.20PM

PI: Walter Orenstein

\$200,000

Phase II: Influenza Immunization Among Health Care Workers: Policies, Practices and Intervention

This project will be looking at the healthcare worker and their beliefs and policies regarding influenza vaccination.

HHS N266800700006C 3/30/07 – 3/31/2014 1.20PM
NIH/NIAID/DMID \$40,586,199 PI: Richard Compans
(Orenstein Co-Investigator)
NIAID Centers of Excellence for Influenza Research and Surveillance

5 U38TP 423095-04 9/1/03-8/31/09 0.60PM
HHS/CDC \$1,287,564
PI: Walter Orenstein (as of 4/19/07) Old PI: Jeffrey Koplan
Bioterrorism & Disaster Preparedness Training
The mission of the Southeastern Center for Emerging Biologic Threats (SECEBT) is to combat the threat of emerging and reemerging biologic agents through a regional collaborative partnership.

HHS/CDC 09/01/2007-08/31/2011 1.20PM
RFA-CD-07-005 1,307,360.00
PI: Walter Orenstein
Improving Public Health Practice through Translation Research (R18)
Delivering Influenza Vaccine to Adolescents - an evaluation of methods for achieving high immunization rates and promoting the use of preventive health services

Merck 10/1/07 – 09/30/08 1.20PM
PI: Walter Orenstein \$240,000
Persistence of humoral and cellular immune responses following age-appropriate vaccination with the MMR vaccine
With recent mumps outbreak in 2006, looking at the immune response to MMR in the college population

Protocol # MI-CP111 8/15/04-12/1/05 1.20PM
Medimmune, Inc. \$307,000
PI: Harry Keyserling, MD (Orenstein Co-Investigator)
A randomized, double-blind trial to assess the safety and relative efficacy of CAIV-T against inactivated influenza vaccine in children 6-59 months of age

Chiron Foundation 06/01/05-07/31/07 0.60PM
PI: Walter Orenstein 84,943 No cost extension
Influenza Immunization Among Health Care Workers: Policies, Practices and Intervention
This project will be looking at the healthcare worker and their beliefs and policies regarding influenza vaccination.

5 P30 AI050409-06S2 (Curran) 9/30/04 – 7/31/07 1.20PM

NIH

\$307,029

(Orenstein Co-Investigator)

Infant Immunizations to Reduce Pneumonia in HIV+ Women

The major goal of this project is to determine whether pneumococcal conjugate vaccination of infants will reduce the burden of pneumococcal disease in HIV-positive women.

24. Formal Teaching:

1. EPIDEMIOLOGY IN ACTION: Immunizable Diseases - November 9, 2000, Rollins School of Public Health, Emory University, Atlanta Georgia
2. IH591B/EPI 591V: Vaccines and Immunization – Making Vaccine Policy – October 3, 2003, Rollins School of Public Health, Emory University, Atlanta, Georgia
3. IH591B/EPI 591V: Vaccines and Immunization – Making Vaccine Policy – October 8, 2004, Rollins School of Public Health, Emory University, Atlanta, Georgia
4. IH591B/EPI 591V: Models for Vaccine Delivery in Developed Countries – November 5, 2004, Rollins School of Public Health, Emory University, Atlanta, Georgia
5. EPIDEMIOLOGY IN ACTION: Immunizable Diseases - November 18, 2004, Rollins School of Public Health, Emory University, Atlanta Georgia
6. Mini Residency Program: University of Puerto Rico, Emory Center of Public Health Preparedness, Vaccine Development Issues, January 11, 2005, Rollins School of Public Health, Emory University, Atlanta, Georgia
7. EPI 562/IH 562: Emerging Infectious Diseases – Vaccine Issues – February 17, 2005, Rollins School of Public Health, Emory University, Atlanta, Georgia
8. Humphrey Fellows – March 28, 2005 – Making Vaccine Policy, Rollins School of Public Health, Emory University, Atlanta, Georgia
9. EPIDEMIOLOGY IN ACTION: Immunizable Diseases – April 28, 2005, Rollins School of Public Health, Emory University, Atlanta, Georgia
10. IH591B/EPI 591V: Epidemiology and Vaccine Preventable Diseases – October 7, 2005, Rollins School of Public Health, Emory University, Atlanta, Georgia
11. EPIDEMIOLOGY IN ACTION: Epidemiology and Vaccine Preventable Diseases – November 8, 2005, Rollins School of Public Health, Emory University, Atlanta, Georgia
12. Introduction of Public Health: Insights from 26 years in Immunization. November 21, 2005, Mount Sinai School of Public Health, New York, New York

12. Infectious Disease Fellows Didactic Conference – Measles, Mumps and Rubella, December 8, 2005, Rita Ann Rollins Room, Rollins School of Public Health, Emory University, Atlanta, Georgia
13. Infectious Disease Fellows Didactic Conference - Preventing Influenza Through Vaccination – Challenges Today, Hopes for the Future, December 15, 2005, Rita Ann Rollins Room, Rollins School of Public Health, Emory University, Atlanta, Georgia
14. Vaccine Policy Issues at Johns Hopkins School of Public Health – Making Vaccine Policy. February 7, 2006, Baltimore, Maryland
15. GH511 International Infectious Diseases Course - Vaccine Preventable Diseases: Overview and Approach, February 15, 2006. Rollins School of Public Health, Emory University, Atlanta, Georgia
16. International Course in Applied Epidemiology - Immunizable Disease, October 3, 2006. Rollins School of Public Health, Emory University, Atlanta, Georgia
17. GH511 International Infectious Diseases Course - Vaccine Preventable Diseases: Overview and Approach, March 28, 2007. Rollins School of Public Health, Emory University, Atlanta, Georgia
18. Vaccine Policy Issues at Johns Hopkins School of Public Health – The Role of Measles Elimination in Development of a National Immunization Program. February 13, 2007, Baltimore, Maryland
19. BIOS 524: Analytical Methods in Infectious Diseases Course - Hot Issues and Controversies in Immunization, April 5, 2007. Rollins School of Public Health, Emory University, Atlanta, Georgia
20. Prologue I – Threats to Human Health – Pandemics, August 14, 2007, Emory School of Medicine, First year medical students, Atlanta, Georgia
21. Vaccine Mandates: Benefits and Risks. Rutgers University MBA Class via videoconference (Dr. Michael Santoro), October 9, 2007
22. International Course in Applied Epidemiology - Immunizable Diseases, October 10, 2007. Rollins School of Public Health, Emory University, Atlanta, Georgia
23. GH566/EPI566: Vaccines and Immunization. Models for Vaccine Delivery in Developed Countries – October 12, 2007. Rollins School of Public Health, Emory University, Atlanta, Georgia

24. CDC's China EPI Course, Post-licensure Vaccine Safety Monitoring. Georgian Terrace, October 19, 2007, Atlanta, Georgia
25. Introduction of Public Health: Insights from 26 Years in Immunization at CDC. Mt. Sinai School of Public Health, November 5, 2007, New York, New York
26. GH 541: Implementation Science. Polio Eradication. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, 2009
27. GH 541: Implementation Science. Polio Eradication. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, 2010
28. GH 541: Implementation Science. Polio Eradication. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2011
29. M2M700 Seminar and Panel. The Critical Role of the Laboratory in the Global Polio Eradication Program (GPEI). Emory University School of Medicine, Atlanta, Georgia, February 20, 2012
30. GH566/EPI566: Immunization Programs and Policies. Models of Vaccine Delivery in Developed Countries, Rollins School of Public Health, Emory University, Atlanta, Georgia, March 2012
31. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2012
32. GH571: Vaccines & Vaccine Preventable Diseases. Polio Eradication: *Progress, Problems and Promise*, Department of Global Health, School of Public Health, Emory University, October 2012
33. Introduction to the Advisory Committee on Immunization Practices (ACIP). Emory Vaccinology Training Program (VTP-T32) Fellows, September 2012
34. GH556/EPI566: Immunization Programs and Policies. Models of Vaccine Delivery in Developed Countries, Rollins School of Public Health, Emory University, Atlanta, Georgia, March 2013
35. Vaccine Policy Issues at Johns Hopkins School of Public Health – Polio Eradication: Progress, Problems and Promise, Baltimore, Maryland, February 2013
36. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2013

37. GH571: Vaccines & Vaccine Preventable Diseases. Polio Eradication: *Progress, Problems and Promise*, Department of Global Health, School of Public Health, Emory University, October 2013
38. GH556/EPI566: Immunization Programs and Policies. Models of Vaccine Delivery in Developed Countries, Rollins School of Public Health, Emory University, Atlanta, Georgia, March 2014
39. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2014
40. Introduction to the Advisory Committee on Immunization Practices (ACIP). Emory Vaccinology Training Program (VTP-T32) Fellows, October 2014
41. Vaccine Policy Issues at Johns Hopkins School of Public Health – The Role of Measles Elimination in Development of a National Immunization Program, Baltimore, Maryland, February 2015
42. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2015
43. Introduction to the Advisory Committee on Immunization Practices (ACIP). Emory Vaccinology Training Program (VTP-T32) Fellows, Emory University, October 2015
44. GH571: Vaccines & Vaccine Preventable Diseases. Polio Eradication: *Progress, Problems and Promise*, Department of Global Health, School of Public Health, Emory University, September 2015
45. GH556/EPI566: Immunization Programs and Policies. Models of Vaccine Delivery in Developed Countries, Rollins School of Public Health, Emory University, Atlanta, Georgia, February 2016
46. Vaccine Policy Issues at Johns Hopkins School of Public Health – The National Vaccine Advisory Committee: how it came to be, and historical and current impact on vaccine policy in the US and beyond, Baltimore, Maryland, March 2016
47. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2016
48. GH571: Vaccines & Vaccine Preventable Diseases. Polio Eradication: *Progress,*

Problems and Promise, Department of Global Health, School of Public Health, Emory University, September 2016

49. Immunizations in the US, Antimicrobial Resistance and Therapeutic Discovery Training Program T32, PI: Shafer, Emory University, October 2016
50. M2M700 Seminar and Panel. Influenza Vaccination: Successes and Failures. Emory University School of Medicine, Atlanta, Georgia, December 2016
51. Introduction to the Advisory Committee on Immunization Practices (ACIP). Emory Vaccinology Training Program (VTP-T32) Fellows, Emory University, January 2017
52. GH556/EPI566: Immunization Programs and Policies. Models of Vaccine Delivery in Developed Countries, Rollins School of Public Health, Emory University, Atlanta, Georgia, February 2017
53. GH584: Evidence-Based Decision Making. Making Difficult Recommendations: Polio Vaccination in the US, Rollins School of Public Health, Emory University, Atlanta, Georgia, March 2017
54. Vaccine Policy Issues at Johns Hopkins School of Public Health – The National Vaccine Advisory Committee: how it came to be, and historical and current impact on vaccine policy in the US and beyond, Baltimore, Maryland, March 2017
55. GH584: Evidence-Based Decision Making. SME for class debate on “Should the US establish national-level school-entry immunization mandates, with no non-medical exemptions?” Rollins School of Public Health, Emory University, Atlanta, Georgia, April 2017
56. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2017
57. GH571: Vaccines & Vaccine Preventable Diseases. Polio Eradication: *Progress, Problems and Promise*, Department of Global Health, School of Public Health, Emory University, October 2017
58. Global Health Challenges Course. Polio Eradication: Progress, Problems and Promise. University of Notre Dame, November 2017
59. Vaccine Policy Issues at Johns Hopkins School of Public Health – The National Vaccine Advisory Committee: how it came to be, and historical and current impact on vaccine policy in the US and beyond, Baltimore, Maryland, February 2018

60. GH556/EPI566: Immunization Programs and Policies. Models of Vaccine Delivery in Developed Countries, Rollins School of Public Health, Emory University, Atlanta, Georgia, March 2018
61. GH584: Evidence-Based Decision Making. Making Difficult Recommendations: Polio Vaccination in the US, Rollins School of Public Health, Emory University, Atlanta, Georgia, March 2018
62. TERMFOUR-1463. DrPH course: The Practice of Public Health Through Vaccine Case Studies - Thimerosal via taped interviews, Live discussions via Skype, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, April 2018
63. GH 541: Implementation Science. Polio Eradication: Progress, Problems and Promise. Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, May 2018

26. Supervisory Teaching / Mentoring:

Masters of Public Health (MPH)

1. Albert E. Barskey, IV, MPH (Epi), Thesis: A comparison of the decline of invasive pneumococcal disease in unvaccinated persons caused by serotypes contained in the pediatric pneumococcal conjugate vaccine. Emory Rollins School of Public Health, awarded 2005. Epidemiologist at CDC
2. Hajime Kamiya, MD, MPH (Epi), Thesis: Evaluation of acute gastroenteritis among Japanese children: Estimation of the health burden of rotavirus in Japan. Emory Rollins School of Public Health, awarded May 2008. Practicing medicine in Japan. 2013 to 2015 – EIS Officer at Centers for Disease Control and Prevention. 2017 -
3. Erin-Joi Collins, MPH (Prevention Science), Thesis: Exploration of Contributing Factors in the Rise of Bordetella Pertussis Incidence. Emory Rollins School of Public Health, defended November 2014, awarded December 2014. Project manager Emory / UGA CEIRS.
4. Jennifer Lynn Brosseau, MPH (Global Epi), Thesis: The impact of antibiotic use on influenza vaccine effectiveness in children aged 6-59 months. Emory Rollins School of Public Health, defended August 2013, awarded December 2015
5. Jerusha Elana Barton, MPH (Epi), Thesis: The Changing Epidemiology of Pertussis in the Acellular Vaccine Era. Emory Rollins School of Public Health, awarded May 2014. CDC Epidemiology Orise Fellow - 2017

6. Victoria Lauren Cowger, MPH (Epi), Thesis: The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan and Afghanistan - January 2011 through September 2013. Emory Rollins School of Public Health, awarded May 2014. Accepted PhD, Harvard September 2017
7. Joseph F. Durbin, MBA, MPH (Prevention Science), Thesis: Secondary Data Analysis of Pilot Implementation for Two-Dimensional Vaccine Barcode Utilization. Emory Rollins School of Public Health, defended December 2014, awarded May 2015. SRA Project Manager, CDC 2017
8. Monica Kimberly Lachey, MPH (Epi), Thesis: Addressing rotavirus vaccination missed opportunities using the National Immunization Survey. Emory Rollins School of Public Health, awarded May 2015. Monica Schroeder (nee Lachey), CSTE 2017
9. Sarah McKinstry, MPH (Epi), Thesis: State level vaccination systems: Is there correlation of success for childhood and adolescent immunizations? Emory Rollins School of Public Health, awarded May 2015. Team lead – Wellcentive 2017
10. Ian Kyle Everitt, MPH (Epi), Thesis: An Assessment of El Paso Physician Knowledge, Attitudes, and Practices Regarding the Clinical Management of Suspected Cases of Pertussis. Emory Rollins School of Public Health, awarded May 2015
11. Anirudh Rao, MPH (Global Epi). Thesis: Evaluation of mass influenza immunization clinics in Puerto Rico during the 2013-14 influenza season. Emory Rollins School of Public Health, awarded May 2016
12. Lillian Flannigan, MPH (Epidemiology). Thesis: Attitudes, beliefs, and characteristics mediating acceptance of childhood non-influenza attenuated and conjugate vaccines in a 2016 national survey of parents. Emory Rollins School of Public Health, awarded May 2017
13. Bethany Sederdahl, MPH (Global Epi). Thesis: Missed Opportunities for Rotavirus Vaccination among U.S. Children 19-35 Months of Age. Emory Rollins School of Public Health, awarded May 2017
14. Piyarat Suntarattiwong, MPH (Global Health). Thesis: Analysis of influenza vaccine effectiveness using the test negative design at clinics around Thailand. Emory Rollins School of Public Health, anticipated August 2018

Humphrey Fellows

1. Thippayawan Thanapaisal, MD, Mentor, Humphrey Fellowship, Emory Rollins

- School of Public Health, Emory University, August 2007 – July 2008. Currently in Thailand practicing medicine and epidemiology
2. Zhijie An, MD, MPH, Mentor, Humphrey Fellowship, Emory Rollins School of Public Health, Emory University, 2016 - 2017. National Immunization Programme, China CDC, E-mail: anzj@chinacdc.cn
 3. Piyanit Tharmaphornpilas, MD, MPH, Mentor, Humphrey Fellowship, Emory Rollins School of Public Health, Emory University, 2016 - 2017. Senior Medical Advisor – Department of Disease Control, Ministry of Public Health, Thailand

Doctor of Philosophy (PhD)

1. Julia Painter, PhD (BSHE), Thesis: The association between attitudes toward vaccination and vaccine uptake among adolescents, Emory Rollins School of Public Health, Emory University, March 2008; defended May 2010. Finished Fellowship in the Emory Vaccinology Training Program, May 2012. Assistant Professor, Research Tract, Emory Rollins School of Public Health. 2013 – EIS Officer at the Centers for Disease Control and Prevention. 2015 - Assistant Professor, Department of Global and Community Health, George Mason University
2. Vinh Quang Bui, PhD (Nutrition Health Sciences), Thesis: The Effect of Zinc Supplementation on Biomarkers of Zinc, Iron, and Copper Status in School Children in Guatemala, Emory Rollins School of Public Health, Emory University, June 16, 2008; defended June 2011
3. Kristin Bratton, PhD (Global Epi), Thesis: Effect of Maternal Influenza Vaccination on Spontaneous Abortion and Stillbirth: A systematic review and meta-analysis. Emory Rollins School of Public Health Awarded, May 2014
4. Allison Chamberlain, PhD (Epi), Thesis: Improving Influenza and Tdap Vaccination among Pregnant Women in Georgia. Emory Rollins School of Public Health Defended, November 2014, Awarded, May 2015. Assistant Professor, Global Health, Rollins School of Public Health, Emory University
5. Jennifer Nicholson Kriss, MPH, PhD (Epi). Thesis: Prevention of infant pertussis through maternal vaccination strategies. Emory Rollins School of Public Health Awarded, December 2015
6. Aaron Wallace, PhD (Epi). Thesis: Measuring and Improving Timely Utilization of Routine Vaccinations in Low & Middle Income Country Settings. Emory Rollins School of Public Health, Awarded, May 2018

NIH Career Grant Mentor

1. Robert A. Bednarczyk, PhD. Co-mentor on K01 award on developing a healthcare system-based intervention to improve HPV vaccine uptake. Awarded 2014. Assistant Professor, Global Health, Rollins School of Public, Emory University

Emory Vaccinology Training Program (T32) Fellows (co-Director, 2015 – present)

1. McKittrick, Tanya, PhD, Ancient antibodies as a vaccine discovery tool for tumor associated carbohydrate antigens, May 2013 – 2015
2. Sukumaran, Lakshmi, MD, MPH, Safety of Tdap vaccine in pregnancy following prior tetanus containing immunizations and co-administration with influenza vaccine, May 2013 – 2015
3. Ellebedy, Ali, PhD, Dissecting human B cell responses to influenza vaccination, May 2014 – 2016
4. Kabbani, Sarah, MD/MSc, Identification of Circulating CD4⁺ T Follicular Helper Cell (T_{FH}) Response after Smallpox Vaccination, May 2014 – 2016
5. Stobart, Christopher. PhD, Development and Evaluation of Respiratory Syncytial Virus (RSV) Live-attenuated Vaccines, May 2014 – 2016
6. Turner, Tiffany, PhD, CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines, May 2014 – 2016
7. Myers, Tanya, PhD/MSc, A Practical Experience in Post-Licensure Vaccine Safety Assessment - Menactra®, July 2015 - June 2017
8. Phadke, Varun, MD, Clinical field trial of maternal Tdap vaccination in Guatemala, July 2015- June 2017
9. Holley, Concerta, PhD, Genetic regulation of the *Neisseria gonorrhoeae* vaccine candidate OmpA, July 2016 – June 2018
10. Kauffman, Robert, PhD, Human B cell responses during *Vibrio cholerae* vaccination and infection, July 2016 – June 2018
11. Collins, Jeffrey M, MD, MPH, MScR, Plasma metabolomics for the assessment of tuberculosis immunity, July 2016 – June 2018
12. Raabe, Vanessa, MSc, MD, Characterization of immune responses to & viral dynamics of Zika virus among pregnant women with acute or recent Zika virus

infection, July 2017 – June 2019

27. Lectureships, Seminar Invitations, and Visiting Professorships:

1. **Orenstein WA.** Monitoring and dissemination of live viral vaccines. Current understanding of persistent viral infections and their implications in human disease -- Summary of a workshop. Presented at the National Institutes of Health, Bethesda, Maryland, October 23-24, 1975. *J Infect Dis* 1976; 133:707-714.
2. **Orenstein, WA.** Attenuated Live Virus Vaccine Use. Presented at the International Symposium on Viruses, Rickettsiae, and Severe Human Disease, Centers for Disease Control, May 24-26, 1988.
3. **Orenstein WA.** Immunization Successes and Challenges. Presented at the National Conference of State Legislatures Health Policy Conference, Charlotte North Carolina, December 1, 2000.
4. **Orenstein WA.** Taking the Coalition Spirit Home! Presented at the Coalition Conference, Savannah Georgia, January 10-12, 2001.
5. **Orenstein WA.** Global Measles Epidemiology. Presented at the American Red Cross Measles Partners Meeting (ARC), Washington DC, January 30, 2001.
6. **Orenstein WA.** Visiting Professor. Vaccines for Today and Tomorrow. Presented at the Children's Hospital, Los Angeles California, February 10, 2001.
7. **Orenstein WA.** National Immunization Update. Presented at the 8th Annual Immunize Georgia's Little Guys Conference, Macon Georgia, February 15, 2001.
8. **Orenstein WA.** Smallpox Vaccination Briefing for Secretary Thompson. Present to Secretary Thompson, Washington DC, October 31, 2001.
9. **Orenstein WA.** The Ending can be the Hardest Part: The Challenges of Disease Eradication. Presented at the Frontiers in Vaccinology, University of Maryland School of Medicine, Center for Vaccine Development, Baltimore Maryland, November 2, 2001.
10. **Orenstein WA.** History and Epidemiology of Global Smallpox Eradication. Presented to launch the Smallpox Response Training Program, Atlanta Georgia, November 7, 2001.

11. **Orenstein WA.** Immunization Update – 2001: Hot Issues in Immunization. Presented at the 14th Annual Infectious Diseases in Children Symposium, New York, New York, November 18, 2001.
12. **Orenstein WA.** Perspectives on Eradication. Polio and Measles. Conversations at the Carter Center, Panelist, Disease Eradication Meeting, Atlanta Georgia, January 31, 2002.
13. **Orenstein WA.** National Immunization Update. Presented at the 9th Annual Immunize Georgia's Little Guys Conference, Macon Georgia, February 14, 2002.
14. **Orenstein WA.** History and Epidemiology of Global Smallpox Eradication. Presented at the Smallpox Training Course for Communications Group, Response/Medical Group, & Laboratory Group, Atlanta Georgia, March 13, 2002.
15. **Orenstein WA.** Overview of Childhood and Adult Immunizations. Presented at the Congressional Black Caucus Health Brain Trust Planning Meeting, Washington DC, March 22, 2002.
16. **Orenstein WA.** Visiting Professor, University of New Mexico School of Medicine and Albuquerque Area Indian Health Service Hospital Combined Grand Rounds. Immunization – Preventing Serious Diseases in Children – *A Public / Private Partnership*, Albuquerque, New Mexico, April 16, 2002.
17. **Orenstein WA.** Visiting Professor, Lovelace Medical Center Grand Rounds. Immunization – Successes, Promises and Challenges, Albuquerque, New Mexico, April 16, 2002.
18. **Orenstein WA.** Keynote Address: Immunization – Preventing Serious Diseases in Children. Presented at the Awards Dinner for Providers who have Improved Rates. National Infant Immunization Week, Albuquerque, New Mexico, April 16, 2002.
19. **Orenstein WA.** Clinical, Diagnostic and Epidemiologic Features of Smallpox. Presented at the Community Forum on Smallpox (Vaccinia) Vaccine Use, Mt. Sinai Hospital, New York, New York, June 6, 2002.
20. **Orenstein WA.** Overview of Childhood Immunization Requirements. Presented at the Public Health Law Conference, Atlanta, Georgia, June 18, 2002.
21. **Orenstein WA.** Vaccine Supply. Presented at the American Enterprise Institute Conference on Vaccine Development and Biodefense: How Does Public Policy Affect Research and Development?, Washington DC, June 27, 2002.

22. **Orenstein WA.** Immunization Registries Development and Progress. Presented at the Every Child by Two Seminar sponsored by Rosalyn Carter and Betty Bumpers, Washington DC, July 11, 2002.
23. **Orenstein WA.** Smallpox – Lessons Learned from the Past – Concerns for the future. Presented at the Columbia Grand Rounds, Milstein Hospital, New York, New York, July 24, 2002.
24. **Orenstein WA.** Pre-attack Vaccination Preparedness with Smallpox Vaccine. Presented to the Secretary’s Council on Public Health Preparedness, Washington DC, August 27, 2002.
25. **Orenstein WA.** Smallpox Vaccine – Associated Adverse Events. Presented at the White House, Office of Vice President’s Staff, Washington DC, September 9, 2002.
26. **Orenstein WA.** New and Forthcoming Vaccines: Smallpox and More. Presented at the Washington Business Group on Health Issues, Washington DC, September 10, 2002.
27. **Orenstein WA.** The National Immunization Program. Presented to Craig Higgins and Brent Jacquet, Congressional Staffers, Washington, DC, October 31, 2002.
28. **Orenstein WA.** Influenza and Pandemic Preparedness. Presented at the CDC Foundation Board of Visitors, Emory Conference Center, Atlanta, Georgia, November 6, 2002.
29. **Orenstein WA.** Orientation for Health Officials. Sponsored by Association of State & Territorial Health Officials (ASTHO) at CDC Clifton Rd, Atlanta Georgia, December 3, 2002.
30. **Orenstein WA.** Introduction to Developing a Vaccination Strategy for Smallpox Preparedness. Satellite broadcast of “CDC Bioterrorism Update: Smallpox Preparedness. December 6, 2002. View entire Broadcast at: <http://www.bt.cdc.gov/agent/smallpox/training/webcast/dec2002/index.asp>
31. **Orenstein WA.** 2003 National Immunization Update. Presented at the 10th Annual Immunize Georgia’s Little Guys, Calloway Gardens Georgia, February 10, 2003.
32. **Orenstein WA.** Smallpox: Lessons from the Past, Strategies for the Future, Clouded by Uncertainty. Presented at Georgetown University, Washington DC, March 3, 2003.
33. **Orenstein WA.** Smallpox: Lessons from the Past, Concerns for the Future. Visiting Professor – Wake Forest, Greensboro North Carolina, March 28, 2003.

34. **Orenstein WA.** Hot Issues in Immunization. Visiting Professor – Wake Forest, Greensboro North Carolina, March 29, 2003.
35. **Orenstein WA.** Immunization Successes, Promises and Challenges. Presented at Public Health, Oklahoma University College, Oklahoma City Oklahoma, April 14, 2003.
36. **Orenstein WA.** Immunization – Past, Present and Future. Presented at the Oklahoma Immunization Awards Dinner, Oklahoma City Oklahoma, April 14, 2003.
37. **Orenstein WA.** Immunization Issues for Today’s Hospitals and Health Care Providers. Presented at the Oklahoma Hospital Association, Oklahoma City Oklahoma, April 14, 2003.
38. **Orenstein WA.** Immunization – Maintaining our Success. Presented at the Oklahoma Tribal Welcome Ceremony, Choctaw Nation Hospital, Talhina Oklahoma, April 15, 2003.
39. **Orenstein WA.** Immunization Update: Importance of Immunizations for Children. Presented at Carl Albert State College, Poteau Oklahoma, April 15, 2003.
40. **Orenstein WA.** Immunization Challenges for the Future. Presented at the East Regional Health Center, Tulsa Oklahoma, April 15, 2003.
41. **Orenstein WA.** Vaccines – Today and Tomorrow. Presented at the Tulsa Rotary Club, Tulsa Oklahoma, April 15, 2003.
42. **Orenstein WA.** Health Services Research in the Immunization Program. Presented to the University of Michigan Research Seminar, Ann Arbor Michigan, August 26, 2003.
43. **Orenstein WA.** Eradication of Vaccine – preventable diseases – Lessons Learned from Smallpox, Polio and Measles. Presented at the Georges Peter Symposium, Providence Rhode Island, November 7, 2003.
44. **Orenstein WA.** Influenza: New Insights on an Old Disease. Visiting Professor. Presented at Harvard University Grand Rounds, Boston Massachusetts, March 23-25, 2004.
45. **Orenstein WA.** Reducing the Burden of Vaccine Preventable Disease – Major Challenges Ahead. Visiting Professor. Presented at Harvard University Grand Rounds, Boston Massachusetts, March 23-35, 2004.
46. **Orenstein WA.** Eradication of Vaccine-preventable Diseases – Lessons Learned from Smallpox, Polio and Measles. Visiting Professor. Presented at 2004 World Health

Week, Vanderbilt Medical School, March 30, 2004.

47. **Orenstein WA.** National and International Response to Outbreaks of Vaccine-Preventable Diseases. Visiting Professor. Presented at the University of Texas Medical Branch at Galveston, Galveston Texas, March 31, 2004.
48. **Orenstein WA.** The Ending can be the hardest part: The Challenges of Disease Eradication. Presented at the Emory University School of Public Health, Atlanta Georgia, April 7, 2004.
49. **Orenstein WA.** Influenza–2003:A Year to Remember. Presented at the Infectious Disease Seminar, Emory University, Atlanta Georgia, April 8, 2004.
50. **Orenstein WA.** Influenza – New Insights on an Old Disease. Visiting Professor. Presented at Grand Rounds, Children’s Medical Center, Dallas Texas, April 28, 2004.
51. **Orenstein WA.** Epidemiology and Vaccine Preventable Diseases. Presented at the Epidemiology in Action Course, Emory School of Public Health, Atlanta Georgia, May 6, 2004.
52. **Orenstein WA.** New Directions in Modeling Infectious Disease. Presented at the Methodologies for Comparing Vaccination Strategies Workshop, Rutgers, South Plainfield, May 7, 2004.
53. **Orenstein WA.** Insights from 26 Years in Immunization Programs. 2004 Jeryl Lynn Hilleman Endowed Lecture of the CDC Foundation, Atlanta Georgia, May 11, 2004.
54. **Orenstein WA.** Vaccines in 2005: What You Need to Know. Presented at the Fourth Annual Vaccine Education Symposium, Vaccine Education Center at The Children’s Hospital of Philadelphia, Philadelphia Pennsylvania, September 18, 2004.
55. **Orenstein WA.** Vaccine Preventable Diseases in Children: Then, Now, and Beyond the Horizon. Presented at Pediatrics Grand Rounds, The Hospital for Sick Children, Toronto Canada, October 20, 2004.
56. **Orenstein WA.** Influenza: Will We Ever Find Our Way Out of the Crisis? Hilda and AC Silverman Lecturer, Pediatric Grand Rounds, Upstate Medical University, Syracuse New York, November 10, 2004.
57. **Orenstein WA.** Vaccines in 2005: New Vaccines and Vaccine Policies. Presented at Medical Rounds, Northeast Georgia Medical Center, Gainesville Georgia, November 12, 2004.
58. **Orenstein WA.** Polio Eradication: Strategy, Progress and Challenges. Presented at

the Department of Medicine Research Seminar, Emory University, Atlanta Georgia, November 18, 2004.

59. **Orenstein WA.** Global Polio Eradication – A Status Report. Presented at the Dunwoody Rotary Club, Ravinia Athletic Club, Dunwoody Georgia, January 7, 2005.
60. **Orenstein WA.** Preventing Influenza Through Vaccination – Challenges Today, Hopes for the Future. Presented at Medicine Grand Rounds, Emory University, Atlanta Georgia, January 11, 2005.
61. **Orenstein WA.** Global Polio Eradication – A Status Report. Presented at the Peachtree City Rotary Club, Peachtree City Georgia, January 27, 2005.
62. **Orenstein WA.** Preventing Influenza Through Vaccination – Challenges Today, Hopes for the Future. Presented to Cystic Fibrosis Center at Emory, Atlanta Georgia, March 1, 2005.
63. **Orenstein WA.** Rubella and Rubella Vaccines in the U.S. – The Road to Elimination. Presented as a panelist at the 2005 Jeryl Lynn Hilleman Endowed Lecture at the 39th National Immunization Conference, Washington DC, March 21, 2005.
64. **Orenstein WA.** Preventing Influenza Through Vaccination – Challenges Today, Hopes for the Future. Presented at the Emerging Infectious Diseases (EIP) Meeting, Atlanta GA, March 22, 2005.
65. **Orenstein WA.** Methods of Improving Immunization Coverage – The Role of the Pediatrician. Presented at the Hugh Carithers, MD Memorial Visiting Professorship Series in Pediatric Infectious Diseases, University of Florida, Jacksonville Florida, April 13, 2005.
66. **Orenstein WA.** Hot Issues in Vaccine Safety. Presented at the Microbiology Noon Conference, University of Florida, Jacksonville Florida, April 13, 2005.
67. **Orenstein WA.** How Vaccine Policy is Made. Presented at the Pediatric Grand Rounds, University of Florida, Jacksonville Florida, April 13, 2005.
68. **Orenstein WA.** Influenza: Will We Ever Find Our Way Out of the Crisis? Presented at the Department of Pediatrics Grand Rounds, Dartmouth Hitchcock Medical Center, Lebanon New Hampshire, May 11, 2005.
69. **Orenstein WA.** Global Polio Eradication- A Status Report. Presented at the Newnan Rotary, Newnan Georgia, July 29, 2005.
70. **Orenstein WA.** Pandemic Influenza. Department of Emergency Medicine Faculty

Retreat, Emory University, Atlanta Georgia, October 28, 2005.

71. **Orenstein WA.** Universal Vaccination Against Influenza – Critical Needs for a Possible New Strategy. Presented at the Health Policy and Management Conference, Rita Ann Rollins Room, Emory University, Atlanta Georgia, December 5, 2005.
72. **Orenstein WA.** The Avian Flu Pandemic. Presented at the 2006 State Health Director’s Conference – North Carolina. Raleigh North Carolina, January 27, 2006.
73. **Orenstein WA.** Public Health’s Role in Surveillance, Professional and Public Education, and Laboratory Support. Presented at the Varicella Zoster Vaccine Foundation Meeting, New York New York, February 3, 2006.
74. **Orenstein WA.** Improving the Control of Influenza – Should We Vaccinate All Children Annually? Visiting Professor – University of Florida Gainesville. Gainesville Florida, February 13, 2006.
75. **Orenstein WA, Stephens D.** The Need for Genomics in Vaccinology. Emory Genetics Seminar, Whitehead Building, Emory University, Atlanta Georgia, February 20, 2006.
76. **Orenstein WA.** Pandemic Influenza: Preparing for the Inevitable. Pediatric Quarterly Faculty Meeting, Emory Clinic Brown Auditorium, Atlanta Georgia, March 13, 2006.
77. **Orenstein WA.** Pandemic Influenza: Preparing for the Inevitable. Emory’s Administrative Council, Emory University Winship Ballroom, Atlanta Georgia, March 29, 2006.
78. **Orenstein WA.** Informal Discussions: Preparing for Pandemic Influenza. Visiting Professor – Yale University, New Haven Connecticut. April 7, 2006.
79. **Orenstein WA.** Pandemic Influenza: Preparing for the Inevitable. Leadership DeKalb, Yerkes Neuroscience Seminar Room, Atlanta Georgia, May 18, 2006.
80. **Orenstein WA.** Achieving Disease Control through Vaccination. CDC Experience, Century Center, Atlanta Georgia, May 22, 2006.
81. **Orenstein, WA.** Universal Vaccination Against Influenza: Has the Time Come? The Eighth Annual Saul Krugman, MD, Lecture, New York University School of Medicine, New York New York, September 5, 2006.
82. **Orenstein, WA.** Universal Vaccination against Influenza: is it time? Visiting Professor, Pediatric Grand Rounds, Children’s Memorial Hospital, Chicago Illinois, September 8, 2006.

83. **Orenstein, WA.** Universal Vaccination against Influenza: is it time? Chicago Area Immunization Campaign Annual Meeting, University of Illinois, Chicago Illinois, September 8, 2006.
84. **Orenstein, WA.** Universal Vaccination against Influenza: is it time? Visiting Professor, Pediatric Grand Rounds, Children's Memorial Hospital, Chicago Illinois, September 8, 2006.
85. **Orenstein, WA.** Shots for a Better Life – New Vaccines for Children and Adults. Presented at Medical Rounds, Northeast Georgia Medical Center, Gainesville Georgia, September 15, 2006.
86. **Orenstein WA, Isakov AP.** Pandemic Influenza Preparedness: Emory University and Other Academic Institutions. Triangle Lecture Series, Emory University, Atlanta Georgia, October 11, 2006.
87. **Orenstein WA.** Pandemic Influenza – How Serious is the Threat? Emory's Family Weekend, Emory University, Atlanta\ Georgia, October 21, 2006.
88. **Orenstein WA.** Vaccination – Successes and Stresses. Public Health Grand Rounds, The George Washington University School of Public Health and Health Services, Washington DC, January 16, 2007.
89. **Orenstein WA.** Pandemic Influenza – How Serious is the Threat? Presented at the Decatur Rotary Club, Decatur Georgia, January 26, 2007.
90. **Orenstein WA.** Immunization Mandates in the United States – a Potential for Other Countries, World Law and World Health Especially Health of Women in Least Developed and Developing Countries, Emory University School of Law, Atlanta Georgia, March 23, 2007.
91. **Orenstein WA, Isakov AP.** Pandemic Influenza Preparedness: Planning at Emory University. Infectious Diseases Research Seminar Series, Rollins School of Public Health, Atlanta Georgia, March 29, 2007.
92. **Orenstein WA.** Universal Vaccination Against Influenza – Has the Time Come? Visiting Professor, University of Colorado, Denver Colorado, December 7, 2007.
93. **Orenstein WA.** Vaccines and Disease Eradication. Alpha Epsilon Delta Lecture, University of Georgia, Athens Georgia, March 31, 2008.
94. **Orenstein WA.** National and International Responses to Outbreaks of Vaccine Preventable Diseases. Visiting Professor, University of Texas Medical Branch, Galveston Texas, April 7, 2008.

95. **Orenstein WA**, Huang Z, Plemper R. Good Ideas Start Small: Southeastern Center for Emerging Biologic Threats Seed Grant Model. 2008-2010 Models of Excellence Lecture Series. Rollins School of Public Health, Emory University, Atlanta Georgia, April 22, 2008.
96. **Orenstein WA**. Insights from 26 years in Immunization Programs – Measles Elimination as a Driving Force. SUNY Visiting Professor, Stony Brook New York, September 2, 2008.
97. **Orenstein WA**. Influenza Pandemics. Primary Care Grand Rounds. SUNY Visiting Professor, Stony Brook New York, September 3, 2008.
98. **Orenstein WA**. Vaccination – Successes and Stresses. SUNY Visiting Professor, Stony Brook New York, September 3, 2008.
99. **Orenstein WA**. Vaccine Safety Issues. SUNY Visiting Professor, Stony Brook New York, September 3, 2008.
100. **Orenstein WA**. Vaccines and Disease Eradication. SUNY Visiting Professor, Stony Brook New York, September 3, 2008.
101. **Orenstein WA**. Influenza Vaccinations: Successes and Failures. Joint Pediatric and Adult ID Conference. SUNY Visiting Professor, Stony Brook New York, September 4, 2008.
102. **Orenstein WA**. Supporting Global Immunization – a Humanitarian Interest and a Self Interest, Pediatric Grand Rounds, Egleston Children’s Hospital, Atlanta Georgia, April 4, 2012.
103. **Orenstein WA**. Polio Eradication: *Progress, Problems, and Promise*. Infectious Diseases Seminar, Emory University, Atlanta Georgia, March 28, 2013.
104. **Orenstein WA**. Supporting Global Immunization – a Humanitarian Interest and a Self Interest. Resident, Fellow, and Faculty Lecture, Children’s Hospital, Los Angeles California, June 13, 2013.
105. **Orenstein WA**. Polio Eradication: *Progress, Problems, and Promise*. Pediatric Grand Rounds, Children’s Hospital, Los Angeles California, June 14, 2013.
106. **Orenstein WA**. Vaccine Advocacy and the Threat of Anti-Vaccination Beliefs. Infectious Diseases Grand Rounds, Children’s Hospital, Los Angeles California, June 14, 2013.

107. **Orenstein WA.** Universal Influenza Vaccination: Promise, Problems, Progress. 29th Annual Immunize Georgia Conference, Calloway Gardens Georgia, September 12, 2013.
108. **Orenstein WA.** Universal Influenza Vaccination: Is it Possible? Clinical and Translational Research Seminar, the Research Institute, Nationwide Children's Hospital, Columbus Ohio, September 16, 2014.
109. **Orenstein WA.** Polio Eradication: Progress, Problems and Promise. Research Institute Retreat, Nationwide Children's Hospital, Columbus Ohio, September 17, 2014.
110. **Orenstein WA.** Vaccine History and Future Perspectives. Jonas Salk Centenary, City College of New York, New York New York, October 23, 2014.
111. **Orenstein WA.** Vaccine History and Future Perspectives. GH Foundations Invited Lecture Series, Bill & Melinda Gates Foundation, Seattle Washington, October 27, 2014.
112. **Orenstein WA.** Eradicating Polio: How the World's Pediatricians Can Help Stop This Crippling Illness Forever? School of Medicine Grand Rounds, Stony Brook University, Stony Brook New York, April 1, 2015.
113. **Orenstein WA.** Influenza Vaccination: Successes and Failures. Residents Talk, Stony Brook University, Stony Brook New York, April 1, 2015.
114. **Orenstein WA.** Eradicating Polio: How the World's Pediatricians Can Help Stop This Crippling Illness Forever. Pediatric Grand Rounds, Vanderbilt Children's Hospital, Nashville Tennessee, May 12, 2015.
115. **Orenstein WA.** Eradicating Polio: How the World's Pediatricians Can Help Stop This Crippling Illness Forever. Seminar, Emory Hope Clinic, Decatur Georgia, May 13, 2015.
116. **Orenstein WA.** Measles Overview. Bill & Melinda Gates Foundation, Global Good Disease Eradication, Seattle Washington, August 10, 2015.
117. **Orenstein WA.** Polio Eradication: Moving Toward the Endgame. Emory Vaccine Center, 3rd Friday, Atlanta Georgia, August 21, 2015.
118. **Orenstein WA.** Measles Epidemiology VPD: Vaccine Preventable Diseases, Bill & Melinda Gates Foundation, Seattle Washington, September 29, 2015.

119. **Orenstein WA.** Polio Eradication: Progress, Problems and Promise. Pediatric Grand Rounds, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, January 6, 2016.
120. **Orenstein WA.** Global Switch Progress. Scientific Seminar, Bill & Melinda Gates Foundation, Seattle Washington, May 16, 2016.
121. **Orenstein WA.** Vaccine Update. Bridging the Gap for Immunization, 23rd Annual Immunize Georgia Conference, Peachtree City Georgia, September 9, 2016.
122. Nathanson N, Hinman A, **Orenstein WA.** "We Were There" Series – Conquering Polio in America: The Cutter Incident and Beyond, CDC, January 25, 2017.
123. Cowger T, Pallansch M, **Orenstein WA,** Burns C. The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan, Bill & Melinda Gates Foundation, Polio Team Meeting, Seattle, Washington, May 24, 2017.
124. Kaja M, Bhaumik S, **Orenstein WA.** Emory Macaque Study Results, Bill & Melinda Gates Foundation, Polio Team Meeting, Seattle, Washington, May 24, 2017.
125. **Orenstein WA.** Vaccines: What they are, how they work, and how they are tested and licensed. Atlanta Science Tavern, Manuel's Tavern, Atlanta, Georgia, June 24, 2017.
126. **Orenstein WA.** IPV: Perspectives from Epidemiology and Clinical Studies, Bill & Melinda Gates Foundation, Polio Team Meeting, July 26, 2017.
127. **Orenstein WA.** Finishing the Job of Eradicating Polio and Sustaining Eradication. Global Health Sciences Grand Rounds, University of California, San Francisco, September 25, 2017.
128. **Orenstein WA.** Polio SAGE Working Group Update & Polio Vaccine Global Supply. PATH Scientific Advisory Board Meeting, Seattle, Washington, October 16, 2017.
129. **Orenstein WA,** Offit PA, Edwards KM. Hot Off the Press: What's New in Plotkin's Vaccines, 7th Edition. Vaccine Dinner Club, Emory University, Atlanta Georgia, October 24, 2017.
130. **Orenstein WA.** Ending an Infectious Disease Permanently: the Polio Eradication Effort – Progress and Lessons Learned. Infectious Diseases Seminar, Emory University, Atlanta Georgia, November 9, 2017.
131. **Orenstein WA.** Influenza Vaccination: Successes and Failures, Infectious Diseases Fellow Seminar, Emory University, Atlanta Georgia, February 8, 2018.

132. **Orenstein WA.** Polio Eradication: Progress, Remaining Challenges, and Research to Address Them. Emory Vaccine Center, 3rd Friday, Atlanta Georgia, March 16, 2018.
 133. **Orenstein WA.** Vaccinology. Georgia AAP Pediatric Infectious Disease and Immunization Conference. Atlanta, Georgia, March 24, 2018.
 134. Keyserling H, **Orenstein WA**, Pickering L. This Just In: Hot topics in Immunizations and ACIP Update. Georgia AAP Pediatric Infectious Disease and Immunization Conference. Atlanta, Georgia, March 24, 2018.
 135. **Orenstein WA.** A Diagonal Approach – Eliminating Measles and Building Health Systems. Keynote Speaker, 10th Annual Vaccine Day, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, April 27, 2018.
28. Invitations to National or International Conferences:
1. **Orenstein WA**, Doster SW, Bart KJ, et al. Epidemiology of rubella and its complications. In: Proceedings of the symposium "Conquest of Agents that Endanger the Brain," sponsored by the National Institute of Mental Health, Office of Prevention; Centers for Disease Control; and Johns Hopkins School of Hygiene and Public Health. Baltimore Maryland, October 28-29, 1982.
 2. **Orenstein WA.** Zoster immune globulin and surveillance of varicella. Presented at the 11th Annual Immunization Conference, St. Louis Missouri, March 2-3, 1976.
 3. **Orenstein WA.** Surveillance of measles and new strategy for measles outbreak control. Presented at the 11th Annual Immunization Conference, St. Louis Missouri, March 2-3, 1976.
 4. **Orenstein WA.** Measles Outbreak Control. Presented at the 12th Annual Immunization Conference, Atlanta Georgia, May 23-26, 1977.
 5. **Orenstein WA**, Ross L, Overturf, GD, et al. Parenteral antibiotics in acute shigellosis. Presented at the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston Massachusetts, October 2-4, 1979.
 6. **Orenstein WA**, Heseltine, P.N.R., Lagagnoux, S.J., et al. Rubella vaccine and hospital employees. Presented at the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston Massachusetts, October 2-4, 1979.
 7. **Orenstein WA**, Overturf GD, Leedom JM. Relative frequency of Legionnaires Disease in children hospitalized with pneumonia. Presented at the 20th Interscience Conference

on Antimicrobial Agents and Chemotherapy, New Orleans Louisiana, September 22-24, 1980.

8. **Orenstein WA.** Measles vaccine efficacy versus age of vaccination. Presented at the 16th Annual Immunization Conference, Atlanta Georgia, May 18-21, 1981.
9. **Orenstein WA, Sirotkin B, Bernier RH, Orenstein DR.** Evaluation of vaccine efficacy in case-control studies. Presented at the 109th annual meeting of the American Public Health Association, Los Angeles California, November 1-5, 1981.
10. **Orenstein, WA, Greaves, WL, Bart, KJ, Hinman, AR.** Prospects for rubella elimination. Presented at the 17th Annual Immunization Conference, Atlanta Georgia, May 18-19, 1982.
11. **Orenstein WA, Marks JS, Hogue CR.** Vaccine efficacy: A new application of case control and case exposure methodology presented at the Society for Epidemiologic Research, Cincinnati Ohio, June 16-18, 1982.
12. **Orenstein WA, Bernier R, Bart KJ, et al.** Massachusetts serosurvey. Presented at the 18th Annual Immunization Conference, Atlanta Georgia. May 16-19, 1983.
13. **Orenstein WA, Brink EW, Bart KJ.** Adult Immunization. Presented at the 18th Annual Immunization Conference, Atlanta Georgia. May 16-19, 1983.
14. **Orenstein WA, Herrmann KL, Bernier RH, et al.** Measles immunity in Massachusetts schoolchildren. Presented at the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Las Vegas Nevada. October 24-26, 1983.
15. **Orenstein WA, Herrmann KL, Bernier RH, et al.** Measles Immunity in Massachusetts schoolchildren. Presented at the 111th Annual meeting American Public Health Association, Dallas Texas. November 13-17, 1983.
16. **Orenstein WA, Herrmann KL, Holmgreen P, et al.** Prevalence of rubella antibodies in Massachusetts Schoolchildren. Presented at the 24th Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington D.C., October 8-10, 1984.
17. **Orenstein WA, Markowitz L, Preblud SR, Hinman AR, Tomasi A, Bart KJ.** Appropriate Age for Measles Vaccination in the United States. Presented at the 19th IABS Congress on "Use and Standardization of Combined Vaccines", Amsterdam The Netherlands, December 10-13, 1985.
18. **Orenstein WA, Herrmann K, Albrecht P, Bernier R, Holmgreen P, Bart KJ, Hinman AR.** Immunity Against Measles and Rubella in Massachusetts Schoolchildren.

Presented at the 19th IABS Congress on "Use and Standardization of Combined Vaccines", Amsterdam The Netherlands, December 10-13, 1985.

19. **Orenstein WA**, Albrecht P, Herrmann KL, Holmgreen P, Bernier R, Bart KJ. Evaluation of low levels of measles antibody: Implications for measles elimination. Presented at the 25th Interscience Conference on Antimicrobial Agents and chemotherapy (ICAAC), Minneapolis Minnesota, September 29-October 2, 1985.
20. **Orenstein WA**, Hinman AR, Preblud SR, Markowitz LE. Additional strategies for measles elimination. Presented at the 21st Annual Immunization Conference, New Orleans Louisiana. June 8-11, 1987.
21. **Orenstein WA**, Markowitz LE, Preblud SR, Hinman AR. Measles in the United States. The results of a single dose vaccination policy. Presented at the XI Scientific meeting of the International Epidemiological Association, Helsinki Finland, August 8-13, 1987.
22. **Orenstein WA**. Ends of the Spectrum. Presented at the 22nd Annual Immunization Conference, San Antonio Texas, June 20-24, 1988.
23. **Orenstein WA**, Markowitz LE, Preblud SR, et al. Strategies for Measles Elimination - 1988. Presented at the 22nd Annual Immunization Conference, San Antonio Texas, June 20-24, 1988.
24. **Orenstein WA**, Allman KC, Eddins D, et al. Preschool Immunization - 1988. Presented at the 22nd Annual Immunization Conference, San Antonio Texas, June 20-24, 1988.
25. **Orenstein WA**, Wassilak SGF, DeForest A, et al. Seroprevalence of Poliovirus Antibodies Among Massachusetts Schoolchildren. Presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles California, October 23-26, 1988.
26. **Orenstein WA**, Markowitz LE, Hersh BS, et al. Measles Elimination - An Elusive Goal. Presented at the Annual Meeting of the American Epidemiological Society, Tampa Florida, March 16-17, 1989.
27. **Orenstein WA**, Bernier RH. Delivering Vaccines to Young Children. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting, Orlando Florida, October 6, 1994.
28. **Orenstein WA**. Potential Opportunities for Persons with Pediatric Infectious Diseases Training in Public Health. Presented at PIDS Strategic Development and Long Range Planning Committee Meeting., Dallas Texas, April 12-13, 1995.

29. **Orenstein WA.** Immunization in Our Town. Presented at the 29th National Immunization Conference, Los Angeles California, May 15-19, 1995.
30. **Orenstein WA,** Grabowsky M, Dini E. Overview of Key Strategies for Improving Immunization Levels. Presented at the 29th National Immunization Conference, Los Angeles California, May 15-19, 1995.
31. **Orenstein WA,** Sutter RW, Izurieta HI, Strebel PM. Current Status of Poliomyelitis in the United States. Presented at the IOM/CDC Workshop on Poliomyelitis Vaccines, June 7-8, 1995.
32. **Orenstein WA.** Opening Address. 30th National Immunization Conference, Washington DC, April 9, 1996.
33. **Orenstein WA.** Opening Address. 31st National Immunization Conference, Detroit Michigan, May 19, 1997.
34. **Orenstein WA.** Opening Address. 32nd National Immunization Conference, Atlanta Georgia, July 21, 1998.
35. **Orenstein WA.** Opening Address. 33rd National Immunization Conference, Dallas Texas, June 21, 1999.
36. **Orenstein WA.** The Role of State Immunization Laws in the Immunization System of the United States. Presented at the 1st Global Conference on Vaccines and Immunization into the Next Millennium, The University of Manchester, Manchester UK, 6-9 September 1999.
37. **Orenstein WA.** Opening Address. 34th National Immunization Conference, Washington DC, July 5, 2000.
38. **Orenstein WA,** Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. After polio: global eradication of measles? Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting, Toronto Canada, September 17-20, 2000.
39. **Orenstein WA.** The National Immunization Program: Achieving Prevention Opportunities Now and in the Future. Presented at the APHA Meeting, Boston Massachusetts, November, 2000.
40. **Orenstein WA,** Pless R, Chen R. Current Approaches to Post-Marketing Vaccine Safety. Presented at the Vaccine Safety Meeting, November 14-15, 2000.

41. **Orenstein WA.** Vaccines: Key Issues in Immunization. Presented at the 13th Annual Infectious Diseases in Children's Symposium, New York New York, November 18, 2000.
42. **Orenstein WA.** Immunization Safety Review Committee, Institute of Medicine, Charge to the Committee. Presented at the IOM Immunization Safety Review Committee Meeting, Washington DC, January 11, 2001.
43. **Orenstein WA.** Immunization Across the Lifespan. Presented at the ASTHO/AAP Coalition Meeting, Washington DC, January 16, 2001.
44. **Orenstein WA.** Welcome to Denver! Immunization Program Managers Meeting. Presented at the Immunization Program Managers Meeting, Washington DC, February 12-15, 2001.
45. **Orenstein WA.** Fragility of the Vaccine Supply. Presented at the NVAC Meeting, Washington DC, February 13, 2001.
46. **Orenstein WA.** Achieving Prevention – Opportunities Now and in the Future: Responding to the IOM Report. Presented at the IOM Committee on Immunization Financing, Washington DC, February 26, 2001.
47. **Orenstein WA.** More Overheads for COID. Presented at the Committee on Infectious Disease (COID) Meeting, Chicago Illinois, March 31, 2001.
48. **Orenstein WA.** Td Shortage. Presented at the Committee on Infectious Disease (COID) Meeting, Chicago Illinois, March 31, 2001.
49. **Orenstein WA.** ITP Following MMR Immunization. Presented at the Committee on Infectious Disease (COID) Meeting, Chicago Illinois, March 31, 2001.
50. **Orenstein WA.** Meeting: ACIP. Presented at the Committee on Infectious Disease (COID) Meeting, Chicago Illinois, March 31, 2001.
51. **Orenstein WA.** Polio Eradication. Presented at the EIS 50th Anniversary Scientific Program, Atlanta Georgia, April 21, 2001.
52. **Orenstein WA.** Vaccines – Myths and Realities. Presented at the National Infant Immunization Week (NIIW), Children's Hospital, Newark New Jersey, April 24-25, 2001.
53. **Orenstein WA.** Vaccines of Today and Tomorrow. Presented at the National Infant Immunization Week (NIIW), The Robert Wood Johnson School of Medicine and Dentistry, New Jersey, April 24-25, 2001.

54. **Orenstein WA.** Opening Address: Immunizations – Providing Protection. 35th National Immunization Conference, Atlanta Georgia, May 29, 2001.
55. **Orenstein WA.** Never a Null Moment: Epidemiology in the World of Vaccine-Preventable Diseases. Presented at the 2001 Conference of Epidemiology in Toronto Canada, June 15, 2001.
56. **Orenstein WA.** Update on the Global Eradication of Polio. Presented at the 2001 Annual Meeting of the American Academy of Pediatrics in San Francisco California, October 22, 2001.
57. **Orenstein WA.** Vaccine Update: Current Recommendations for the Pediatrician. Presented at the 2001 Annual Meeting of the American Academy of Pediatrics in San Francisco California, October 23, 2001.
58. **Orenstein WA.** Overview of Immunization and Health Disparity Issues and the Potential Public Health Implications in the United States. Presented at the National Foundation for Infectious Diseases Summit in San Francisco California, October 24, 2001.
59. **Orenstein WA.** Immunization Update 2001: Hot Issues in Immunization. Presented at the 14th Annual Infectious Diseases in Children Symposium, New York New York, November 18, 2001.
60. **Orenstein WA.** Elimination of Endemic Measles: The United States Experience. Presented in Korea, December 4, 2001.
61. **Orenstein WA.** NIP Strategies and Plans. Presented in Korea, December 6, 2001.
62. **Orenstein WA.** History and Epidemiology of Global Smallpox Eradication. Presented at the Smallpox Response Team Training Course, Atlanta Georgia, January 9, 2002.
63. **Orenstein WA.** Immunization Finance. Presented at the IOM Workshop on Immunization Finance, Los Angeles California, January 17, 2002.
64. **Orenstein WA.** National Immunization Goals. Presented at the 2002 Program Manager’s Meeting, Atlanta Georgia, January 22, 2002.
65. **Orenstein WA.** National Immunization Program Report to the National Vaccine Committee. Presented at the National Vaccine Committee Meeting, Washington DC, February 5, 2002.

66. **Orenstein WA.** Reaching New Heights in Immunizations. Presented at the AAP / ASTHO Coalition Meeting, Washington DC, February 7, 2002.
67. **Orenstein WA.** Vaccine Supply – CDC Concerns. Presented at the Vaccine Supply Meeting, Washington DC, February 11, 2002.
68. **Orenstein WA.** National Immunization Program Report to the Advisory Committee on Immunization Practices. Presented at the ACIP Meeting, Atlanta Georgia, February 21, 2002.
69. **Orenstein WA.** The National Immunization Program. Presented at the IOM Committee on Vaccine Purchase Finance, Washington DC, March 11-12, 2002.
70. **Orenstein WA.** “Calling the Shots”: A Great Success. Presented at the IOM Meeting, Washington DC, March 18, 2002.
71. **Orenstein WA.** 2002 Program Review. CDC, Atlanta Georgia, March 25, 2002.
72. **Orenstein WA.** Immunization – Successes, Promises and Challenges. Presented at the National Infant Immunization Week, Albuquerque New Mexico, April 15, 2002.
73. **Orenstein WA.** Make Every Visit Count. Media Kick off Event at the National Infant Immunization Week, Albuquerque New Mexico, April 15, 2002.
74. **Orenstein WA.** Speech – Launch Hispanic PSA Campaign Media Kick off Event at the National Infant Immunization Week, Albuquerque New Mexico, April 15, 2002.
75. **Orenstein WA.** Opening Address: The Year in Review. 36th National Immunization Conference, Denver Colorado, April 29, 2002.
76. **Orenstein WA.** The National Influenza Vaccine Summit, Atlanta Georgia, May 22-23, 2002.
77. **Orenstein WA.** Clinical, Diagnostic and Epidemiologic Features of Smallpox. Presented at the Smallpox Partners Meeting, Marriott Marquis, Atlanta Georgia, May 30, 2002.
78. **Orenstein WA.** Clinical, Diagnostic and Epidemiologic Features of Smallpox. Presented at the ACIP Meeting, Atlanta Georgia, June 18, 2002.
79. **Orenstein WA.** Clinical, Diagnostic and Epidemiologic Features of Smallpox. Presented at the DHHS Region IV Smallpox Meeting, Washington DC, August 15-16, 2002.

80. **Orenstein WA.** PHPS Orientation. Public Health Prevention Specialists Fall Course. Bellsouth Conference Center, Atlanta Georgia, September 19, 2002.
81. **Orenstein WA.** The Impact of Global Immunization Programs. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting, San Diego California, September 27, 2002.
82. **Orenstein WA.** Preparing for a Smallpox Emergency (Status as of October 18, 2002). Presented to the Committee on Infectious Diseases (COID), Boston Massachusetts, October 19, 2002.
83. **Orenstein WA.** Growing, Connecting and Protecting through Immunization Registries. Presented at the Immunization Registry Conference, Philadelphia Pennsylvania, October 21, 2002.
84. **Orenstein WA.** Immunization Update – 2002: Hot Topics in Immunization. Presented at the 15th Annual Infectious Diseases in Children Symposium, New York New York, November 17, 2002.
85. **Orenstein WA.** Smallpox Vaccination: Federal Activities. Presented at the NVAC Meeting, Washington DC, February 5, 2003.
86. **Orenstein WA.** Looking Forward – Immunization 2003. Presented at the AAP/ASTHO Coalition Meeting, Washington DC, February 12, 2003.
87. **Orenstein WA.** Looking Forward – Immunization 2003. Presented at the ACIP Meeting, Atlanta Georgia, February 26-27, 2003.
88. **Orenstein WA.** Immunization Update: Looking Back at 2002, Looking forward at the Coming Year. Presented at the 37th Annual National Immunization Conference, 2003, Chicago Illinois, March 17-20, 2003.
89. **Orenstein WA.** Vaccine Safety, Risk Assessment and Risk Management. Presented at the COID Meeting, Washington DC, April 5-6, 2003.
90. **Orenstein WA.** Vaccines and Your Child. Presented at the WIC Parent Talk – NIIW Meeting, Los Angeles California, April 9-12, 2003.
91. **Orenstein WA.** The Ending Can be the Hardest Part: The Challenges of Disease Eradication. Presented at the NIIW, Los Angeles California, April 9-12, 2003.
92. **Orenstein WA.** The Impact of Global Immunization Programs. Presented at the NIIW, Los Angeles California, April 9-12, 2003.

93. **Orenstein WA.** Immunization – Preventing Serious Diseases in Children. Presented at the NIIW, Los Angeles California, April 9-12, 2003.
94. **Orenstein WA.** Hot Issues in Immunization. Presented at the NIIW, Los Angeles California, April 9-12, 2003.
95. **Orenstein WA.** Smallpox Epidemiology and Clinical Disease. Presented at the PAS Smallpox Symposium, Seattle Washington, May 4, 2003.
96. **Orenstein WA.** Vaccine Shortages – Cause and Effects. Presented at the PAS Smallpox Symposium, Seattle Washington, May 5, 2003.
97. **Orenstein WA.** Immunization Achievements. Presented at the Healthy People 2010 Progress Review Workgroup at the Centers for Disease Control, Atlanta Georgia, June 5, 2003.
98. **Orenstein WA.** National Smallpox Vaccination Program Update. Presented at the Public Health Law Conference, Sheraton Colony Square, Atlanta Georgia, June 16, 2003.
99. **Orenstein WA.** National Immunization Program Update. Presented at the ACIP, Atlanta Georgia June 18-19, 2003.
100. **Orenstein WA.** Overview of the National Immunization Program. Presented to the Korean Ministry of Health and Welfare, Republic of Korea in Atlanta Georgia, July 25, 2003.
101. **Orenstein WA.** Financing Vaccines in the 21st Century: Assuring Access and Availability. Presented at the IOM Vaccine Report on Vaccine Finance, Washington DC, July 28, 2003.
102. **Orenstein WA.** Healthy People 2010 Progress Review. Presented at the CDC Washington Office, Washington DC, August 20, 2003.
103. **Orenstein WA.** Immunization – Preventing Serious Diseases in Children. Presented to the Immunization Summit, Houston Texas, September 30, 2003.
104. **Orenstein WA.** National Immunization Program Report. Presented at the NVAC Meeting, Washington DC, October 7-8, 2003.
105. **Orenstein WA.** Progress in Meeting Healthy People 2010 Goals. Presented at the NVAC Meeting, Washington DC, October 7-8, 2003.
106. **Orenstein WA.** National Immunization Program Report. Presented at the ACIP

Meeting, Atlanta Georgia, October 16, 2003.

107. **Orenstein WA.** Protect yourself. Protect your loved ones. Get your flu vaccine!
Presented at the Influenza Flu Campaign, Indianapolis Indiana, October 22-23, 2003.
108. **Orenstein WA.** Influenza – A Preventable Burden. Presented at the Influenza Flu Campaign, Indianapolis Indiana, October 22-23, 2003.
109. **Orenstein WA.** Building on Your Success. Presented at the 2003 Registry Conference, Atlanta Georgia, October 27, 2003.
110. **Orenstein WA.** National Immunization Program Report. ACIP Presentation at COID Meeting, New Orleans Louisiana, November 2, 2003.
111. **Orenstein WA.** National Immunization Program Overview: Achievements and Challenges. Presented at the CDC Orientation for Health Officials, Atlanta Georgia, December 3, 2003.
112. **Orenstein WA.** Measles Elimination in the United States of America. Presented at the Measles Symposium, Tokoyo Japan, January 17, 2004.
113. **Orenstein WA.** An Overview of the Epidemic Intelligence Service. Presented at the St. Jude's / PIDS Microbial Research Conference, Memphis Tennessee, February 21, 2004.
114. **Orenstein WA.** Vaccine Safety: Issues, Approaches and Challenges. Frontiers in General Pediatrics, Atlanta Georgia, March 20-21, 2004.
115. **Orenstein WA.** The Challenges of Vaccine Preventable Diseases. Presented at the NIIW Meeting, New York Academy of Medicine, New York New York, April 22, 2004.
116. **Orenstein WA.** Influenza – 2003: A Year to Remember. Presented at the NIIW Meeting, New York Academy of Medicine, New York New York, April 22, 2004.
117. **Orenstein WA.** Hot Issues on Vaccine Safety. Presented at the Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 4, 2004.
118. **Orenstein WA.** Hot Topics in Immunization. Seminar 2 – Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 4, 2004
119. **Orenstein WA.** Reducing the Burden of Influenza. Presented at the Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 5, 2004.

120. **Orenstein WA.** Hot Topics in Immunization. Seminar 3 – Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 5, 2004
121. **Orenstein WA.** Smallpox – What You Need to Know. Presented at the Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 7, 2004.
122. **Orenstein WA.** Hot Topics in Immunization. Seminar 1 – Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 7, 2004.
123. **Orenstein WA.** Maximizing the Impact of Vaccines. Presented at the Pediatrics in the Islands – Clinical Pearls 2004, Maui Hawaii, July 8, 2004.
124. **Orenstein WA.** Vaccine Update. Presented at the Update and Intensive Review of Internal Medicine 2004, Department of Medicines of Columbia University Medical Center and Beth Israel Deaconess Medical Center, The Plaza, New York New York, August 1-7, 2004.
125. **Orenstein WA** and Halperin S. Moderators: Bridging the Generation Gap in Vaccines, 42nd Annual Infectious Disease Society of America (IDSA) Meeting, Boston Massachusetts, October 2, 2004.
126. **Orenstein WA.** Chairperson, Expert Review of estimated levels and trends of measles mortality: 1999-2003. World Health Organization – Immunization, Vaccines and Biologicals – Vaccine Assessment and Monitoring. Atlanta Georgia, January 12-13, 2005.
127. **Orenstein WA.** Flu Vaccine: What happened? How to avoid a repeat? John F. Kennedy School of Government/ the Commonwealth Fund Bipartisan Congressional Health Policy Conference, Fort Lauderdale Florida, January 13-15, 2005.
128. **Orenstein WA.** Adult Immunization – Successes, Promises and Challenges. Presented as the Keynote speaker at the 10th Annual Massachusetts Adult Immunization Conference, Worcester Massachusetts, April 26, 2005.
129. **Orenstein WA.** Vaccine Supply – The Best of Times, the Worst of Times. Presented at the 2005 Council of State and Territorial Epidemiologists (CSTE) Conference – Forging Collaborations and Partnerships to Support Public Health Practice. Albuquerque New Mexico, June 6, 2005.
130. **Orenstein WA.** Vaccine Shortages. Presented at the Southeastern Center for Emerging Biologic Threats (SECEBT) – Vaccines: Not Enough or Not Enough Time? Meeting, Memphis Tennessee, June 17, 2005.
131. **Orenstein WA.** Purchase Options for Influenza Vaccines in the Setting of Pandemic,

National Vaccine Advisory Committee/Pandemic Influenza Working Group Meeting, Washington DC, July 19, 2005.

132. **Orenstein WA.** Vaccine Financing. Visiting Professor, Merck, Inc., Philadelphia Pennsylvania, July 27, 2005.
133. **Orenstein WA** and Marcuse EK. Vaccine Safety Issues and Immunization Hesitancy. Seminar #S376, American Academy of Pediatrics' 2005 National Conference and Exhibition, Washington DC, October 10, 2005.
134. **Orenstein WA.** Vaccine Safety Controversies. General Session, American Academy of Pediatrics' 2005 National Conference and Exhibition, Washington DC, October 11, 2005.
135. **Orenstein WA** and Marcuse EK. Vaccine Safety Issues and Immunization Hesitancy. Seminar #S426, American Academy of Pediatrics' 2005 National Conference and Exhibition, Washington DC, October 11, 2005.
136. **Orenstein WA.** Vaccines – Hot Issues in Immunization. Keynote Presentation, 18th Annual Infectious Diseases in Children Symposium, New York City New York, November 19, 2005.
137. **Orenstein WA.** Expanding Annual Influenza Vaccination Beyond the Currently-Recommended Groups. LO: Featured Session, Programmatic Issues Track: Influenza Issues, the 40th National Immunization Conference (NIC) of CDC, Atlanta Georgia, March 9, 2006.
138. **Orenstein WA.** Adult Immunization – Past, Present and Future. MTP 047: Meet the Professor. American College of Physicians Annual Session, Philadelphia Pennsylvania, April 6-8, 2006.
139. **Orenstein WA.** The Adolescent Platform in Immunization. The University of California San Francisco presents the 39th Annual Advances & Controversies in Clinical Pediatrics, San Francisco California, June 1-3, 2006.
140. **Orenstein WA.** Influenza: Will it always be a crisis?. The University of California San Francisco presents the 39th Annual Advances & Controversies in Clinical Pediatrics, San Francisco California, June 1-3, 2006
141. **Orenstein WA.** Hot Issues and Controversies in Immunization. The University of California San Francisco presents the 39th Annual Advances & Controversies in Clinical Pediatrics, San Francisco California, June 1-3, 2006
142. **Orenstein WA.** Influenza Prevention through Vaccination – The Promise and Reality.

The 20th Annual Anna Zager Symposium and Lectureship in Pediatrics – Vaccinations in the 21st Century, Haifa Israel, October 18, 2006.

143. **Orenstein WA.** Dealing with Vaccine Safety Controversies – the Science and Does it Matter? The 20th Annual Anna Zager Symposium and Lectureship in Pediatrics – Vaccinations in the 21st Century, Haifa Israel, October 18, 2006.
144. **Orenstein WA.** The Vaccine System in the United States: From Vaccine Development to Licensure and Use. National Foundation for Infectious Diseases – Clinical Vaccinology Course, Atlanta Georgia, November 3-5, 2006.
145. **Orenstein WA.** Universal Influenza Vaccination in the United States: Are We Ready? Association of Immunization Managers Meeting, Atlanta Georgia, December 6-8, 2006.
146. **Orenstein WA.** Vaccination Financing – Potential Solutions. 2007 National Immunization Congress, Chicago Illinois, February 27, 2007.
147. **Orenstein WA.** Federal Funding – Perspective from a Former “Fed”. 2007 National Immunization Congress, Chicago Illinois, February 27, 2007.
148. **Orenstein WA.** Vaccination Against Influenza and the Risk of Avian Influenza. XXXII Congreso de la Asociación Mexicana de Infectología y Microbiología Clínica Xii Congreso de la Asociación Mexicana par el Estudio de las Infecciones Nosocomiales, Aguascalientes Mexico, March 9, 2007.
149. **Orenstein WA.** Vaccines – Post Approval Considerations. World Vaccine Congress 2007, Washington DC, March 22, 2007.
150. **Orenstein WA.** Immunization Session: Vaccine Financing. 27th Annual National Pediatric Infectious Disease Seminar, Atlanta Georgia, April 11-14, 2007.
151. **Orenstein WA.** Vaccine Safety Monitoring – Perspectives from a Former Immunization Program Director. Vaccine Safety Datalink National Meeting, Atlanta Georgia, April 24-26, 2007.
152. **Orenstein WA.** Moving Vaccines to Vaccination: Achieving Optimal Control of Disease. The Dr. Charles Mérieux Award Lecture, Tenth Annual Conference on Vaccine Research, Baltimore Maryland, April 29-May 2, 2007.
153. **Orenstein WA.** Vaccine Safety Monitoring – Perspectives from a Former Immunization Program Director. Centers for Disease Control and Prevention Immunization Safety Office External Scientific Consultancy Meeting, Atlanta Georgia, May 10, 2007.

154. **Orenstein WA.** Vaccine Mandates: Benefits and Risks. The Stanley Plotkin Lecture, Eighth Advanced Vaccinology Course, Les Pensières France, May 23, 2007.
155. **Orenstein WA.** Vaccination – Infrastructure and Financing. Prophylactic Cancer Vaccine Policy Review Group Meeting, American Cancer Society, Washington DC, June 20, 2007.
156. **Orenstein WA.** Pediatric Immunization Financing (Summary of Discussion at the AAP/AMA Immunization Congress). Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP) Meeting, Atlanta Georgia, June 27, 2007.
157. **Orenstein WA.** Influenza Vaccine Policy and Development. Immunobiology of Influenza Virus Infection: Approaches for an Emerging Zoonotic Disease, University of Georgia, Athens Georgia, July 29-31, 2007.
158. **Orenstein WA.** Who’s Paying for Vaccines? Vaccine Education Symposium – CHOP Philadelphia Pennsylvania, September 15, 2007.
159. **Orenstein WA.** Achieving and Maintaining Polio Eradication. Polio Immunization: Moving Forward NIH, NIAID, Bethesda Maryland, September 19-20, 2007.
160. **Orenstein WA.** Vaccine Preventable Diseases: Why They Haven’t Gone Away. Infectious Disease Society of America Meeting, San Diego California, October 4, 2007.
161. **Orenstein WA.** A Tale of Two Vaccine Safety Concerns Rotashield (Original Rotavirus Vaccine) –Thimerosal. American Medical Writers Association Meeting, Atlanta Georgia, October 11, 2007.
162. **Orenstein WA.** Vaccines. Keynote: 20th Annual Infectious Diseases in Children Symposium, New York New York, October 20, 2007.
163. **Orenstein WA.** What is Needed to Address Immunization Issues? AAP NCE Seminar #472, Immunizations: Issues Facing Pediatricians in 2008, San Francisco California, October 30, 2007.
164. **Orenstein WA.** Recent Outbreaks and Local Conflicts over Vaccination. Global Challenge of Vaccination: Legal Challenges, Ethical Conundrums, Tokyo Japan, December 20, 2007.
165. **Orenstein WA.** Draft Priorities of the National Vaccine Plan. Institute of Medicine, Washington DC, March 3, 2008.
166. **Orenstein WA.** Vaccination – Successes and Stresses. Merck & Co National Meeting, Atlanta Georgia, March 4, 2008.

167. **Orenstein WA.** Measles and Measles Vaccine: USA and Internationally. 42nd National Immunization Conference, Atlanta Georgia, March 18, 2008.
168. **Orenstein WA.** Waning Immunity. International Conference on Emerging Infectious Diseases 2008, Atlanta GA, March 19, 2008.
169. **Orenstein WA.** Vaccination – Successes and Stresses. STATE OF THE ART LECTURE, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando Florida, April 2, 2008.
170. **Orenstein WA.** Managing public health decisions in the face of vaccine safety uncertainty: The examples of Rhesus rotavirus vaccine and thimerosal. Pediatric Academic Societies & Asian Society for Pediatric Research 2008 Joint Meeting, Honolulu Hawaii, May 6, 2008.
171. **Orenstein WA.** The challenges of the global conquest of meningococcus. Meningococcus Scientific Exchange Meeting, Siena Italy, July 2, 2008.
172. **Orenstein WA.** Ensuring willingness to be vaccinated: the content of advocacy programmes. Evaluating the Acceptability of Vaccine and Vaccination Programmes: An Individual and Public Health Perspective, Le Pensières France, July 7-9, 2008.
173. **Orenstein WA.** Vaccine Safety. National Medical Association Annual Convention and Scientific Assembly – Pediatric Section – Immunization Symposium, Atlanta Georgia, July 30, 2008.
174. **Orenstein WA.** Vaccines, Operationalization of Pandemic Plans – from Plan to Action Influenza A (H1N1) - Lessons learned and preparedness for the future- Cancun Quitana Roo Mexico, July 3, 2009.
175. **Orenstein WA.** Keynote Speaker: Polio, presented at the 3rd Global Vaccine Congress held in Singapore, October 4-6, 2009.
176. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Atlanta Georgia, November 13, 2009.
177. **Orenstein WA.** Vaccines for Developing Countries. 6th World Congress of the World Society for Pediatric Infectious Diseases – WSPID Plenary Symposium I, Buenos Aires Argentina, November 19, 2009.

178. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, San Diego California, March 2010.
179. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Bethesda Maryland, November 2010.
180. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Chicago Illinois, March 2011.
181. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Atlanta Georgia, November 4, 2011.
182. **Orenstein WA.** The Polio Endgame – Securing Eradication. Pedicon 2012, Gurgaon India, January 21, 2012.
183. **Orenstein WA.** Polio Eradication – an Overview. DoVC Partners Meeting, Bill & Melinda Gates Foundation, Washington DC, February 14, 2012.
184. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Chicago Illinois, March 12, 2012.
185. **Orenstein WA.** An Overview of Vaccinology, South Dakota Public Health Conference, Sioux Falls South Dakota, June 7-8, 2012.
186. **Orenstein WA.** Act Locally, Think Globally: The Role of Immunization in Georgia to our Community and to the World, 19th Annual Georgia Immunization Conference, Macon Georgia, September 13, 2012.
187. **Orenstein WA.** Polio and Measles Eradication: Promise, Problems, and Progress, Closing Plenary, Infectious Disease Society of America, San Diego California, October 21, 2012.
188. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Miami Florida, November 2, 2012.
189. **Orenstein WA.** Critical issues with regard to existing polio vaccines, Adjuvanted IPV Program – Bill & Melinda Gates Foundation, London England, November 30, 2012.
190. **Orenstein WA.** Keynote Address: An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Chicago Illinois, March 8, 2013.

191. **Orenstein WA.** Symposium 2: Measles and rubella – will they ever be eradicated? 16th Annual Conference on Vaccine Research, Sponsored by the National Foundation for Infectious Diseases, Baltimore Maryland, April 22, 2013.
192. **Orenstein WA.** Supporting Global Immunization – a Humanitarian Interest and a Self Interest, California AAP Meeting, Squaw Valley Lake Tahoe, May 5, 2013.
193. **Orenstein WA.** Universal Influenza Vaccination: Promise, Problems, Progress, California AAP Meeting, Squaw Valley Lake Tahoe, May 5, 2013.
194. **Orenstein WA.** An Overview of Vaccinology, California AAP Meeting, Squaw Valley Lake Tahoe, May 5, 2013.
195. **Orenstein WA.** Paediatric Infectious Disease and Immunology Course, Vaccination – Success, Hurdles, and Failure, Hong Kong Infectious Disease Week 2013, Hong Kong June 2013.
196. **Orenstein WA.** Paediatric Infectious Disease and Immunology Course, Vaccine Advocacy and the Threat of Anti-Vaccination Beliefs, Hong Kong Infectious Disease Week 2013, Hong Kong, June 2013.
197. **Orenstein WA.** Influenza Pathogenesis and Immunology Center (IPIRC) Center Update, 7th Annual CEIRS meeting, Memphis Tennessee, July 8-10, 2013.
198. **Orenstein WA.** Symposium 34: Polio Eradication. Vaccines in the Global Polio Eradication Initiative. IDWeek 2013, San Francisco California, October 3-6, 2013.
199. **Orenstein WA.** Polio – a vaccine prevented and a vaccine caused disease. Eradicating disease regardless of cause. Vaccine Safety Datalink (VSD) Annual Meeting, Centers for Disease Control and Prevention, Atlanta Georgia, November 5, 2013.
200. **Orenstein WA.** An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Cambridge Massachusetts, November 15-17, 2013.
201. **Orenstein WA.** Safety Considerations of switching from OPV to IPV and the safety of the use of IPV with other vaccines in combination in routine immunization. Safety of inactivated poliovirus vaccine session. WHO GACVS, Geneva Switzerland, December 11, 2013.
202. **Orenstein WA.** Global Polio Eradication Efforts: Are The Americas at Risk? ASTHO Infectious Disease Policy Committee Meeting, Webinar, January 21, 2014.

203. **Orenstein WA.** Polio Eradication –ending both a vaccine-preventable and vaccine-caused disease? Southern Infectious Disease Club at the 2014 Southern Regional Meeting, New Orleans Louisiana, February 20, 2014.
204. **Orenstein WA.** An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Seattle Washington, March 21-23, 2014.
205. **Orenstein WA.** Feery Oration: Polio Eradication: Progress, Problems, Promise and Lessons. National Immunisation Conference, Melbourne Australia, June 16, 2014.
206. **Orenstein WA.** Plenary 1: Coverage and Implementation Measles Elimination / Eradication - Using a “vertical program” to build a “horizontal one” – the US Experience. 14th National Immunisation Conference, Melbourne Australia, June 17, 2014.
207. **Orenstein WA** Keynote: Maternal Immunization - Assuring safety of mother and child, 2014 ISO Clinical Immunization Safety Assessment (CISA) Project annual scientific meeting, CDC, Atlanta Georgia, August 20, 2014.
208. **Orenstein WA.** An Overview of Vaccinology. Public Health Clinical Vaccinology Course, CDC, Atlanta Georgia, September 3, 2014.
209. **Orenstein WA.** Universal Influenza Vaccination: Is it Possible? Clinical and Translational Research Seminar, The Research Institute at Nationwide Children’s Hospital, Columbus Ohio, September 16, 2014.
210. **Orenstein WA.** Polio Eradication: Progress, Problems and Promise. The Research Institute Retreat, Nationwide Children’s Hospital, Columbus Ohio, September 17, 2014.
211. **Orenstein WA.** Let’s celebrate victory over polio: India’s challenges, achievements and goals. 5th Annual USA India Business Summit (UIBS), Atlanta Georgia, September 18, 2014.
212. **Orenstein WA.** Current and Future Vaccination Strategies, Desirable Vaccine Characteristics and Endpoints. Translational and Regulatory Science of Polio Vaccines and Antivirals Meeting, National Institutes of Health, Bethesda Maryland, September 22, 2014.
213. **Orenstein WA.** Vaccine History and Future Perspectives. Jonas Salk Centenary, City College of New York, New York New York, October 23, 2014.
214. **Orenstein WA.** Vaccines History and Future Perspectives. Gates Foundation Invited Lecture Series, Seattle Washington, October 27, 2014.

215. **Orenstein WA.** An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Houston Texas, November 7, 2014.
216. **Orenstein WA.** An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Houston Texas, November 7, 2014.
217. **Orenstein WA.** Polio Eradication: The Endgame Strategy. Infectious Disease in Children Symposium, New York New York, November 23, 2014.
218. **Orenstein WA.** An Overview of Vaccinology, Clinical Vaccinology Course, National Foundation for Infectious Diseases, Denver Colorado, March 13, 2015.
219. **Orenstein WA.** Influenza Vaccination: Successes and Failures. 12th Annual Georgia Emerging Infections Program Meeting, Atlanta Georgia, March 27, 2015.
220. **Orenstein WA.** Interventions for Reducing Parental Vaccine Refusal and Vaccine Hesitancy. Session 1110: Drop Your Assumptions and Pick Up the Evidence: Update on Strategies to Reduce Parental Vaccine Refusal and Hesitancy. Pediatric Academic Societies, San Diego California, April 25, 2015.
221. **Orenstein WA.** Measles Elimination/Eradiation - Using a “vertical program” to build a “horizontal one” – the US Experience. XVI Congreso Lationamericano de Infectología Pediátrica, LXII Congreso Anual Sociedad Puertorriqueña de Pediatría, San Juan Puerto Rico, June 27, 2015.
222. **Orenstein WA.** Polio Eradication: *Progress, Problems and Promise*. XVI Congreso Lationamericano de Infectología Pediátrica, LXII Congreso Anual Sociedad Puertorriqueña de Pediatría, San Juan Puerto Rico, June 27, 2015.
223. **Orenstein WA.** Key Drivers of Vaccine Innovation in the Developed World. Global Health 2035: Mission Grand Convergence meeting, Siena Italy, July 18, 2015.
224. **Orenstein WA.** Measles Overview, Global Good: The Science of Disease Eradication and Elimination, Bill & Melinda Gates Foundation, Seattle Washington, August 9-10, 2015.
225. **Orenstein WA.** Influenza Vaccination: It’s for all of us. Georgia AAP Pediatric Vaccine Symposium, Athens Georgia, August 22, 2015.
226. **Orenstein WA.** Reemergence of Vaccine Preventable Diseases. International Conference on Emerging Infectious Diseases (ICEID), Atlanta Georgia, August 25, 2015.

227. **Orenstein WA.** Legacy of Polio Resources. Third Center for Strategic and International Studies (CSIS) Polio Working Group Meeting, Washington DC, September 16, 2015.
228. **Orenstein WA.** An Overview of Vaccinology. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Bethesda Maryland, November 13, 2015.
229. **Orenstein WA.** Smallpox and Polio Eradication: commonalities, differences, and lessons learned for future eradication strategies. 9th World Congress of WSPID, Rio de Janeiro Brazil, November 20, 2015.
230. **Orenstein WA.** Polio Eradication: Problems, Progress, Promise. Children’s Hospital of Philadelphia (CHOP), Pediatric Grand Rounds, Philadelphia Pennsylvania, January 6, 2016.
231. **Orenstein WA.** Midterm Review Update: Global Measles and Rubella Strategic Plan 2012-2020. Meeting of Midterm Review Project Team and SAGE Working Group on Measles and Rubella, Johannesburg South Africa, March 13-14, 2016.
232. **Orenstein WA.** An Overview of Vaccinology. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Phoenix Arizona, March 18, 2016.
233. **Orenstein WA.** Polio Eradication: Problems, Progress, Promise. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Phoenix Arizona, March 18, 2016.
234. **Orenstein WA.** Immunizations in the US. American Academy of Pediatrics and the Japanese Pediatric Society, Sapporo Japan, May 13, 2016. (presented via webinar)
235. **Orenstein WA.** Midterm Review Update: Global Measles and Rubella Strategic Plan 2012-2020. Accelerating Progress Towards Measles and Rubella Elimination, Geneva Switzerland, June 21-23, 2016.
236. **Orenstein WA.** Vaccine Hesitancy in the United States. CHF-ICLEN – Advanced Vaccinology Course, Delhi India, June 10, 2016.
237. **Orenstein WA.** Polio Eradication Endgame: What are the next steps? CHF-ICLEN – Advanced Vaccinology Course, Delhi India, June 11, 2016.
238. **Orenstein WA.** Measles Vaccination: Reducing Serious Morbidity and Mortality While Strengthening Routine Immunization Programs. CHF-ICLEN – Advanced Vaccinology Course, Delhi India, June 12, 2016.

239. **Orenstein WA.** Polio Eradication Endgame: What are the next steps? CHF-ICLEN – Advanced Vaccinology Course, Delhi India, June 11, 2016.
240. **Orenstein WA.** Polio Eradication: Problems, Progress, Promise. 34th Annual Conference on Pediatric Infectious Diseases, Vail Colorado, July 31, 2016.
241. **Orenstein WA.** Measles Elimination/Eradiation – Using a “Vertical Program” to Build a “Horizontal One” – the US Experience. 34th Annual Conference on Pediatric Infectious Diseases, Vail Colorado, August 2, 2016.
242. **Orenstein WA.** Midterm Review Update: Global Measles and Rubella Strategic Plan 2012-2020. SAGE, Geneva Switzerland, August 2016.
243. **Orenstein WA.** Midterm Review Update: Global Measles and Rubella Strategic Plan 2012-2020. Accelerating Progress Towards Measles and Rubella Elimination, SAGE, Geneva Switzerland, October 2016.
244. **Orenstein WA.** Midterm Review Update: Global Measles and Rubella Strategic Plan 2012-2020. Accelerating Progress Towards Measles and Rubella Elimination, Advocacy Meeting, Geneva Switzerland, October 2016.
245. **Orenstein WA.** An Overview of Vaccinology. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Philadelphia, Pennsylvania, November 4-6, 2016.
246. **Orenstein WA.** Polio Eradication: Problems, Progress, Promise. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Philadelphia, Pennsylvania, November 4-6, 2016.
247. **Orenstein WA.** IPV: Perspectives from epidemiology and clinical studies. SAGE Polio Working Group, Geneva, Switzerland, February 6, 2017.
248. **Orenstein WA.** An Overview of Vaccinology. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Chicago, Illinois, March 9-12, 2017.
249. **Orenstein WA.** Polio Eradication: Problems, Progress, Promise. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Chicago, Illinois, March 9-12, 2017.
250. **Orenstein WA.** Epidemiologic Evaluations of Vaccine Effectiveness: Vaccine Study Designs. Vaccinology in Developing Countries Course, Aga Khan University sponsored in Dubai UAE, April 14-15, 2017.

251. **Orenstein WA.** Surveillance of Infection and Disease: Polio Eradication Example. Vaccinology in Developing Countries Course, Aga Khan University sponsored in Dubai UAE, April 14-15, 2017.
252. **Orenstein WA.** Access of Vaccine in LMIC and Considerations for Vaccine Introduction. Vaccinology in Developing Countries Course, Aga Khan University sponsored in Dubai UAE, April 14-15, 2017.
253. **Orenstein WA.** Risk Factors for Vaccine Failure. Vaccinology in Developing Countries Course, Aga Khan University sponsored in Dubai UAE, April 14-15, 2017.
254. **Orenstein WA.** Expanding the Polio Legacy to Future Generations at “Polio and Polio Vaccination: Present, Future and Beyond”, International Fellowship of Rotarian Healthcare Professionals (Celebrating 50 years), Rotary International & CDC, Atlanta, GA, June 9, 2017.
255. **Orenstein WA.** The Effects of Vaccine Confidence on the Immunization System: A Retrospective, Vaccine Confidence Meeting, Atlanta, Georgia, August 16, 2017.
256. **Orenstein WA.** Finishing the Job of Eradicating Polio and Sustaining Eradication. Webinar hosted by Health4TheWorld International Grand Rounds on Polio on World Polio Day, October 24, 2017.
257. **Orenstein WA.** An Overview of Vaccinology. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Bethesda, Maryland, November 3-4, 2017.
258. **Orenstein WA.** Polio Eradication: Problems, Progress, Promise. Clinical Vaccinology Course, National Foundation for Infectious Diseases, Bethesda, Maryland, November 3-4, 2017.
259. **Orenstein WA.** Value of NITAG Recommendations to an Immunization Program, to Government, to Key Partners, and to the Public. Advanced Seminar on Evidence-based Decision Making for Immunization, Chinese Center for Disease Control and Prevention with WHO, Beijing, China, December 12-14, 2017.
260. **Orenstein WA.** Influenza Case Study. Advanced Seminar on Evidence-based Decision Making for Immunization, Chinese Center for Disease Control and Prevention with WHO, Beijing, China, December 12-14, 2017.
261. **Orenstein WA.** The Role of Measles & Rubella Elimination in Development of the U.S. Immunization Program. Advanced Seminar on Evidence-based Decision Making for Immunization, Chinese Center for Disease Control and Prevention with WHO, Beijing, China, December 12-14, 2017.

262. **Orenstein WA.** Vaccine Innovation – Virtual live talk with Barbara Howe, GlaxoSmithKline Vaccines, 20th anniversary of the US vaccine business. Atlanta to Dallas Texas, February 28, 2018.
263. **Orenstein WA.** With Polio Eradication Succeeding, Should Measles Eradication Come Next? World Vaccine Congress, Washington, DC, April 5, 2018.
264. **Orenstein WA.** History of Vaccines. Chinese Vaccinology Course (CNVAC), University of Chinese Academy of Sciences, Beijing, China, July 30, 2018.
265. **Orenstein WA.** Herd Immunity – It’s Importance and How to Achieve It. Chinese Vaccinology Course (CNVAC), University of Chinese Academy of Sciences, Beijing, China, August 1, 2018.
29. Other Activities:
- a. Congressional Briefings:
- Orenstein WA.** National Immunization Program – Achievements and Challenges. Presented at Senate and Hill Briefings, Washington DC, August 5-6, 2003.
- Orenstein WA.** Stop the Flu – Give it your best shot. Influenza Briefing, Sponsored by Representative Majette, Senators Miller and Chambliss. Capitol Hill Rm HC-6, Washington DC, September 21, 2004.
- Orenstein WA** and Fukuda K. Pandemic Influenza 101. Sponsored by Representatives Gingrey and Scott and Senator Chambliss. Dirksen Senate Building, G11, Washington DC, March 8, 2005.
- Orenstein WA,** Offit P, and Hurvitz J. The Development and Distribution of Vaccines: Providing the Shot in the Arm to the Push for Immunization. Sponsored by *Health Affairs* and Alliance for Health Reform. Dirksen Senate Building, G50, Washington DC, May 23, 2005.
- Orenstein WA.** Avian Influenza. Democratic Health Care Task Force in the House of Representatives – Congressman Frank Pallone, Jr (NJ) – Chair. Washington DC, October 20, 2005.
- Orenstein WA.** 317 Funding needs. Every Child by Two with Bill Foege and Betty Bumpers. Washington DC, March 21, 2007.

b. Press Conferences:

Orenstein WA. Childhood Immunization Update. National Partnership for Immunization Congressional Briefing and National Immunization Awareness Month Press Conference, Washington DC, July 31, 2002.

Orenstein WA and Word BM. Racial Disparities and Immunization: An Unnecessary and Preventable Public Health Challenge. Presented in a National Press Briefing to the National Association of Black Journalists, Washington DC, August 8, 2003.

NFID/NCAI Annual Influenza/Pneumococcal Press Conference – National Press Club, Washington DC, September 23, 2004. **Orenstein WA.** Upcoming Influenza Season a Clear and Present Danger to High-risk.

AMA and National PTA Media Briefing – Back to School: Child and Adolescent Health, Scholastic Inc., New York New York, August 11, 2005. **Orenstein WA.** Give Children a Shot at the Future –Preventing Vaccine-Preventable Diseases.

c. Congressional Testimony:

Hearing on US Influenza Vaccine Supply, US House of Representatives – Committee on Government Reform – February 10, 2005. “Averting Future Influenza Vaccine Shortages”. Washington DC.

30. Bibliography

a. Published and accepted articles (clinical, basic science, other) in refereed journals:

1. From the NIH – Summary of the Presentations from Workshop. Current understanding of persistent viral infections and their implications in human disease. *J Infect Dis* 1976; 133(6):707-714. (See Presentations section)
2. Mills J, **Orenstein WA**, Cohen SN. Enteritis associated with pneumococci. *Am J Dis Child.* 1973; 126:244-245.
3. Modlin JF, **Orenstein WA**, Brandling-Bennett D. Current status of mumps in the United States. *J Infect Dis.* 1975; 132:106-109.
4. **Orenstein WA.** Immunizable diseases of childhood. *Urban Health* 1976; 51:22-23.
5. Landrigan PJ, Baker EL, Feldman RG, Cox DH, Eden KV, **Orenstein WA**, Mather JA, Yankel AJ, Von Lindern IH. Increased lead absorption with anemia and slowed nerve conduction in children near a lead smelter. *J Pediatrics.* 1976; 89:904-910.

6. Fraser DW, Tsai TR, **Orenstein WA**, Parkin WE, Beecham HJ, Shamar RJ, Harris J, Mallison GF, Martin GM, McDade JE, Sheperd CC, Brachman PS. Legionnaires' disease. Description of an epidemic. *New Eng J. Med.* 1977; 297:1189-1197.
7. **Orenstein WA**. Halsey NA, Hayden G, Eddins DL, Conrad JL, Witte JJ, Modlin JF, Prebuld SR, Nieberg PL, Hinman AR. Current status of measles in the United States. 1973-1977. *J Infect Dis.* 1978; 137:847-853.
8. Marks, JS, Halpin, T.J., **Orenstein WA**. Measles Vaccine Efficacy in Children Previously Vaccinated at 12 Months of Age. *Pediatrics* 1978; 62:955-960.
9. Shelton JD, Jacobson JE, **Orenstein WA**, Schulz KF, Donnel HD Jr. Measles Vaccine Efficacy: Influence of age at vaccination vs. duration of time since vaccination. *Pediatrics* 1978; 62:961-964.
10. Hayden GF, Prebuld SR, **Orenstein WA**, Conrad JL. Current Status of Mumps Vaccine in the United States. *Pediatrics* 1978; 62:965-969.
11. **Orenstein WA**, Irvin J, Jennings MR, Giandelia J, Halpin TJ, Mark SJS, Conrad JL. Measles in a rural Ohio county. *Am J Epidemiol.* 1980; 111:777-789.
12. **Orenstein WA**, Wu E, Wilkins J, Robinson K, Francis DP, Timko N, Wayne R. Simultaneous amebic liver abscess and hepatitis A. *Am J Gastroenterol.* 1981; 75:52-54.
13. **Orenstein WA**, Heseltine PNR, LeGagnoux SJ, Portnoy B. Rubella vaccine and susceptible hospital employees. Poor physician participation. *JAMA* 1981; 245:711-713.
14. **Orenstein WA**, Wu E, Wilkins J, Robinson K, Francis DP, Timko N, Wayne R. Hospital-Acquired Hepatitis A: Report of an Outbreak. *Pediatrics.* 1981; 67:494-497.
15. **Orenstein WA**, Heymann DL, Ellis RJ, Rosenberg RL, Nakano J, Halsey NA, Overturf GD, Hayden GF, Witte JJ. Prophylaxis of varicella in high-risk children: Dose response effect of zoster immune globulin. *J Pediatr.* 1981; 98:368-373.
16. **Orenstein WA**, Eddins DL, Hinman AR. Routine Immunizations. Guidelines to Antibiotic therapy. 1981; 7:1-3.
17. **Orenstein WA**, Overturf GD, Leedom JM, Alvarado R, Geffner M, Tryer A, Chan L, Hayes V, Starc T, Portnoy B. The frequency of Legionella infection

- prospectively determined in children hospitalized with pneumonia. *J Pediatr.* 1981; 99:403-406.
18. **Orenstein WA**, Ross L, Overturf GD, Wilkins J, Redfield DR, Underman A. Antibiotic treatment of acute shigellosis: Failure of cefamandole compared with trimethoprin/sulfamethoxazole and ampicillin. *Am J Med Sci.* 1981; 282:27-33.
 19. Goodman RA, **Orenstein WA**, Hinman AR. Vaccination and disease prevention for adults. *JAMA* 1982; 248:1607-1610.
 20. Marks JS, Hayden GF, **Orenstein, WA**. Methodologic issues in the evaluation of vaccine effectiveness. Measles vaccine at 12 vs. 15 months. *Am J Epidemiol.* 1982; 116:510-523.
 21. Goodman RA, Carder CC, Allen JR, **Orenstein WA**, Finton RJ. Nosocomial Hepatitis A: transmission by an adult patient with diarrhea. *Am J Med.* 1982; 73:220-226.
 22. Hinman AR, Eddins DL, Kirby CD, **Orenstein WA**, Bernier RH, Turner PM, Bloch AB. Progress in measles elimination. *JAMA* 1982; 247:1592-1595.
 23. Goodman RA, **Orenstein WA**, Munro TF, Smith SC, Sikes RK. Impact of Influenza A in a nursing home. *JAMA* 1982; 247:1451-1453.
 24. Amler RW, Bloch AB, **Orenstein WA**, Bart KJ, Turner TM JR, Hinman AR. Imported Measles in the United States. *JAMA* 1982; 248:2129-2133.
 25. Bloch AB, Amler RW, **Orenstein WA**, Bart KJ, Hinman AR. Status of measles elimination. *Pediatr Infect Dis.* 1982; 1:308-309.
 26. Greaves WL, **Orenstein WA**, Stetler HC, Preblud SR, Hinman AR, Bart KJ. Prevention of rubella transmission in medical facilities. *JAMA* 1982; 248:861-864.
 27. Hinman AR, Bart KJ, **Orenstein WA**, Preblud SR. Rational strategy for rubella vaccination. *Lancet* 1983; 1:39-41.
 28. Hinman AR, **Orenstein WA**, Bloch AB, Bart KJ, Eddins DL, Amler RW, Kirby CD. Impact of measles in the United States. *Rev Infect Dis.* 1983; 5:439-444.
 29. Langmuir AD, **Orenstein WA**. Current impact of measles: Summary. *Rev Infect Dis.* 1983; 5:474-476.

30. Hinman AR, Kirby CD, Eddins DL, **Orenstein WA**, Bernier RH, Turner PM, Bart KJ. Elimination of indigenous measles from the United States. *Rev Infect Dis.* 1983; 5:538-545.
31. Greaves WL, **Orenstein WA**, Hinman AR, Hersesian WS. Clinical efficacy of rubella vaccine. *Pediatr Infect Dis.* 1983; 2:284-286.
32. Bart KJ, **Orenstein, WA**, Hinman AR, Amler RW. Measles and Models. *Int J Epidemiol* 1983; 12:263-266.
33. Amler RW, Kim-Farley RJ, **Orenstein WA**, Doster SW, Bart KJ. Measles on Campus. *J Am Coll Health* 1983; 32:53-57.
34. **Orenstein WA**, Bart K J, Hinman AR, Preblud SR, Greaves WL, Doster SW, Stetler HC, Sirotkin B. The opportunity and obligation to eliminate rubella from the United States. *JAMA* 1984; 251: 1988-1994.
35. Preblud SR, **Orenstein, WA**, Bart KJ. Varicella: Clinical manifestations, epidemiology and health impact in children. *Ped Infect Dis* 1984; 3:505-509.
36. Kim-Farley RJ, Rutherford G, Lichfield P, HSU ST, **Orenstein WA**, Schonberger LB, Bart KJ, Liu KJ, Lin CC. Outbreak of paralytic poliomyelitis, Taiwan. *Lancet* 1984; 2:1322-1324.
37. Kim-Farley RJ, Bart KJ, Schonberger LB, **Orenstein WA**, Nkowane BM, Hinman AR, Kew OM, Hatch MH, Kaplan JE. Poliomyelitis in the USA: Virtual elimination of disease caused by wild virus. *Lancet* 1984; 2:1315-1317.
38. Wassilak SG, Bernier RH, Herrmann KL, **Orenstein WA**, Bart KJ, Amler R. Measles seroconfirmation using dried capillary blood specimens in filter paper. *Pediatr Infect Dis.* 1984; 3:117-121.
39. Serdula MK, Marks JS, Herrmann KL, **Orenstein WA**, Hull AD, Bomgaars MR. Therapeutic abortions following rubella infection in pregnancy: The potential impact on the incidence of congenital rubella syndrome. *Am J Public Health* 1984; 74:1249-1251.
40. Amler RW, **Orenstein WA**. Measles: Current status and outbreak control on campus. *J Am Coll Health* 1984; 33:64-66.
41. Preblud SR, **Orenstein WA**, Koplán JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. *Postgrad Med J* 1985; 61(suppl 4):17-22.

42. **Orenstein WA**, Preblud SR, Bart KJ, Hinman AR. Methods of assessing the impact of congenital rubella infection. *Rev Infect Dis* 1985; 7:S22-S28.
43. Bart KJ, **Orenstein WA**, Preblud SR, Hinman AR. Universal immunization to interrupt rubella. *Rev Infect Dis* 1985; 7:S177-S184.
44. Bart SW, Stetler HC, Preblud SR, Williams NM, **Orenstein WA**, Bart KJ, Hinman AR. Fetal risk associated with rubella vaccine: An update. *Rev Infect Dis* 1985; 7:S95-S102.
45. Amler RW, **Orenstein WA**. Measles in Young Adults: The case for vigorous pursuit of immunization. *Postgrad Med* 1985; 77:251-258,261.
46. Bart KJ, **Orenstein WA**, Preblud SR, Hinman AR, Lewis FL Jr, Williams NM. Elimination of rubella and congenital rubella from the United States. *Pediatr Infect Dis* 1985; 7:14-21.
47. Kim-Farley R, Bart S, Stetler HS, **Orenstein WA**, Bart K, Sullivan K, Halpin T, Sirotkin B. Clinical mumps vaccine efficacy. *Am J Epidemiol* 1985; 121:593-597.
48. Stetler HC, Garbe PL, Dwyer DM, Facklam RR, **Orenstein WA**, West GR, Dudley KJ, Bloch AB. Outbreaks of Group A Streptococcal abscesses following Diphtheria-Tetanus Toxoid-Pertussis Vaccination. *Pediatrics* 1985; 75:299-303.
49. Bloch AB, **Orenstein WA**, Ewing WM, Spain WH, Mallison GF, Hemann KL, Hinman AR. Measles outbreak in a pediatric practice: Airborne transmission in an office setting. *Pediatrics* 1985; 75:676-683.
50. White CC, Koplan JP, **Orenstein WA**. Benefits, risks and costs of immunization for measles, mumps and rubella. *Am J Public Health* 1985; 75:739-744.
51. Wassilak SG, **Orenstein WA**, Strickland PL, Butler CA, Bart KJ. Continuing measles transmission in students despite a school-based outbreak control program. *Am J Epidemiol* 1985; 122:208-217.
52. Jones EE, Kim-Farley RJ, Algunaid M, Parvez MA, Ballad YA, Hightower AW, **Orenstein WA**, Broome CV. Diphtheria: a possible foodborne outbreak in Hodeida, Yemen Arab Republic. *Bull World Health Organ* 1985; 63(2):287-293.
53. Bloch AB, **Orenstein WA**, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR. Health Impact of Measles Vaccination in the United States. *Pediatrics* 1985; 76:524-532.

54. Stetler HC, **Orenstein WA**, Bart KJ, Brink EW, Brennan JP, Hinman AR. History of Convulsions and use of pertussis vaccine. *J Pediatr* 1985; 107:175-179.
55. Hinman AR, Bart KJ, **Orenstein, WA**. New Vaccines. *Int J Epidemiol* 1985; 14:502-503.
56. Frank JA, Jr, **Orenstein WA**, Bart KJ, el-Tantawy N, Davis RM, Hinman AR. Major impediments to measles elimination. The modern epidemiology of an ancient disease. *Am J Dis Child* 1985; 139:881-888.
57. **Orenstein WA**, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B. Field evaluation of vaccine efficacy. *Bull World Health Organ* 1985; 63(6):1055-1068.
58. Stetler HC, Mullen JR, Brennan JP, **Orenstein WA**, Bart KJ, Hinman AR. Adverse events following immunization with DTP vaccine. *Dev Biol Stand* 1985; 61:411-421.
59. Davis RM, **Orenstein, WA**, Frank JA, Jr, Sacks JJ, Dales LG, Preblud SR, Bart KJ, Williams NM, Hinman AR. Transmission of Measles in Medical Settings. 1980 through 1984. *JAMA* 1986; 255:1295-1298.
60. Patriarca PA, Weber JA, Parker RA, **Orenstein WA**, Hall WN, Kendal AP, Schonberger LB. Risk factors for outbreaks of influenza in nursing homes. *Am J Epidemiol* 1986; 124:114-119.
61. Nkowane BM, Wassilak SGF, McKee PA, O'Mara DJ, Dellaportas S, Istre GR, **Orenstein WA**, Bart KJ. Pertussis epidemic in Oklahoma: Difficulties in preventing transmission. *Am J Dis Child* 1986; 140:433-437.
62. Stetler HC, **Orenstein WA**, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. *Pediatrics* 1986; 77:471-476.
63. **Orenstein WA**, Herrmann KL, Holmgren P, Bernier R, Bart KJ, Eddins DL, Fiumara NJ. Prevalence of rubella antibodies in Massachusetts schoolchildren. *Am J Epidemiol* 1986; 124:290-298.
64. **Orenstein WA**, Herrmann K, Albrecht P, Bernier R, Holmgren P, Bart KJ, Hinman AR. Immunity against measles and rubella in Massachusetts schoolchildren. *Dev Biol Stand* 1986; 65:75-83.

65. **Orenstein WA**, Markowitz L, Preblud SR, Hinman AR, Tomasi A, Bart KJ. Appropriate age for measles vaccination in the United States. *Dev Biol Stand* 1986; 65:13-21.
66. Bart KJ, **Orenstein WA**, Hinman AR. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles. *Dev Biol Stand* 1986; 65:45-52.
67. Cochi SL, Fleming DW, Hull HF, Preblud SR, **Orenstein WA**. Haemophilus influenzae b polysaccharide vaccine. Physician acceptance and use of a new vaccine. *Am J Dis Child* 1986; 140:1226-1230.
68. **Orenstein WA**, Albrecht P, Herrmann KL, Bernier R, Bart KJ, Rovira EZ. The plaque neutralization test as a measure of prior exposure to measles virus. *J Infect Dis* 1987; 155:146-149.
69. Sienko DG, Friedman C, McGee HB, Allen MJ, Simonson WF, Wentworth BB, Shope TC, **Orenstein WA**. A measles outbreak at university medical settings involving health care providers. *Am J Public Health* 1987; 77:1222-1224.
70. Davis RM, Markowitz LE, Preblud SR, **Orenstein WA**, Hinman AR. A cost-effectiveness analysis of measles outbreak control strategies. *Am J Epidemiol* 1987; 126:438-449.
71. Davis RM, Whitman ED, **Orenstein WA**, Preblud SR, Markowitz LE, Hinman AR. A persistent outbreak of measles despite appropriate prevention and control measures. *Am J Epidemiol* 1987; 126:438-449.
72. Markowitz LE, Tomasi A, Sirotkin BI, Carr RW, Davis RW, Preblud SR, **Orenstein WA**. Measles Hospitalizations, United States, 1977-84: comparison with national surveillance data. *Am J Public Health* 1987; 77:866-868.
73. Nkowane BM, Bart SW, **Orenstein, WA**, Baltier M. Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. *Am J Public Health* 1987; 77:434-438.
74. Funkhouser AW, Wassilak SG, **Orenstein WA**, Hinman AR, Moritmer EA Jr. Estimated effects of a delay in the recommended vaccination schedule for diphtheria and tetanus toxoids and pertussis vaccine. *JAMA* 1987; 257:1341-1346.
75. Nkowane BM, Wassilak SG, **Orenstein WA**, Bart KJ, Schonberger LB, Hinman AR, Kew OM. Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. *JAMA* 1987; 257:1335-1340.

76. Bart KJ, **Orenstein WA**, Hinman AR. The current status of immunization principles: recommendations for use and adverse reactions. *J Allergy Clin Immunol* 1987; 79:296-315 (erratum *J Allergy Clin Immunol* 1987; 79:975).
77. Hinman AR, Foege WH, de Quadros CA, Patriarca PA, **Orenstein WA**, Brink EW. The case for global eradication of poliomyelitis. *Bull World Health Organ* 1987; 65(6):835-840.
78. Stetler HC, Mullen JR, Brennan JP, Livengood JR, **Orenstein WA**, Hinman AR. Monitoring system for adverse events following immunization. *Vaccine* 1987; 5(3):169-174.
79. Patriarca PA, Laender F, Palmeira G, Oliveira MJ, Lima Filho J, Dantes MC, Cordeiro MT, Risi JB Jr, **Orenstein WA**. Randomized trial of alternative formulations of oral polio vaccine in Brazil. *Lancet* 1988; 27; 1(8583):429-433.
80. McLaughlin M, Thomas P, Onorato I, Rubinstein A, Oleske J, Nicholas S, Kasinski K, Guigli P, **Orenstein W**. Live virus vaccines in human immunodeficiency virus-infected children: a retrospective survey. *Pediatrics* 1988; 82(2):229-233.
81. Markowitz LE, Tomasi A, Hawkins CE, Preblud SR, **Orenstein WA**, Hinman AR. International measles importations United States, 1980-1985. *Int J Epidemiol* 1988; 17(1):187-192.
82. Hightower AW, **Orenstein WA**, Martin SM. Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. *Bull World Health Organ* 1988; 66(1):99-105.
83. Cochi SL, Preblud SR, **Orenstein WA**. Perspectives on the relative resurgence of mumps in the United States. *Am J Dis Child* 1988; 142(5):499-507.
84. Hinman AR, Koplan JP, **Orenstein WA**, Brink EW. Decision analysis and polio immunization policy. *Am J Public Health* 1988; 78(3):301-303.
85. Hinman AR, Koplan JP, **Orenstein WA**, Brink EW, Nkowane BM. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. *Am J Public Health* 1988; 78(3):291-295.
86. **Orenstein WA**, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. *Epidemiol Rev* 1988; 10:212-241.

87. Funkhouser AW, Wassilak SG, Hinman AR, **Orenstein WA**, Mortimer EA Jr. Age at pertussis immunization as it relates to current epidemiology and disease control. *Tokai J Exp Clin Med* 1988; 13 Suppl: 111-115.
88. Cochi SL, Edmonds LE, Dyer K, Greaves WL, Marks JS, Rovira EZ, Preblud SR, **Orenstein WA**. Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. *Am J Epidemiol* 1989; 129(2):349-361.
89. Markowitz LE, Preblud SR, **Orenstein WA**, Rovira EZ, Adams NC, Hawkins CE, Hinman AR. Patterns of transmission in measles outbreaks in the United States, 1985-1986. *N Engl J Med* 1989; 320(2):75-81.
90. Chen RT, Goldbaum GM, Wassilak SG, Markowitz LE, **Orenstein WA**. An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. *Am J Epidemiol* 1989; 129(1):173-182.
91. Livengood JR, Mullen JR, White JW, Brink EW, **Orenstein WA**. Family history of convulsions and use of pertussis vaccine. *J Pediatr* 1989; 115:527-31.
92. Hutchins SS, Escolan J, Markowitz LE, Hawkins C, Kimbler A, Morgan RA, Preblud SR, **Orenstein WA**. Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. *Pediatrics* 1989; 83:369-374.
93. Onorato IM, **Orenstein WA**, Hinman AR, Rogers MF, Koplan JP. Immunization of asymptomatic HIV-infected children with measles vaccine: assessment of risks and benefits. *Med Decis Making* 1989; 9:76-83.
94. Sutter RW, Brink EW, Cochi SL, Kew OM, **Orenstein WA**, Biellik RJ, Hinman AR. A new epidemiologic and laboratory classification system for paralytic poliomyelitis cases. *Am J Public Health* 1989; 79:495-498.
95. Hutchins SS, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, **Orenstein WA**, Hull HF. A school based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. *Am J Epidemiol* 1990; 132: 157-168.
96. **Orenstein WA**, Bernier RH. Surveillance. Information for action. *Pediatr Clin North Am* 1990; 37: 709-734.
97. Markowitz LE, **Orenstein WA**. Measles vaccines. *Pediatr Clin North Am* 1990; 7:603-625.

98. Slater PE, **Orenstein WA**, Morag A, Avini A, Handscher R, Green MS, Costin C, Yarrow A, Rishpon, S, Havkin O, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. *Lancet* 1990; 335:1192-5; discussion 1196-1198.
99. Hinman AR, **Orenstein WA**. Immunization practice in developed countries. *Lancet* 1990; 335(8691):707-710.
100. Schwartz J, Landrigan PJ, Baker EL Jr, **Orenstein WA**, von Lindern IH. Lead-induced anemia: dose-response relationships and evidence for a threshold. *Am J Public Health* 1990; 80:165-168.
101. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, **Orenstein WA**. Measles Antibody: Reevaluation of Protective Titers. *J Infect Dis* 1990; 162:1036-1042.
102. **Orenstein WA**, Atkinson W, Mason D, Bernier RH. Barriers to vaccinating preschool children. *J Health Care Poor Underserved* 1990; 1 (3):315-30.
103. Hersh BS, Markowitz LE, Hoffman RE, Hoff DR, Doran MJ, Fleishman JC, Preblud SR, **Orenstein WA**. A measles outbreak at a college with a prematriculation immunization requirement. *Am J Public Health* 1991; 81:360-364.
104. Novello AC, Wise PH, Kleinman DV, **Orenstein WA**, Sepe SI. From the Surgeon General, US Public Health Service. Healthy Children Ready to Learn--The Challenge to the Medical Community. *JAMA* 1991; 265:1364.
105. Weber DJ, Rutala WA, **Orenstein WA**. Prevention of mumps, measles, and rubella among hospital personnel. *J Pediatr* 1991; 119:322-326.
106. Chen RT, Moses JM, Markowitz LE, **Orenstein WA**. Adverse events following measles-mumps-rubella and measles vaccinations in college students. *Vaccine* 1991; 9:297-299.
107. Hinman AR, **Orenstein WA**, Mortimer EA Jr. When, where, and how do immunizations fail? *Ann Epidemiol* 1992; 2(6):805-812.
108. Atkinson WL, Hadler SC, Redd SB, **Orenstein WA**. Measles surveillance--United States, 1991. *MMWR CDC Surveill Summ (United States)* Nov 20 1992; 41 (6):1-12.
109. Markowitz LE, Albrecht P, **Orenstein WA**, Lett SM, Pugliese TJ, Farrell D. Persistence of measles antibody after revaccination. *J Infect Dis* 1992; 166 (1):205-208.

110. Cutts FT, **Orenstein WA**, Bernier RH. Causes of low preschool immunization coverage in the United States. *Annu Rev Public Health* 1992; 13:385-398.
111. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, **Orenstein WA**, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. *Clin Infect Dis* 1992; 14 (2):568-579.
112. Cutts FT, Zell ER, Mason D, Bernier RH, Dini EF, **Orenstein WA**. Monitoring progress toward US preschool immunization goals. *JAMA* 1992; 267 (14):1952-5.
113. Robertson SE, Markowitz LE, Berry DA, Dini EF, **Orenstein WA**. A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. *Public Health Rep* 1992; 107 (1):24-31.
114. Bernier RH, Dietz VJ, Lyons AE, McKnight HL, Mullen JH, Omara DJ, Bender K, Broome CV, Cary AH, Caserta VM, Fessler KA, Guerra FA, Gursky EA, Hutchins VL, Katz SE, Lenart JC, Lewin JC, Marcuse EK, McQuire ML, Mitchem F, Mortimer EA, Mountain KL, Nannis PW, Nora AH, Nye CH, Strain JE, Stevens D, Stubbs PE, Thompson FE, Vanburen RC, Dietz V, Bart KJ, Bernier R, **Orenstein WA**. Standards for Pediatric Immunization Practices. *JAMA* 1993; 269(N14):1817-1822.
115. **Orenstein WA**, Brugliera PD. Immunization in medical education. Preface. *Am J Prev Med*. 1994; 10 Suppl: v-viii.
116. **Orenstein WA**, Bernier RH. Crossing the divide from vaccine technology to vaccine delivery. The critical role of providers. *JAMA* 1994; 272:1138-1139.
117. **Orenstein WA**, Markowitz LE, Atkinson WL, Hinman AR. Worldwide measles prevention (review). *Isr J Med Sci* 1994; 30:469-481.
118. Dowdle WR, **Orenstein WA**. Quest for life-long protection by vaccination. *Proc Natl Acad Sci U S A* 1994; 91:2464-2468.
119. Haber M, **Orenstein WA**, Halloran ME, Longini Jr. IM. The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak. *Am J Epidemiol* 1995; 141(10):980-990
120. Cochi SL, **Orenstein WA**. Commentary: China's giant step toward the global eradication of poliomyelitis. *Pediatr Infect Dis J*. 1995, 14 (4):315-316.

121. **Orenstein WA**, Hadler S, Kuritsky JN, Bernier RH. Rotavirus vaccines - from licensure to disease reduction. *J Infect Dis* 1996; 174 (Suppl 1):S118-124.
122. Grabowsky M, **Orenstein WA**, Marcuse EK. The critical role of provider practices in under vaccination. *Pediatrics*. 1996; 97 (5):735-737.
123. **Orenstein WA**, Hadler S, Wharton M. Trends in Vaccine-Preventable Diseases. *Semin in Pediatr Infect Dis* 1997; Vol 8, No. 1:23-33
124. **Orenstein WA**. Rapporteur's Summary of the Symposium. Brown F, Greco D, Mastrantonio P, Salmaso S, Wassilak S: Pertussis Vaccine Trials. *Dev Biol Stand* 1997; 89:397-403.
125. Gershon AA, Gardner P, Peter G, Nichols K, **Orenstein W**. Quality standards for immunization. Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis* 1997; 25 (4):782-786.
126. Hadler SC, **Orenstein WA**. Public health application of acellular pertussis vaccines. *Dev Biol Stand* 1997; 89:355-361.
127. Weniger BR, Chen RT, Jacobson SH, Sewell EC, Deuson R, Livengood JR, **Orenstein WA**. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. *Vaccine* 1998; 16 (19):1885-1897.
128. **Orenstein WA**. Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. *Clin Infect Dis* 1999; 28 (Suppl 2):S147-S150.
129. **Orenstein WA**, Hinman AR. The immunization system in the United States – the role of school immunization laws. *Vaccine* 1999; Vol 17 (Suppl 3):S19-S24.
130. **Orenstein WA**, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. Measles eradication: is it in our future? *Am J Public Health* 2000; 90(10):1521-1525.
131. **Orenstein WA**, Rodewald LE. Successful control of vaccine-preventable diseases requires more than vaccines. *Am J Prev Med* 2000; 19(3S):13-14.
132. Cordero JF, **Orenstein WA**. Future of the national immunization survey. *Am J Prev Med* 2001; 20(4 Suppl):84-85.
133. Fine PE, Sutter RW, **Orenstein WA**. Stopping a polio outbreak in the post-eradication era. *Dev Biol* 2001; 105:129-47. Discussion: 149-150.

134. Schwartz B, **Orenstein WA**. Vaccination policies and programs: the federal government's role in making the system work. *Primary Care: Clinics in Office Practice* 2001; 28(4):697-711.
135. Gardner P, Pickering LK, **Orenstein WA**, Gershon AA, Nichol KL. Infectious Diseases Society of America. Guidelines for quality standards for immunization. *Clin Inf Dis* 2002; 35(S):503-511.
136. Hinman AR, **Orenstein WA**, Williamson DE, Darrington D. Childhood immunization: laws that work. *J Law Med Ethics* 2002; 30(3 Suppl):122-127.
137. Matthews GW, Murphy AM, Lopez W, **Orenstein WA**. Workshop on smallpox legal preparedness: what have we learned from smallpox legal preparedness? *J Law Med Ethics* 2003; 31(4 Suppl):S39-40.
138. **Orenstein WA**, Papania MJ, Wharton ME. Measles elimination in the United States. *J Infect Dis* 2004; 189 (Suppl 1):S1-3.
139. Hinman AR, **Orenstein WA**, Papania MJ. Evolution of measles elimination strategies in the United States. *J Infect Dis* 2004; 189 (Suppl 1):S17-22.
140. Hutchins SS, Papania MJ, Amler R, Maes EF, Grabowsky M, Bromberg K, Glasgow V, Speed T, Bellini WJ, **Orenstein WA**. Evaluation of the measles clinical case definition. *J Infect Dis* 2004; 189 (Suppl 1):S153-159.
141. Hinman AR, **Orenstein WA**, Rodewald L. Financing immunizations in the United States. *Clin Infect Dis* 2004; 38(10):1440-1446.
142. Santoli JM, Klein JO, Peter G, **Orenstein WA**. Disruptions in the supply of routinely recommended childhood vaccines in the United States. *Pediatr Infect Dis J* 2004; 23(6):553-534.
143. Meissner C, Strebel P, **Orenstein WA**. Measles vaccines and the potential for worldwide eradication of measles. *Pediatrics* 2004; 114(4):1065-1069.
144. Alexander LN, Seward J F, Santibanez TA, Pallansch MA, Kew OM, Prevots D R, Strebel PM, Cono J, Wharton M, **Orenstein WA**, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. *JAMA* 2004; 292(14):1696-1701.
145. Gazmararian JA, Buehler JW, Stephens DS, Dixon T, Elon L, Schild L, **Orenstein WA**, Koplan J. Impact of bioterrorism preparedness on the public health response to 2003-2004 influenza vaccine crisis. *Public Health Rep* 2005; 120(6):589.

146. **Orenstein WA**, Douglas RG, Rodewald LE, Hinman AR. U.S. Vaccines: Success, Structure and Stress. *Health Affairs* 2005; 24(3):599-610.
147. **Orenstein WA**. Introduction for the pharmacoeconomic impact of universal immunization in the United States. *Managed Care Consultant* 2005; 4(1):4.
148. Stephens DS, Zughair SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, **Orenstein WA**, Arnold K, Schuchat A, Farley, MM and the Georgia Emerging Infectious Program. Rapid decline of the incidence of macrolide resistance in *Streptococcus pneumoniae* following introduction of the pneumococcal conjugate vaccine: a population-based assessment. *Lancet* 2005; 365(9462):855-863.
149. Rodewald L, **Orenstein WA**, Mason DD, Cochi SL. Vaccine Supply Problems – A Centers for Disease Control Perspective. *Clin Infect Dis* 2006; 42(S2):S104-S110.
150. Gazmararian JA, **Orenstein WA**, Wortley P, Buehler J, Elon L, Koplan JP, Schild L, Dixon T, Stephens DS. Preventing Influenza: Vaccine Systems and Practices in the Southeast. *Public Health Rep* 2006; 121(6):684-694.
151. **Orenstein WA**. The role of measles elimination in development of a National Immunization Program. *Ped Infect Dis J* 2006; 25(12):1093-1101.
152. Coleman MS, Washington ML, **Orenstein WA**, Gazmararian JA, Prill MM. Interdisciplinary epidemiologic and economic research needed to support a universal childhood influenza vaccination policy. *Epidemiol Rev* 2006, 28:41-46. DOI: 10.1093/epirev/mxj008.
153. Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, **Orenstein W**, Stephens DS. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. *Vaccine* 2007; 25:5390-5398. doi:10.1016/j.vaccine.2007.04.088
154. Orenstein EW, DeSerres G, Haber MJ, Shay DK, Bridges C, Gargiullo P, **Orenstein WA**. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. *Int J Epidemiol*, 2007; 36(3):623-631.
155. Gazmararian JA, Coleman M, Prill M, Hinman AR, Ribner BS, Washington M, Janssen A, **Orenstein WA**. Influenza Vaccination of Health Care Workers: Policies and Practices of Hospitals in a Community Setting. *Am J Infect Control* 2007; 35(7):441-447

156. Strikas RA, Neff LJ, Cono J, Knutson D, Henderson J, **Orenstein WA**. US Civilian Smallpox Preparedness and Response Program, 2003. *Clin Infect Dis* 2008; 46 Suppl 3:S157-167.
157. Pazol K, Gazmararian JA, Prill MM, O'Malley EM, Jelks D, Coleman MS, Hinman AR, **Orenstein WA**. Private Pediatric Clinic Characteristics Associated with Influenza Immunization Efforts in the State of Georgia: A pilot Evaluation. *Open Health Serv Policy J*. 2008; 1:38-44.
158. **Orenstein WA**, Schaffner W. Lessons Learned: Role of Influenza Vaccine Production, Distribution, Supply, and Demand—What It Means for the Provider. *Am J Med* 2008; 121(7 Suppl 2):S22-27.
159. Salmon DA, Pan WK, Omer SB, Navar AM, **Orenstein W**, Marcuse EK, Taylor J, deHart MP, Stokley S, Carter T, Halsey NA. Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. *Hum Vacc* 2008; 4(4):286-291.
160. Swerdlow DL, Roper MH, Morgan J, Schieber RA, Sperling LS, Sniadack MM, Neff L, Miller JW, Curtis CR, Marin ME, Iskander J, Moro P, Hightower P, Levine NH, McCauley M, Heffelfinger J, Damon I, Török TJ, Wharton M, Mast EE, Mootrey GT; Smallpox Vaccine Cardiac Adverse Events Working Group. Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003. *Clin Infect Dis* 2008; 46 Suppl 3:S234-241.
161. Omer SB, Salmon DA, **Orenstein WA**, de Hart MP, Halsey N. Vaccine Refusal, Mandatory Immunization, and the Risks of Vaccine-Preventable Diseases. *New Engl J Med* 2009; 360:1981-1988.
162. Lindley MC, Shen AK, **Orenstein WA**, Rodelwald LE, Birkhead GS. Financing the delivery of vaccines to children and adolescents: challenges to the current system. *Pediatrics* 2009; 124(Suppl 5):S548-S557.
163. Birkhead GS, **Orenstein WA**, Almquist JR. Reducing financial barriers to vaccination in the United States: call to action. *Pediatrics* 2009; 124(Suppl 5): S451-S454.
164. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, Keyserling HL, Ploss A, Rice CM, **Orenstein WA**, Mulligan MJ, Ahmed R. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. *J Immunol* 2009; 183 (12): 7919-7930.

165. Rodewald LE, **Orenstein WA**. Vaccinating adolescents—new evidence of challenges and opportunities. *J Adolesc Health* 2009; 45(5):427-429.
166. Kamiya H, Nakano T, Inoue M, Kamiya H, Abd TT, Patel M, **Orenstein WA**, Parashar UD. A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus. *J Infect Dis.* 2009; 200 Suppl 1: S140-146.
167. Compans RW, **Orenstein WA**. Vaccines for pandemic influenza. Preface. *Curr Top Microbiol Immunol* 2009; 333: v-viii.
168. Schwartz B, **Orenstein WA**. Prioritization of pandemic influenza vaccine: rationale and strategy for decision making. *Curr Top Microbiol Immunol* 2009; 333:495-507.
169. Pazol K, Prill MM, Gazmararian JA, O'Malley EM, Jelks D, Coleman MS, Hinman AR, **Orenstein WA**. Support for universal childhood vaccination against influenza among private pediatric clinics and public health departments in Georgia. *J Public Health Manag Pract* 2009; 15(5):393-400.
170. Wassilak S, **Orenstein W**. Challenges faced by the global polio eradication initiative. *Expert Rev Vaccines* 2010; 9(5):447-449.
171. Harro C, Betts R, **Orenstein W**, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N. Safety and Immunogenicity of Novel *Staphylococcus aureus* Vaccine: Results from the study of the first vaccine dose range in humans. *Clin Vaccine Immunol* 2010; 17(2):1868-1874. PMID: PMC2008200.
172. Painter JE, Sales JM, Pazol K, Wingood GM, Windle M, **Orenstein WA**, DiClemente RJ. Psychosocial correlates of intention to receive an influenza vaccination among rural adolescents. *Health Educ Res* 2010; 25(5):853-864.
173. Gazmararian JA, **Orenstein W**, Prill M, Hitzhusan HB, Coleman MS, Pazol, Oster NV. Maternal knowledge and attitudes toward influenza vaccination: a focus group study in metropolitan Atlanta. *Clin Pediatr* 2010; 49(11):1018-1025.
174. Berman PP, **Orenstein WA**, Hinman AR, Gazmararian J. Stakeholder attitudes toward influenza vaccination policy in the United States. *Health Promot Pract* 2010; 11(6):807-816.
175. Painter JE, Sales JM, Pazol K, Wingood GM, Windle M, **Orenstein WA**, DiClemente RJ. Adolescent attitudes toward influenza vaccination and vaccine

uptake in a school-based influenza vaccination intervention: a mediation analysis. *J Sch Health* 2011; 81(6):304-312. doi: 10.1111/j.1746-1561.2011.00595.x.

176. Monto AS, Black S, Plotkin SA, **Orenstein WA**. Response to the 2009 pandemic: effect on influenza control in wealthy and poor countries. *Vaccine* 2011; 29(38):6427-6431.
177. Choudhury P, Thacker N, Gargano LM, Weiss PS, Vashishtha VM, Amladi T, Pazol K, **Orenstein WA**, Omer SB, Hughes JM. Attitudes and perceptions of private pediatricians regarding polio immunization in India. *Vaccine* 2011; 29(46):8317-8322.
178. Hinman AR, **Orenstein WA**, Schuchat A; Centers for Disease Control and Prevention (CDC). Vaccine-preventable diseases, immunizations, and MMWR--1961-2011. *MMWR Surveill Summ* 2011; 60(Suppl 4):49-57.
179. Gargano LM, Pazol K, Sales JM, Painter JE, Morfaw C, Jones LM, Weiss P, Buehler JW, Murray DL, Wingood GM, **Orenstein WA**, DiClemente RJ, Hughes JM. Multicomponent interventions to enhance influenza vaccine delivery to adolescents. *Pediatrics* 2011; 128(5):e1092-1099.
180. Sales JM, Painter JE, Pazol K, Gargano LM, **Orenstein W**, Hughes JM, DiClemente RJ. Rural parents' vaccination-related attitudes and intention to vaccinate middle and high school children against influenza following educational influenza vaccination intervention. *Hum Vaccin* 2011; 7(11):1146-1152.
181. Hinman AR, **Orenstein WA**, Schuchat A. Vaccine-preventable diseases, immunizations, and the Epidemic Intelligence Service. *Am J Epidemiol* 2011; 174(11 Suppl):S16-22.
182. Gargano LM, Thacker N, Choudhury P, Weiss PS, Pazol K, Bahl S, Jafari HS, Arora M, **Orenstein WA**, Hughes JM, Omer SB. Attitudes of pediatricians and primary health center physicians in India concerning routine immunization, barriers to vaccination, and missed opportunities to vaccinate. *Pediatr Infect Dis J*. 2012; 31(2):e37-42.
183. Chamberlain AT, Seib K, Wells K, Hannan C, **Orenstein WA**, Whitney EA, Hinman AR, Berkelman RL, Omer SB. Perspectives of immunization program managers on 2009-10 H1N1 vaccination in the United States: a national survey. *Biosecur Bioterror* 2012; 10(1):142-150.
184. Thacker N, Choudhury P, Gargano LM, Weiss PS, Pazol K, Bahl S, Jafari HS, Arora M, Dubey AP, Vashishtha VM, Agarwal R, Kumar A, **Orenstein WA**, Omer SB, Hughes JM. Comparison of attitudes about polio, polio immunization,

and barriers to polio eradication between primary health center physicians and private pediatricians in India. *Int J Infect Dis* 2012; 16(6):e417-423. doi: 10.1016/j.ijid.2012.02.002.

185. Chamberlain AT, Wells K, Seib K, Kudis A, Hannan C, **Orenstein WA**, Whitney EA, Hinman AR, Buehler JW, Omer SB, Berkelman RL. Lessons learned from the 2007 to 2009 Haemophilus influenzae type B vaccine shortage: implications for future vaccine shortages and public health preparedness. *J Public Health Manag Pract* 2012; 18(3):E9-E16.
186. Gargano LM, Thacker N, Choudhury P, Weiss PS, Pazol K, Bahl S, Jafari HS, Arora M, **Orenstein WA**, Hughes JM, Omer SB. Predictors of administration and attitudes about pneumococcal, Haemophilus influenzae type b and rotavirus vaccines among pediatricians in India: a national survey. *Vaccine* 2012; 30(24):3541-3545.
187. Bednarczyk RA, Davis R, Ault K, **Orenstein W**, Omer SB. Sexual activity related outcomes after human papilloma virus vaccination of 11 to 12 year olds. *Pediatrics* 2012; 130:798-805.
188. Edupuganti S, Eidex RB, Keyserling H, Akondy RS, Lanciotti R., **Orenstein W**, del Rio C, Pan Y, Querec T, Lipman H, Barrett A, Ahmed R, Teuwen D, Cetron M, Mulligan MJ. YF-Ig Study Team. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. *Am J Trop Med Hyg* 2013; 88(1):172-177.
189. Thacker N, Choudhury P, Gargano LM, Weiss PS, Pazol K, Vashishtha VM, Bahl S, Jafari HS, Kumar A, Arora M, Venczel L, **Orenstein WA**, Omer SB, Hughes JM. Attitudes and Practices of Auxiliary Nurse Midwives and Accredited Social Health Activists in Uttar Pradesh and Bihar Regarding Polio Immunization in India. *J Trop Pediatr* 2013; 59(4):266-273.
190. Richards JL, Hansen C, Bredfeldt C, Bednarczyk RA, Steinhoff MC, Gbewonyo-Adjaye, D, Ault K, Gallagher M, **Orenstein WA**, Davis RL, Omer SB. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. *Clin Infect Dis* 2013; 56(9):1216-1222.
191. Estívariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, **Orenstein WA**. Poliovirus vaccination options for achieving eradication and securing the endgame. *Curr Opin Virol* 2013; 3(3):309-315. doi: 10.1016/j.coviro.2013.05.007.

192. van Santen KL, Bednarczyk RA, Adjaye-Gbewonyo D, **Orenstein WA**, Davis R, Omer SB. Effectiveness of Pneumococcal Conjugate Vaccine in Infants by Maternal Influenza Vaccination Status. *Pediatr Infect Dis J* 2013; 32(11):1180-1184. Doi:10.1097/INF.ob013e3812a26752.
193. Mergler MJ, Omer SB, Pan WKY, Boggan-Navar, AM, **Orenstein WA**, Marcuse EK, Taylor J, deHart MP, Carter TC, Damico A, Halsey N, Salmon DA. Are recent medical graduates more skeptical of vaccines? *Vaccine* 2013; 31(41):4591-4595. doi: 10.1016/j.vaccine.2013.07.039.
194. Gargano LM, Thacker N, Choudhury P, Weiss PS, Russ RM, Pazol K, Arora M, **Orenstein WA**, Omer SB, Hughes JM. Pediatricians' perceptions of vaccine effectiveness and safety are significant predictors of vaccine administration in India. *Int Health* 2013; 5(3):205-210. doi: 10.1093/inthealth/iht018.
195. Bednarczyk RA, Curran EA, **Orenstein WA**, Omer SB. Health disparities in human papillomavirus vaccine coverage: trends analysis from the National Immunization Survey-Teen, 2008-2011. *Clin Infect Dis* 2014; 58(2):238-241. doi: 10.1093/cid/cit707.
196. Omer SB, Peterson D, Curran EA, Hinman A, **Orenstein WA**. Legislative challenges to school immunization mandates, 2009-2012. *JAMA* 2014; 311(6):620-621. doi: 10.1001/jama.2013.282869.
197. Opel DJ, Feemster KA, Omer SB, **Orenstein WA**, Richter M, Lantos JD. A 6-month-old with vaccine-hesitant parents. *Pediatrics* 2014; 133(3):526-530. doi: 10.1542/peds.2013-2723.
198. Ault KA, Hurwitz JA, Zimet GD, Omer SB, **Orenstein W**. The acceptability of a novel group B streptococcus vaccine in pregnant women. *Obstet Gynecol* 2014; 123 (Suppl 1):131S-132S. doi: 10.1097/01.AOG.0000447099.00426.85.
199. Haber M, An Q, Foppa IM, Shay DK, Ferdinands JM, **Orenstein WA**. A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies. *Epidemiol Infect* 2014; 22:1-10. PMID: PMC4336850.
200. Seib K, Chamberlain A, Wells K, Curran E, Whitney EA, **Orenstein WA**, Hinman AR, Omer SB. Challenges and changes: immunization program managers share perspectives in a 2012 national survey about the US immunization system since the H1N1 pandemic response. *Hum Vaccin Immunother* 2014; 10(10):2915-2921. doi:10.4161/21645515.2014.972798.
201. Walton LR, **Orenstein WA**, Pickering LK. The history of the United States

Advisory Committee on Immunization Practices (ACIP). *Vaccine* 2015; 33(3):405-414. doi: 10.1016/j.vaccine.2014.09.043.

203. Chamberlain AT, Seib K, Ault KA, **Orenstein WA**, Frew PM, Malik F, Cortés M, Cota P, Whitney EA, Flowers LC, Berkelman RL, Omer SB. Factors Associated with Intention to Receive Influenza and Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccines during Pregnancy: A Focus on Vaccine Hesitancy and Perceptions of Disease Severity and Vaccine Safety. *PLoS Curr.* 2015; 7. pii:ecurrents.outbreaks.d37b61bceebae5a7a06d40a301cfa819. PMID: PMC4353696.
204. Cohen MA, Gargano LM, Thacker N, Choudhury P, Weiss PS, Arora M, **Orenstein WA**, Omer SB, Hughes JM. Assessing the role of providers' vaccination behaviors in attaining routine immunization coverage in India. *J Trop Pediatr* 2015; 61(4):244-249. doi: 10.1093/tropej/fmv023.
205. Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. *Future Microbiol* 2015; 10(5):791-808. doi: 10.2217/fmb.15.19.
206. Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortés M, Whitney EA, Berkelman RL, Orenstein WA, Omer SB. Improving influenza and Tdap vaccination during pregnancy: A cluster-randomized trial of a multi-component antenatal vaccine promotion package in late influenza season. *Vaccine* 2015; 33(30):3571-3579. doi: 10.1016/j.vaccine.2015.05.048.
207. Okitika TA, Barnabas RV, Rue T, Weisman J, Harris NA, Orenstein WA, Wasserheit JN. "Polio Eradication" Game may increase public interest in global health. *Games Health J* 2015; 4(3):195-201. doi: 10.1089/g4h.2014.0045.
208. Iqbal S, Shi J, Seib K, Lewis P, Moro PL, Woo EJ, Shimabukuro T, Orenstein WA. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12. *Lancet Infect Dis* 2015; 15(10):1175-1182. doi: 10.1016/S1473-3099(15)00059-6.
209. Walton LR, Orenstein WA, Pickering LK. Lessons learned from making and implementing vaccine recommendations in the U.S. *Am J Prev Med* 2015; pii: S0749-3797(15)00333-5. doi: 10.1016/j.amepre.2015.06.023.
210. Smith PJ, Marcuse EK, Seward JF, Zhao Z, Orenstein WA. Children and adolescents unvaccinated against measles: Geographic clustering, parents' beliefs, and missed opportunities. *Public Health Rep* 2015; 130(5):485-504. PMID: PMC4529833

211. Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, Li R, Klein NP, Hambidge SJ, Naleway AL, Lugg MM, Jackson ML, King JP, DeStefano F, Omer SB, Orenstein WA. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. *Obstet Gynecol* 2015; 126(5):1069-1074.
212. Bednarczyk RA, **Orenstein WA**, Omer SB. Impact of gender-specific Human Papillomavirus Vaccine recommendations on uptake of other adolescent vaccines: Analysis of the NIS-Teen (2008-2012). *J Public Health Manag Pract* 2015 Aug 14. [Epub ahead of print] PMID: PMC4753144
213. Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP, Jackson ML, Hambidge SJ, Lugg MM, Li R, Weintraub ES, Bednarczyk RA, King JP, DeStefano F, **Orenstein WA**, Omer SB. Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. *JAMA* 2015; 314(15):1581-1587. doi:10.1001/jama.2015.12790.
214. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, **Orenstein WA**. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. *J Infect Dis* 2016; 213(8):1216-1223. doi:10.1093/infdis/jiv457. PMID: PMC4799662.
215. Chang DH, Bednarczyk RA, Becker ER, Hockenberry JM, Weiss PS, **Orenstein WA**, Omer SB. Trends in U.S. hospitalizations and inpatient deaths from pneumonia and influenza, 1996-2011. *Vaccine* 2016; 34(4):486-494. doi: 10.1016/j.vaccine.2015.12.003.
216. Smith PJ, Stokley S, Bednarczyk RA, **Orenstein WA**, Omer SB. HPV vaccination coverage of teen girls: the influence of health care providers. *Vaccine* 2016; 34(13):1604-1610. doi: 10.1016/j.vaccine.2016.01.061.
217. Chamberlain AT, Berkelman RL, Ault KA, Rosenberg ES, **Orenstein WA**, Omer SB. Trends in reasons for non-receipt of influenza vaccination during pregnancy in Georgia, 2004-2011. *Vaccine* 2016; 34(13):1597-1603. doi:10.1016/j.vaccine.2016.01.058.
218. Garon J, Seib K, **Orenstein WA**, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. *Expert Rev Vaccines*. 2016 Jun;15(6):693-708. doi: 10.1586/14760584.2016.1140041
219. Fulton TR, Phadke VK, **Orenstein WA**, Hinman AR, Johnson WD, Omer SB. Protective effect of contemporary pertussis vaccines: A systematic review and

meta-analysis. *Clin Infect Dis* 2016; 62(9):1100-1110. doi: 10.1093/cid/ciw051. PMID: PMC4826451.

220. **Orenstein WA**, Seib K. Beyond vertical and horizontal programs: a diagonal approach to building national immunization programs through measles elimination. *Expert Rev Vaccines* 2016; 15(7):791-793. doi: 10.1586/14760584.2016.1165614.
221. Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortes M, Whitney EA, Berkelman RL, **Orenstein WA**, Omer SB. Impact of a multi-component antenatal vaccine promotion package on improving knowledge, attitudes and beliefs about influenza and Tdap vaccination during pregnancy. *Hum Vaccin Immunother* 2016; 15:1-8. DOI: 10.1080/21645515.2015.1127489.
222. **Orenstein WA**, Simon R. Introduction to issue of highlighted research presented at the 2015 National Foundation for Infectious Diseases Annual Conference on Vaccine Research. *Vaccine* 2016; 34(30):3522-3524. doi: 10.1016/j.vaccine.2016.05.001.
223. Bednarczyk RA, **Orenstein WA**, Omer SB. Estimating the number of measles-susceptible children and adolescents in the United States using data from the National Immunization Survey-Teen (NIS-Teen). *Am J Epidemiol* 2016; 184(2):148-56. doi: 10.1093/aje/kwv320.
224. Frew PM, Fisher AK, Basket MM, Chung Y, Schamel J, Weiner JL, Mullen J, Omer SB, **Orenstein WA**. Changes in childhood immunization decisions in the United States: Results from 2012 & 2014 National Parental Surveys. *Vaccine*. 2016; 34(46):5689-5696. doi: 10.1016/j.vaccine.2016.08.001.
225. Omer SB, Kazi AM, Bednarczyk RA, Allen KE, Quinn CP, Aziz F, Sial K, Phadke VK, Tondella ML, Williams MM, **Orenstein WA**, Ali SA. Epidemiology of pertussis among young Pakistani infants: A community-based prospective surveillance study. *Clin Infect Dis*. 2016; 63(suppl 4):S148-S153. PMID: PMC5106628.
226. Kriss JL, Frew PM, Cortes M, Malik FA, Chamberlain AT, Seib K, Flowers L, Ault KA, Howards PP, **Orenstein WA**, Omer SB. Evaluation of two vaccine education interventions to improve pertussis vaccination among pregnant African American women: A randomized controlled trial. *Vaccine*. 2017; 35(11):1551-1558. doi: 10.1016/j.vaccine.2017.01.037.
227. Cowger TL, Burns CC, Sharif S, Gary HE Jr, Iber J, Henderson E, Malik F, Zahoor Zaidi SS, Shaukat S, Rehman L, Pallansch MA, **Orenstein WA**. The role of supplementary environmental surveillance to complement acute flaccid

paralysis surveillance for wild poliovirus in Pakistan - 2011-2013. *PLoS One*. 2017; 12(7):e0180608. doi: 10.1371/journal.pone.0180608. eCollection 2017.

228. Pickering LK, **Orenstein WA**, Sun W, Baker CJ. FDA licensure of and ACIP recommendations for vaccines. *Vaccine*. 2017; 35(37):5027-5036. doi: 10.1016/j.vaccine.2017.07.023.
229. Smith PJ, Shaw J, Seither R, Lopez A, Hill HA, Underwood M, Knighton C, Zhao Z, Ravanam MS, Greby S, **Orenstein WA**. Vaccine exemptions and the kindergarten vaccination coverage gap. *Vaccine*. 2017; 35(40):5346-5351. doi: 10.1016/j.vaccine.2017.08.036.
230. Ainslie KEC, Shi M, Haber M, **Orenstein WA**. On the bias of estimates of influenza vaccine effectiveness from test-negative studies. *Vaccine*. 2017; 35(52):7297-7301. doi: 10.1016/j.vaccine.2017.10.107.
231. Shi M, An Q, Ainslie KEC, Haber M, **Orenstein WA**. A comparison of the test-negative and the traditional case-control study designs for estimation of influenza vaccine effectiveness under nonrandom vaccination. *BMC Infect Dis*. 2017; 17(1):757. doi: 10.1186/s12879-017-2838-2.
232. **Orenstein WA**, Cairns L, Hinman A, Nkowane B, Olivé JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. *Vaccine*. 2018; 36 Suppl 1:A1-A34. doi: 10.1016/j.vaccine.2017.09.026.
233. **Orenstein WA**, Cairns L, Hinman A, Nkowane B, Olivé JM, Reingold AL. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. *Vaccine*. 2018; 36 Suppl 1:A35-A42. doi: 10.1016/j.vaccine.2017.10.065.
234. Thompson KM, Gellin BG, Hinman AR, **Orenstein WA**. The National Vaccine Advisory Committee at 30: Impact and opportunity. *Vaccine*. 2018; 36(11):1330-1344. doi 10.1016/j.vaccine.2018.01.068.
235. Anderson EJ, Daugherty MA, Pickering LK, **Orenstein WA**, Yagev R. Protecting the community through child vaccination. *Clin Infect Dis*. 2018; 67(3):464-471. doi: 10.1093/cid/ciy142.

b. Manuscripts submitted: (n/a)

c. Review articles:

1. **Orenstein WA**, Weisfeld JS, Halsey NA. Diphtheria and tetanus toxoids and pertussis vaccine, combined. In Halsey N.A., de Quadros C.A., Coordinators: Recent advances in immunization. A bibliographic review. Scientific Publication No. 451, Pan American Health Organization, Washington, D.C. 1983; 30-51.
2. **Orenstein WA**, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. *Epidemiol Rev* 1988; 10:212-241.
3. Atkinson WL, **Orenstein WA**, Krugman S. The resurgence of measles in the United States, 1989-1990. *Annu Rev Med* 1992; 43:451-463.
4. Markowitz LE, Preblud SR, Fine PE, **Orenstein WA**. Duration of live measles vaccine-induced immunity. *Pediatr Infect Dis J* 1990; 9:101-110.
5. Chen RT, **Orenstein WA**. Epidemiologic Methods in Immunization Programs. *Epidemiol Rev* 1996; 18(2):99-117.
6. Rabinovich NR, **Orenstein WA**. Vaccines Overview. *Epidemiol Rev* 1999; 21(1):1-6.
7. Pickering LK, **Orenstein WA**. Development of pediatric vaccine recommendations and policies. *Semin in Pediatr Infect Dis* 2002; 13(3):148-154.
8. Papania MJ, **Orenstein WA**. Defining and assessing measles elimination goals. *J Infect Dis* 2004; 189 (Suppl 1):S23-26. Review
9. Hinman AR, **Orenstein WA**, Santoli JM, Rodewald LE, Cochi SL. Vaccine Shortages: History, Impact, and Prospects for the Future. AR Review in [Advance10.1146/annurev.publhealth.27.021405.102248](https://doi.org/10.1146/annurev.publhealth.27.021405.102248), Sept 2005. *Annu Rev Public Health* 2006. 27:235-259.
10. **Orenstein WA**, Mootrey GT, Pazol K, Hinman AR. Financing Immunization of Adults in the United States. *Clin Pharmacol Ther* 2007; 82(6):764-768.
11. Fiebelkorn AP, Seward JF, **Orenstein WA**. A global perspective of vaccination of healthcare personnel against measles: Systematic review. *Vaccine* 2014; 32(38):4823-4839. 2013; pii: S0264-410X(13)01504-1. doi: 10.1016/j.vaccine.2013.11.005.
12. **Orenstein WA**, Seib K, Graham-Rowe D, Berkley S. Contemporary Vaccine Challenges: Improving Global Health One Shot at a Time. *Sci Transl Med* 2014; 6(253):253ps11.

13. Bratton KN, Wardle MT, **Orenstein WA**, Omer SB. Maternal Influenza Immunization and Birth Outcomes of Stillbirth and Spontaneous Abortion: A Systematic Review and Meta-analysis. *Clin Infect Dis* 2015; 60(5):e11-e19. Epub 2014 Nov 18.
14. Bandyopadhyay AS, Garon J, Seib K, **Orenstein WA**. Polio vaccination: past, present and future. *Future Microbiol* 2015; 10(5):791-808. doi: 10.2217/fmb.15.19. Epub 2015 Mar 31. Review.
15. Garon JR, **Orenstein WA**. Understanding the host-pathogen interaction saves lives: lessons from vaccines and vaccinations. *Curr Opin Immunol* 2015; 36:8-13. doi: 10.1016/j.coi.2015.04.003. Epub 2015 May 16. Review.
16. Garon JR, Cochi SL, **Orenstein WA**. The challenge of global poliomyelitis eradication. *Infect Dis Clin North Am* 2015; 29(4):651-665. doi:10.1016/j.idc.2015.07.003. Review.
17. Seib K, Pollard AJ, de Wals P, Andrews RM, Zhou F, Hatchett RJ, Pickering LK, **Orenstein WA**. Policy making for vaccine use as a driver of vaccine innovation and development in the developed world. *Vaccine*. 2017; 35(10):1380-1389. doi: 10.1016/j.vaccine.2016.10.080. Review.
18. Goodson JL, Alexander JP, Linkins RW, **Orenstein WA**. Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach. *Expert Rev Vaccines*. 2017; 16(12):1203-1216. doi: 10.1080/14760584.2017.1393337.
19. **Orenstein WA**, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. *Vaccine*. 2018; 36 Suppl 1:A1-A34. doi: 10.1016/j.vaccine.2017.09.026.
20. Thompson KM, Gellin BG, Hinman AR, **Orenstein WA**. The National Vaccine Advisory Committee at 30: Impact and opportunity. *Vaccine*. 2018; 36(11):1330-1344. doi: 10.1016/j.vaccine.2018.01.068.

d. Symposium contributions: N/A

e. Book chapters:

1. Hinman AR, Bart KJ, **Orenstein WA**. Immunization in Mandel GL, Douglas RG Jr, Bennett JE eds: *Principles and Practice of Infectious Diseases*. John Wiley and Sons, New York, 1985, pp 1688-1698.

2. **Orenstein WA**, Hinman AR, Bart KJ. Measles in Last JM ed. Maxcy Rosenau Public Health and Preventive Medicine, Appleton-Century-Crofts/Norwalk, Connecticut, 1986, pp 157-161.
3. Preblud SR, **Orenstein WA**. Mumps in Last JM ed. Maxcy Rosenau Public Health and Preventive Medicine, Appleton-Century-Crofts/Norwalk, Connecticut, 1986, p. 168-170.
4. Preblud SR, **Orenstein WA**. Chickenpox in Last JM ed. Maxcy Rosenau Public Health and Preventive Medicine, Appleton-Century- Crofts/Norwalk, Connecticut, 1986 pp 170-173.
5. **Orenstein WA**, Bart SW, Bart KJ, Sirotkin B, Hinman AR. Epidemiology of rubella and its complications in Gruenberg EM ed. Vaccinating against brain syndromes: The campaign against measles and rubella. Oxford University Press, New York, 1986, pp 49-69.
6. Bloch AB, **Orenstein WA**, Wassilak SG, Stetler HC, Turner PM Jr, Amler RW, Bart KJ, Hinman AR. Epidemiology of measles and its complications in Gruenberg EM ed. Vaccinating against brain syndromes: The campaign against measles and rubella. Oxford University Press, New York, 1986, pp 5-20.
7. Hinman AR, Bart KJ, **Orenstein WA**, Kirby CD, Bloch AB. History of measles control efforts in Gruenberg EM ed. Vaccinating against brain syndromes: The campaign against measles and rubella. Oxford University Press, New York, 1986, pp 36-46.
8. Bart KJ, **Orenstein, WA**, Bart SW, Hinman AR. Rubella and congenital rubella infection: The history of control efforts in Gruenberg EM ed. Vaccinating against brain syndromes: The campaign against measles and rubella. Oxford University Press, New York, 1986, pp 96-113.
9. Hayden GF, **Orenstein WA**. Measles and Rubella Viruses in Donowitz LG ed. Hospital-Acquired Infection in the Pediatric Patient. Williams and Wilkins, Baltimore, 1988, pp 218-225.
10. Wassilak SGF, **Orenstein WA**. Tetanus in Plotkin SA, Mortimer EA Jr. ed. Vaccines. W. B. Saunders Company, Philadelphia, 1988, pp 45-73.
11. Hinman AR, **Orenstein WA**. Measles, Mumps, Rubella in Textbook of Internal Medicine, Kelley WN (ed), Lippincott Co, Philadelphia, 1989, pp 1642-1646.

12. **Orenstein WA**, Wassilak SGF, Hinman AR. Tetanus in Hoeprich PD, Jordan MC ed. *Infectious Diseases, Fourth Edition*. J. B. Lippincott Co., Philadelphia, 1989, pp 1173-1182.
13. Hinman AR, **Orenstein WA**, Bart, KR, Preblud SR. Immunization in Mandell GL, Douglas R, Bennett JE. *Principles and Practice of Infectious Diseases, 3rd Edition*, Churchill Livingstone, NY, 1990, pp 2320-2334.
14. **Orenstein WA**, Wassilak SGF. Tetanus in *Bacterial Infections of Humans, Epidemiology and Control. Second Edition*. Plenum Medical Book Company, New York, 1991, pp 726-726.
15. **Orenstein WA**, Hinman AR. Measles, Mumps, and Rubella in *Textbook of Internal Medicine*, Kelley WN (ed), Second Edition, Lippincott Co, Philadelphia, 1992, pp 1486-1491.
16. **Orenstein WA**, Markowitz LE, Hinman AR. Measles in Last JM ed. *Maxcy-Rosenau Public Health and Preventive Medicine, 13th Edition*, Appleton & Lange/Norwalk, Connecticut, 1992, pp 65-68.
17. **Orenstein WA**. Immunization in *Cecil Textbook of Medicine*, Wyngaarden JB, Smith Lloyd H. Jr., Bennett JC, eds. 19th Edition, W.B. Saunders Co., Philadelphia, 1992, pp 55-61.
18. **Orenstein WA**, Markowitz LE, Atkinson WL, Hinman AR. The experience with measles in the United States in *Measles and Poliomyelitis*, Kurstak E. ed. Springer-Verlag, Austria, 1993, pp 25-35.
19. Williams WW, Atkinson WL, Holmes SJ, **Orenstein WA**. Nosocomial measles, mumps, rubella, and other viral infections. In: Mayhall CG. *Hospital Epidemiology and Infection Control*. Baltimore, MD: Williams and Wilkins; 1996, pp 523-35.
20. **Orenstein WA**, Hinman AR. Measles, Mumps, and Rubella. In: *Textbook of Internal Medicine, 3rd Edition*. Ed Kelley. Lippincott-Raven, Philadelphia 1997.
21. **Orenstein WA**, Redd SC, Markowitz LE, Hinman AR. Measles. In: *Public Health and Preventive Medicine, 14th Edition*. Eds Maxey, Rosenau, Last. York Production Services, New York. 1998, pp 89-93.
22. **Orenstein WA**. Commentary on 'Impact of a new universal purchase vaccine program in North Carolina'. In: *Year Book of Pediatrics*. Ed Stockman, III JA. Mosby - Year Book. 1999, pp 47-48.

23. Wassilak SGF, **Orenstein WA**, Sutter RW. Tetanus Toxoid. In: Vaccines. Eds. Plotkin SA, Orenstein WA. W. B. Saunders Company, Philadelphia. 1999, pp 441-474.
24. **Orenstein WA**, Hinman AR, Rodewald LE. Public Health Considerations — United States. In: Vaccines. Eds. Plotkin SA, Orenstein WA. W. B. Saunders Company, Philadelphia. 1999, pp 1006 - 1032.
25. Sutter RW, **Orenstein WA**, Wassilak SGF. Chapter 37 - Tetanus. In: Bacterial Infections of Humans, 3rd Edition. Eds. Evans AS and Brachman PS. Plenum, New York, 1998, pp 741-757.
26. **Orenstein WA**. Chapter 15 - Immunization. Part IV. Preventative Health Care. In: Cecil Textbook of Medicine, 21st Edition, Eds. Goldman L and Bennett JC. W. B. Saunders Company, Orlando, Florida. 2000, pp 40-50. Also full book on-line through MDConsult.
27. Chen RT, **Orenstein WA**. Evaluation of Immunization Programs. In: Epidemiologic Methods for Infectious Diseases. Thomas JC, Weber DJ, Eds. Oxford: Oxford University Press 2001, pp 344-72.
28. Perry RT, Papania M, Wharton M, **Orenstein WA**. Chapter 3 Infectious Diseases, Specific Infections: Measles. In: Gellis & Kagan's Current Pediatric Therapy, 17th Edition, Eds. Burg FD, Ingelfinger JR, Polin RA and Gershon AA. WB Saunders, New York, New York; 2002; pp 134-137.
29. Hadler SC, **Orenstein WA**. Active Immunization. In: Long SS, Pickering LK, and Prober CG, Eds. Principles and Practice of Pediatric Infectious Diseases, 2nd Edition. Churchill, Livingstone Press, Philadelphia, Pennsylvania; 2003; pp 45-65.
30. Wassilak SGF, Murphy TV, Roper MH, **Orenstein WA**. Tetanus Toxoid. In Vaccines, 4th Edition. Eds. Plotkin SA, Orenstein WA. Elsevier, Inc, W. B. Saunders Company, Philadelphia. 2004; pp 745-782.
31. **Orenstein WA**, Rodewald LE, Hinman AR. Public Health and Regulatory Issues. In Vaccines, 4th Edition. Eds. Plotkin SA, Orenstein WA. Elsevier, Inc., W. B. Saunders Company, Philadelphia. 2004; pp 1357 - 1386.
32. **Orenstein WA**. Chapter 16 – Immunization. Part III – Preventative and Environmental Medicine. In: Cecil Textbook of Medicine, 22nd Edition. Eds Goldman L and Ausiello D. Saunders, Philadelphia 2004; pp 64-74.

33. **Orenstein WA**, Wharton M, Bart KJ. Chapter 319 - Immunizations. In Principles and Practice of Infectious Diseases, 5th Edition. Eds Mandel, Bennett, and Dolin. W. B. Saunders, New York. 2004; pp 3557-3589.
34. Dayan GH, Reef S, **Orenstein WA**. Rubella. In: Current Pediatric Therapy, 18th edition. Eds Burg F, Ingelfinger J, Polin R, Gershon A. Saunders: Elsevier, New York. 2004
35. Perry RT, **Orenstein WA**. Measles. In: Current Pediatric Therapy, 18th edition. Eds Burg F, Ingelfinger J, Polin R, Gershon A. Saunders: Elsevier, New York. 2004
36. **Orenstein WA**, Papania M, Strebel P, Hinman AR. Measles. In: Public Health and Preventive Medicine, 15th edition. Eds Wallace RB, Kohatsu N. McGraw-Hill, New York, 2004
37. **Orenstein WA**, Wharton M, Bart KJ, Hinman AR. Immunization. Chapter 319. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 6th edition. Eds Mandell GL, Bennet JE, Dolin R. Elsevier, Churchill Livingstone, Philadelphia, Pennsylvania, 2005, pp 3557-3589.
38. Williams WW, Hutchins S, **Orenstein WA**, Rodewald L. Chapter 11: Immunization and Preventive Care. In: Multicultural Medicine and Health Disparities. Eds. Satcher D, Pames RJ. McGraw-Hill, New York. 2006, pp 233-249.
39. Hinman AR, **Orenstein WA**. Chapter 4: A Shot at Prevention: Immunizations Against Infectious Disease. In: Silent Victories – The History and Practice of Public Health in Twentieth-Century America. Eds: Ward JW, Warren C. Oxford University Press, New York, 2007, pp. 63-80.
40. **Orenstein WA**, Hinman AR, Rodewald LR. Vaccine Production and Supply: Vulnerabilities in the Present System. The Jordan Report, Accelerated Development of Vaccines 2007. US Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, NIH Publication No. 06-6057, May 2007, pp21-27. Available on-line: <http://www3.niaid.nih.gov/about/organization/dmid/PDF/Jordan2007.pdf>
41. **Orenstein WA**, Pickering LK. Chapter 170 – Immunization Practices. In Nelson Textbook of Pediatrics, 18th edition. Eds. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Elsevier, Inc., Philadelphia, PA, 2007, pp1058-1070.
42. **Orenstein, WA**. Chapter 16 – Immunization. In Cecil Textbook of Medicine, 23rd edition. Eds. Goldman L, Ausiello DA. Elsevier, Inc., Philadelphia, PA, 2008, pp70-85.

43. **Orenstein, WA**, Papania M, Strebel P. Chapter 9 – Measles. In Maxy-Rosenau-Last Public Health and Preventive Medicine, 15th edition. Eds. Wallace RB, Kohatsu N. McGraw-Hill, 2007, pp 101-107.
44. Pickering LK, **Orenstein WA**. Chapter 007– Active Immunization. In Principles and Practices of Pediatric Infectious Diseases: 3rd edition. Eds. Long SS, Prober CG, Pickering LK. Churchill Livingstone, Elsevier, Inc, 2008
45. **Orenstein WA**, Rodewald LE, Hinman AR, Schuchat A. Chapter 67 - Immunization in the United States. In Vaccines, 5th edition. Eds. Plotkin SA, Orenstein WA, Offit PA. Elsevier, Inc, 2008, pp 1479-1511.
46. Wassilak SGF, Roper MH, Kretsinger K, **Orenstein WA**. Chapter 31 – Tetanus Toxoid. In Vaccines, 5th edition. Eds. Plotkin SA, Orenstein WA, Offit PA. Elsevier, Inc, 2008, pp 805-841.
47. Gallagher KM, Plotkin SA, Katz SC, **Orenstein WA**. Chapter 13 – Measles, Mumps, and Rubella. In Vaccines: A Biography of Scientific Achievement. Springer-Verlag Berlin Heidelberg, Germany. 2009; pp 223-247.
48. Schwartz B, **Orenstein WA**. Prioritization of Pandemic Influenza Vaccine: Rationale and Strategy for Decision-Making. In Current Topics in Microbiology & Immunology: Vaccines for Pandemic Influenza, Compans, RW, Orenstein, W, eds. Springer-Verlag Berlin Heidelberg, Germany. 2009; 495-507.
49. **Orenstein WA**, Pickering LK, Mawle A, Hinman AR, Wharton M. Immunization. Chapter 320. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7th edition. Eds Mandell GL, Bennet JE, Dolin R. Elsevier. 2009; pp 3917-3949.
50. **Orenstein WA**, Atkinson W. Immunization. Chapter 17. In Cecil Textbook of Medicine, 24th Edition. Eds Goldman L, Shafer AI. Elsevier. 2011; pp 63-75.
51. **Orenstein WA**, Pickering LK. Chapter 165 – Immunization Practices. In Nelson Textbook of Pediatrics, 19th edition. Eds. Kliegman RM, Stanton BF, St. Geme J, Schor N, Behrman RE. Elsevier, Inc., Philadelphia, PA, 2011; pp 881-892.
52. Kroger AT, Mawle AC, Pickering LK, **Orenstein WA**. Chapter 6 - Active Immunization. In Principles and Practice of Pediatric Infectious Disease, Fourth Edition. Eds. Long SS, Pickering LK, Prober CG. Churchill Livingstone, 2012, pp 44-68.

53. Rodewald LE, **Orenstein WA**, Hinman AR, Schuchat A. Chapter 67 - Immunization in the United States. In *Vaccines*, 6th Edition. Eds. Plotkin SA, Orenstein WA, Offit PA. Elsevier, Inc, 2013, pp 1310-1333.
54. Roper MH, Wassilak SGF, Tiwari TSP, **Orenstein WA**. Chapter 33 – Tetanus Toxoid. In *Vaccines*, 6th Edition. Eds. Plotkin SA, Orenstein WA, Offit PA. Elsevier, 2013, pp 746-772.
55. **Orenstein WA**, Cooper L, Seib K. Nurturing Partnerships: Implementing a National Immunization Program in the United States, Chapter 5. In: *Global Child Health Advocacy: On the Front Lines*. Eds. Berman S, Palfrey JS, Bhutta Z, Grange AO. American Academy of Pediatrics (AAP), 2013, pp 41-52.
56. Reef S, **Orenstein WA**. Rubella Virus – Chapter 31. In *Viral Infections of Humans: Epidemiology and Control*, 5th Edition. Eds. Kaslow RA, Stanberry LR, LeDuc JW, Springer. 2014, pp 733-744.
57. **Orenstein WA**, Pickering LK, Kroger AL. Immunization. Chapter 321. In: *Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases*, 8th edition. Eds Bennet JE, Dolin R, Blaser MJ. Elsevier, Philadelphia, PA, 2015, pp 3516-3553.
58. Pickering LK, **Orenstein WA**. Chapter 172 – Immunization Practices. In *Nelson Textbook of Pediatrics*, 20th edition. Eds. Kliegman RM, Stanton BF, St. Geme J, Schor N. Elsevier, Philadelphia, PA, 2016, pp 1242-1259.
59. Strikas RA, **Orenstein WA**. Immunization. Chapter 18. In *Goldman-Cecil Medicine*, 25th Edition. Eds Goldman L, Shafer AI. Elsevier, Philadelphia, PA, 2016, pp 65-68.
60. Roper MH, Wassilak SGF, Scobie HM, Ridpath, **Orenstein WA**. Chapter 58 – Tetanus Toxoid. In *Plotkin’s Vaccines*, 7th edition. Eds. Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Elsevier, Philadelphia, PA, 2018, pp 1052-1080.
61. Cohn A, Rodewald LE, **Orenstein WA**, Schuchat A. Chapter 73 - Immunization in the United States. In *Plotkin’s Vaccines*, 7th edition. Eds. Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Elsevier, Philadelphia, PA, 2018, pp 1421-1440.
62. Strikas RA, Mawle AC, Pickering LK, **Orenstein WA**. Chapter 6 - Active Immunization. In *Principles and Practice of Pediatric Infectious Disease*, Fifth Edition. Eds. Long SS, Prober CG, Fischer M. Elsevier, Philadelphia, PA, pp 44-68.
63. Bernstein HH, **Orenstein WA**. Chapter 172 – Immunization Practices. In *Nelson Textbook of Pediatrics*, 21st edition. Eds. Kliegman RM, Stanton BF, St. Geme J, Schor N. Elsevier, Philadelphia, PA, In preparation (submitted June 2017).

64. Strikas RA, **Orenstein WA**. Immunization. Chapter 18. In Goldman-Cecil Medicine, 26th Edition. Eds Goldman L, Shafer AI. Elsevier, Philadelphia, PA, in preparation
65. **Orenstein WA**. 16th edition of Maxcy-Rosenau-Last Public Health and Preventive Medicine, in preparation

f. Books edited and written:

1. Plotkin SA, **Orenstein WA** eds. Vaccines, Third Edition, W. B. Saunders Company, Philadelphia, PA, 1999, pp 1-1230.
2. Plotkin SA, **Orenstein WA** eds. Vaccines, Fourth Edition, W. B. Saunders Company, Philadelphia, PA, 2004, pp 1-1662.
3. Plotkin SA, **Orenstein WA**, Offit PA eds. Vaccines, Fifth Edition, Elsevier, Inc. 2008, pp 1-1725.
4. Compans RW, **Orenstein WA** eds. Current Topics in Microbiology & Immunology: Vaccines for Pandemic Influenza, Springer-Verlag Berlin Heidelberg, Germany. 2009; pp 1-512.
5. Plotkin SA, **Orenstein WA**, Offit PA eds. Vaccines, Sixth Edition, Elsevier, Inc. 2013, pp1-1550.
6. Plotkin SA, **Orenstein WA**, Offit PA, Edwards K. eds. Plotkin's Vaccines, Seventh Edition, Elsevier, Philadelphia, PA, 2018, pp1-1644.

g. Book reviews:

1. **Orenstein WA**. Vaccines. Preventing Disease and Protecting Health. De Quadros CA ed. Pan American Health Organization, 2004. Lancet Infect Dis 2005; 5(10):607.
2. **Orenstein WA**. The Grand Challenge for the Future: Vaccines for Poverty-related Diseases from Bench to Field. Kaufmann SHE, Lambert PH editors. Birkhauser Advances in Infectious Diseases (BAID), Berlin, Germany, 2005. N Eng J Med 2006; 354:651-652.

h. Manuals, videos, computer programs, and other teaching aids:

1. **Orenstein WA**, Abramson J, Cochi S. Immunization: Now and Into the Future. American Academy of Pediatrics – PREP Audio Journal production for practicing pediatricians and house officers training to be primary care providers. Inaugural

- volume (CD) – taped October 25, 2005. Produced January 2006, Distributed March 2006 Volume 1, Issue 2.
2. **Orenstein WA.** Influenza and Pandemic Influenza: A Primer. Cyberounds, an on-line Grand Rounds presentation by InterMDnet under Conferences, Public Health section, www.cyberounds.com, 2006.
 3. **Orenstein WA**, Myers MG, Marcuse E . Countering Vaccine Misinformation. American Academy of Pediatrics – PREP Audio Journal production for practicing pediatricians and house officers training to be primary care providers. Recorded in May 2008; distributed in January 2009 Volume 4, Number 1. <http://www.prepaudio.org/default.aspx?id=89>
 4. **Orenstein WA** (Advisor). JABBED – Love, Fear, and Vaccines. Educational news film for Public Broadcasting Systems (PBS) NOVA by Tangled Bank Studios, LLC through Howard Hughes Medical Institute, Recorded 2013-2014. Aired in Australia SBS in early 2014, encores in July, and September 2014. This video has won 3 major awards in science and journalism for the director.
 5. **Orenstein WA** (Advisor). JABBED – Love, Fear, and Vaccines renamed for US audience to: Vaccines – Calling the Shots. Educational news film for Public Broadcasting Systems (PBS) NOVA by Tangled Bank Studios, LLC through Howard Hughes Medical Institute, Recorded 2013-2014. Aired on PBS NOVA, September 10, 2014.
 6. Zimmerman RK, **Orenstein WA.** CME: Influenza: Revisiting the Need for Preparedness as Other Outbreaks Make Headlines. Global Academy for Medical Education, February 2015 (available until February 2017). <http://www.globalacademycme.com/cme-topics/internal-medicine-family-practice/pediatrics/cme-library/single-article/influenza-revisiting-the-need-for-preparedness-as-other-outbreaks-make-headlines/65e5107a2aa056605d8152ac026d0368.html>
 7. **Orenstein WA**, Hinman AR. Reddit Chat - Science AMA Series: Vaccines Policy and Development. March 20, 2015. http://www.reddit.com/r/science/comments/2zown8/science_ama_series_we_are_walt_orenstein_and_alan/
 8. Garon J, **Orenstein WA.** Learning from Smallpox: How to eradicate a disease. TED-Ed video, March 2015, <http://ed.ted.com/lessons/learning-from-smallpox-how-to-eradicate-a-disease-julie-garon-and-walter-a-orenstein>

9. Waynoike S, Seib K, **Orenstein WA**. Managing Monitoring and Evaluation in an Immunization Program. Toolkit for International Association of Immunization Managers (IAIM), Sabin Vaccine Institute, 2015, www.sabin.org
10. Waynoike S, Seib K, **Orenstein WA**. Managing Surveillance of Vaccine Preventable Diseases. Toolkit for International Association of Immunization Managers (IAIM), Sabin Vaccine Institute, 2015, www.sabin.org
11. Nathanson N, Hinman A, **Orenstein WA**. "We Were There" Series – Conquering Polio in America: The Cutter Incident and Beyond. CDC, 2017. Webinar: <https://www.cdc.gov/od/science/wewerethere/polio/index.html>

i. Other publications:

LETTERS, COMMENTS, and EDITORIALS

1. Hall BD, **Orenstein WA**. Noonan's phenotype in an offspring of an alcoholic mother. Letter to the Editor. *Lancet* 1974; 1:680-681.
2. Bloch AB, **Orenstein, WA**, Hinman AR. Autarcesis against measles in early infancy. *J Infect Dis* 1981; 143:753-754.
3. Preblud SR, **Orenstein, W.A**. Rubella immunization post partum. *J Pediatr* 1981; 98:1030-1031.
4. **Orenstein WA**, Bloch AB, Bernier RH, Bart K, Hinman AR. Measles vaccination in infants - Reply. *JAMA* 1982; 247:1272-1274.
5. **Orenstein WA**, Greaves WL, Editorial. Congenital rubella syndrome: A continuing problem. *JAMA* 1982; 247:1174-1175.
6. Kim-Farley R, Brink E, **Orenstein WA**, Bart K. Vaccination and breast feeding. *JAMA* 1982; 248:2451-2452.
7. **Orenstein WA**, Bart KJ, Hinman AR, Preblud SR. Prevention of rubella in hospitals. *Am J Infect Control* 1983; 11:204-205.
8. Doster SW, Stetler HC, **Orenstein WA**, Bart KJ, Hinman AR. Editorial: Measles and rubella: our remaining responsibilities. *Amer J Publ Health* 1983; 73:490-492.
9. Amler RW, **Orenstein WA**, Bart KJ. Editorial: Aerosolized measles vaccine -- will it open the window? *Rev Infect Dis* 1983; 5:524-526.

10. Brink EW, **Orenstein WA**, Bart KJ, Hinman AR. More on Pertussis. *N Engl J Med* 1983; 309:985-986.
11. Amler RW, **Orenstein WA**, Bart KJ. The immune response to aerosolized measles vaccine (editorial). *JAMA* 1984; 251:2048.
12. Wassilak SGF, Brink EW, **Orenstein WA**, Bart KJ. Reduced dose of DTP vaccine. *J Pediatr* 1985; 106:693-695.
13. Preblud SR, **Orenstein WA**, Lopez C, Herrmann, KL, Hinman, AR. Postpartum rubella immunization. *J Infect Dis* 1986; 154:367-369.
14. Patriarca PA, Brink EW, **Orenstein, WA**, Bernier, RH, Hinman, AR. Efficacy of acellular pertussis vaccine. *J Pediatr* 1986; 108:632-633.
15. Onorato IM, Jones TS, **Orenstein WA**. Immunizing children infected with HIV (letter). *Lancet* 1988; 13:1(8581):354-355.
16. Onorato IM, **Orenstein WA**. Immunization of HIV-infected children (letter). *J Pediatr* 1988; 112(2):333-334.
17. **Orenstein WA**, Ferrara CP, Sprauer MA, Williams WW, Strikas RA. Pharmacists' role in immunization. *Am J Hosp Pharm* 1990; 47(6):1273-1274.
18. **Orenstein WA**. DTP vaccine litigation, 1988. *Am J Dis Child* 1990; 144(5):517.
19. **Orenstein WA**, Bernier RH, Chen RT. Pertussis - A disease and a vaccine that are not going away. Editorial. *West J Med* 1989; 150:339-341.
20. **Orenstein WA**, Wassilak SGF, Strebel PM, Bernier RH, Blackwelder WC. Efficacy of pertussis vaccine (letter). *J Pediatr* 1990; 117:508.
21. Stehr-Green PA, Cochi SL, Preblud SR, **Orenstein WA**. Evidence against increasing rubella seronegativity among adolescent girls. *Am J Public Health* 1990; 80(1):88:66-69.
22. **Orenstein WA**, Plotkin S. Providing MMR vaccine to children. *Minn Med* 1991; 74:7-8.
23. Hardy IR, Strebel PM, Wharton M, **Orenstein WA**. 1993 Pertussis epidemic in Cincinnati (comment). *New Engl J Med* 1994; 331:1455-1456.
24. Dietz V, Zell E, Eddins D, Bernier R, **Orenstein WA**. Vaccination coverage in the United States. *Lancet* 1994; 344:1439-1440.

25. **Orenstein WA**, Bernier RH. Toward immunizing every child on time. *Pediatrics* (editorial) 1994; 94:545-547.
26. Redd SC, Wharton M, Hadler, SD, **Orenstein WA**. The measles-mumps-rubella vaccination program in Finland. *New Engl J Med* 1995; 332 (16):1102-1103.
27. **Orenstein WA**, Cordero JF, Willis BM. Childhood immunization registries. *JAMA* 1996; 275 (17):1312-1313.
28. Hinman AR, **Orenstein WA**, Papania MJ. Invited Commentary: Epidemiology of transmissible diseases after elimination. *Amer J Epidemiol* 2000; Vol 151, No. 11, 1049-1052.
29. Chu SY, Singleton JA, McCauley MM, **Orenstein WA**, Hughes JM, Mawle AC, Modlin JF. Influenza vaccine for healthy working adults. [Letter] *JAMA* 2001; 285(3):291-292.
30. Gazmararian JA, Buehler JW, Stephens DS, Dixon T, Elon L, Schild L, **Orenstein W**, Koplan J, State Working Group. Impact of bioterrorism preparedness on the public health response to the 2003-2004 influenza vaccine crisis. *Public Health Rep* 2005; 120:589.
31. Seward J, **Orenstein WA**. Commentary: The Case for Universal Varicella Immunization. *Ped Infect Dis* 2006; 25(1):45-46.
32. **Orenstein WA**, Hinman AR, Strebel PJ. Measles: The Need for 2 Opportunities for Prevention. *Clin Infect Dis* 2006; 42(3):320-321.
33. Hinman AR, **Orenstein WA**, Rodewald LE. EDITORIAL – Vaccines- victories and challenges. *Am J Epidemiol* 2006; 164(3):197-199. DOI: 10.1093/aje/kwj205
34. Hinman AR. **Orenstein WA**. Adult immunization: what can we learn from the childhood immunization program? *Clin Infect Dis* 2007; 44(12):1532-1535. On-line: <http://www.journals.uchicago.edu/CID/journal/issues/v44n12/51162/51162.html>
35. **Orenstein WA**, Strebel PM, Hinman AR. Building an immunity fence against measles. *J Infect Dis* 2007; 196(10):1433-1435.
36. John TJ, Plotkin SA, **Orenstein WA**. Building on the success of the Expanded Programme on Immunization: enhancing the focus on disease prevention and control. *Vaccine* 2011; 29(48):8835-8837.

37. Seward JF, **Orenstein WA**. Editorial commentary: a rare event: a measles outbreak in a population with high 2-dose measles vaccine coverage. *Clin Infect Dis* 2012; 55(3):403-405.
38. **Orenstein WA**, Hinman AR. Measles: the burden of preventable deaths. *Lancet* 2012; 379(9832):2130-2131.
38. Seward JF, **Orenstein WA**. A rare event: a measles outbreak in a population with high 2-dose measles vaccine coverage. *Clin Infect Dis* 2012; 55(3):403-405. doi: 10.1093/cid/cis445.
39. **Orenstein WA**, Paulson JA, Brady MT, Cooper LZ, Seib K. Global vaccination recommendations and thimerosal. *Pediatrics* 2013; 131(1):149-151. doi: 10.1542/peds.2012-1760.
40. Omer SB, **Orenstein WA**, Koplan JP. Go big and go fast--vaccine refusal and disease eradication. *N Engl J Med* 2013; 368(15):1374-1376. doi: 10.1056/NEJMp1300765.
41. Bhutta ZA, **Orenstein WA**; Scientific experts against polio. Scientific declaration on polio eradication. *Vaccine* 2013; 31(27):2850-2851. doi: 10.1016/j.vaccine.2013.04.024.
42. Sniadack DH, **Orenstein WA**. A measles eradication goal is upon us; can rubella and congenital rubella syndrome be far behind? *Vaccine* 2013; 31(24):2659-2660. doi: 10.1016/j.vaccine.2013.04.019.
43. Fouchier RA, Kawaoka Y, Cardona C, Compans RW, García-Sastre A, Govorkova EA, Guan Y, Herfst S, **Orenstein WA**, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG. Gain-of-function experiments on H7N9. *Science* 2013; 341(6146):612-613. doi: 10.1126/science.341.6146.612.
44. Fouchier RA, Kawaoka Y, Cardona C, Compans RW, García-Sastre A, Govorkova EA, Guan Y, Herfst S, **Orenstein WA**, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG. Avian flu: Gain-of-function experiments on H7N9. *Nature* 2013; 500(7461):150-151. doi: 10.1038/500150a.
45. Mundel T, **Orenstein WA**. No country is safe without global eradication of poliomyelitis. *N Engl J Med* 2013; 369(21):2045-2046. doi: 10.1056/NEJMe1311591.
46. Parashar U, **Orenstein WA**. Editorial Commentary: Intussusception and Rotavirus Vaccination – Balancing Risk Against Benefit. *Clin Infect Dis* 2013; 57(10):1435-

1437. doi: 10.1093/cid/cit532.
47. Stephens DS, Ahmed R, **Orenstein WA**. Vaccines at what price? *Vaccine* 2014; 32(9):1029-1030. doi: 10.1016/j.vaccine.2013.12.066.
 48. Garon JR, **Orenstein WA**. Overcoming barriers to polio eradication in conflict areas. *Lancet Infect Dis* 2015; 15(10):1122-1124. doi: 10.1016/S1473-3099(15)00008-0.
 49. Garon JR, **Orenstein WA**. A worldwide shift in polio vaccines for routine immunization. *Lancet* 2015; 386(10011): 2375-2377. doi: 10.1016/S0140-6736(15)00243-3.
 50. **Orenstein WA**, Garon JR. Low oral poliovirus vaccine immunogenicity in developing countries. *Lancet Infect Dis*. 2016; pii: S1473-3099(16)30050-0. doi: 10.1016/S1473-3099(16)30050-0.
 51. **Orenstein WA**. DA Henderson-physically gone but his impact will live on forever. *Ann Epidemiol*. 2017; 27(3):155-156. doi: 10.1016/j.annepidem.2017.01.003.
 52. **Orenstein WA**, Ahmed R. Simply put: Vaccination saves lives. *Proc Natl Acad Sci U S A*. 2017; 114(16):4031-4033. doi: 10.1073/pnas.1704507114.
 53. Hinman AR, **Orenstein WA**. Collaborating to achieve Global Vaccine Action Plan goals. *Lancet*. 2017; 390(10093):451-452. doi: 10.1016/S0140-6736(17)31370-3.
 54. Weinbaum CM, **Orenstein WA**. Using Disease Epidemiology to Optimize Immunization Schedules. *JAMA Pediatr*. 2017; 171(10):944-945. doi: 10.1001/jamapediatrics.2017.2375.
 55. Zimmerman LA, Reef SE, **Orenstein WA**. Rubella Vaccine-A Tale of Appropriate Caution and Remarkable Success. *JAMA Pediatr*. 2018; 172(1):95-96. doi: 10.1001/jamapediatrics.2017.4178. PMC58724148
 56. Durrheim DN, **Orenstein WA**, Schluter WW. Assessing population immunity for measles elimination – The promise and peril of serosurveys. *Vaccine* 2018; 36(28):4001-4003. Doi: 10.1016/j.vaccine.2018.04.036.

MONOGRAPHS

1. Schaffner W, Harrison LH, Kaplan SL, Miller E, **Orenstein W**, Peter G, Rosenstein NE. The changing epidemiology of meningococcal disease among US children, adolescents and young adults. National Foundation for Infectious Diseases – Research Prevention Education issued July 2004.

2. Schaffner W, Harrison LH, Kaplan SL, Miller E, **Orenstein W**, Peter G, Rosenstein NE. The changing epidemiology of meningococcal disease among US children, adolescents and young adults. National Foundation for Infectious Diseases – Research Prevention Education issued November 2004.
3. Strengthening Adult Immunization: A Call to Action. Partnership for Prevention issued May 2005. <http://www.prevent.org/images/stories/calltoaction.pdf>
4. Public Trust in Vaccines: Defining a Research Agenda. A Report of the American Academy of Arts & Sciences issued April 2014, <https://www.amacad.org/vaccines>

POSTERS/PRESENTATIONS

1. Bardenheier BH, Jumaan A, Stokley S, **Orenstein WA**. Factors associated with higher rates of adolescent varicella immunity among enrollees of commercial health insurance plans. Presented at the 42nd National Immunization Conference (NIC), Atlanta, Georgia, March 18, 2008. Abstract available online: <http://cdc.confex.com/cdc/nic2008/webprogram/Paper15554.html>.
2. Pazol K, Gazmararian JA, Prill MA, O'Malley EM, Jelks DD, Coleman MS, Hinman AR, **Orenstein WA**. Characteristics and attitudes of private pediatric providers in Georgia: Association with influenza immunization efforts. Presented at the 42nd National Immunization Conference (NIC), Atlanta, Georgia, March 18, 2008. Abstract available online: <http://cdc.confex.com/cdc/nic2008/webprogram/Paper15645.html>.
3. Gargano LM, Pazol K, Sales JM, Painter JE, Morfaw C, Jones LM, Weiss P, Wingood G, **Orenstein WA**, DiClemente RJ, Hughes JM. Evaluation of Multi-Component Interventions to Increase Influenza Vaccine Uptake in Adolescents. Oral Presentation. Society for Adolescent Health and Medicine. March 29-April 1, 2011, Seattle WA.
4. Gargano LM, Thacker N, Choudhury P, Pazol P, Weiss P, Bahl S, Jafari HS, **Orenstein WA**, Omer SB, Hughes JM. Primary Health Center Medical Officer and Private Pediatrician Perceptions of Respiratory and Enteric Disease Susceptibility and Severity in India. Poster Presentation. American Society of Tropical Medicine and Hygiene. November 3-7, 2010, Atlanta, GA.
5. Gargano LM, Thacker N, Choudhury P, Pazol P, Weiss P, Ugra D, Bahl S, Jafari HS, **Orenstein WA**, Omer SB, Hughes JM. Attitudes and Practices of Private Pediatricians and Primary Health Center Medical Officers Regarding Immunization in India. Poster Presentation. International Conference on Emerging Infectious Diseases. July 11-14, 2010. Atlanta, GA.

6. Gargano LM, Thacker N, Choudhury P, Pazol K, Weiss P, Bahl S, Jafari HS, **Orenstein WA**, Hughes JM, Omer SB. Important Barriers to Routine Immunization and Correlates of Missed Opportunities to Vaccinate among Pediatricians and Primary Health Center Physicians in India. Oral Presentation. 139th American Public Health Association Annual Meeting. October 29-November 2, 2011. Washington, DC.
7. Hurvitz JA, Omer S, Zimet G, **Orenstein W**, Ault KA. The acceptability of a novel group B Streptococcus Vaccine in pregnant women. Emory Medical Student Research Day, April 17, 2014, Atlanta, GA.
8. Hurvitz JA, Omer S, Zimet G, **Orenstein W**, Ault KA. Poster #57, The acceptability of a novel group B Streptococcus Vaccine in pregnant women. 2014 Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, April 26-30, 2014, Chicago, IL.
9. Lachey M, Bednarczyk R, Anderson AJ, **Orenstein WA**. Poster 1858, Addressing Rotavirus Vaccination Missed Opportunities Using the National Immunization Survey. Poster Session 250: Vaccines: Improving Immunization Uptake. IDWeek 2015, San Diego, CA, October 10, 2015.
10. Bednarczyk R, **Orenstein WA**, Omer SB. Poster 1866, Estimating the Number of Measles-susceptible Children in the United States Using the NIS-Teen. Poster Session 250: Vaccines: Improving Immunization Uptake. IDWeek 2015, San Diego, CA, October 10, 2015.

ABSTRACTS

1. Sales JM, Painter JE, Pazol K, Gargano LM, Jones L, **Orenstein WA**, Hughes JM and DiClemente RJ. Changes in Rural Parents' Vaccination-related Attitudes and Intention to Vaccinate Middle and High School Children Against Influenza Following Influenza Vaccination Intervention. 138th APHA Annual Meeting. November 6-10, 2010. Denver, CO.
2. Ault KA, Hurwitz JA, Zimet GD, Omer SB, **Orenstein W**. The acceptability of a novel group B streptococcus vaccine in pregnant women. *Obstet Gynecol* 2014; 123 Suppl 1:131S-2S. doi: 10.1097/01.AOG.0000447099.00426.85.
3. Iqbal S, Shi J, Lewis P, Seib K, Moro P, Shimabukuro T, **Orenstein W**. Safety of Inactivated Poliovirus Vaccine in the US Vaccine Adverse Event Reporting System, 2000–2012. 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology (ASM) meeting in Washington, DC, September 3, 2014.

COMMITTEES

1. Gibson JJ, Kainer MA, Raskin SE, Weber DJ, **Orenstein WA**, Hughes JM. Healthcare infections associated with care and treatment of humans and animals, *Emerg Infect Dis* 2008; 14:1835-1985.
2. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2008-2009. *Pediatrics* 2008; 122(5):1135-1141.
3. Pickering LK, Baker CJ, Freed GL, Gall SA, Grogg SE, Poland GA, Rodewald LE, Schaffner S, Stinchfield P, Tan L, Zimmerman RK, **Orenstein WA**. Immunization Programs for Infants, Children, Adolescents, and Adults: Clinical Practice Guidelines by the Infectious Disease Society of America. *Clin Infect Dis* 2009; 49(6):817-840.
4. National Vaccine Advisory Committee. Financing vaccination of children and adolescents: National Vaccine Advisory Committee Recommendations. *Pediatrics* 2009; 124 Suppl 5:S558-S562.
5. Committee on Infectious Diseases. Policy statement—recommendations for the prevention and treatment of influenza in children, 2009-2010. *Pediatrics*.2009; 124(4):1216-1226.
6. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statement—Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. *Pediatrics* 2009; 124(6):1694-1701.
7. Rogan WJ, Brady MT. Committee on Environmental Health; Committee on Infectious Diseases. Drinking water from private wells and risks to children. *Pediatrics* 2009; 123(6):1599-1605.
8. Rogan WJ, Brady MT. Committee on Environmental Health; Committee on Infectious Diseases. Drinking water from private wells and risks to children. *Pediatrics* 2009; 123(6): e1123-1137.
9. Committee on Infectious Diseases; American Academy of Pediatrics. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. *Pediatrics* 2009; 123(5):1412-1420.
10. American Academy of Pediatrics Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedules—United States, 2009. *Pediatrics* 2009; 123(1):189-190.

11. Committee on Infectious Diseases. Policy statement—Recommended childhood and adolescent immunization schedules—United States, 2010. *Pediatrics* 2010; 125(1):195-196.
12. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of *Streptococcus pneumoniae* infection in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). *Pediatrics* 2010; 126(1):186-190.
13. Frankowski BL, Bocchini JA Jr; Council on School Health and Committee on Infectious Diseases. Head lice. *Pediatrics* 2010; 126(2):392-403.
14. Rubin LG, Papsin B; Committee on Infectious Diseases and Section on Otolaryngology-Head and Neck Surgery. Cochlear implants in children: surgical site infections and prevention and treatment of acute otitis media and meningitis. *Pediatrics* 2010; 126(2):381-391.
15. Bernstein HH, Starke JR; Committee on Infectious Diseases. Policy statement—recommendation for mandatory influenza immunization of all health care personnel. *Pediatrics* 2010; 126(4):809-815.
16. Committee on Infectious Diseases; American Academy of Pediatrics. Policy statement--recommended childhood and adolescent immunization schedules--United States, 2011. *Pediatrics* 2011; 127(2):387-388.
17. Committee on Infectious Diseases. Rabies-prevention policy update: new reduced-dose schedule. *Pediatrics* 2011; 127(4):785-787.
18. Committee on Infectious Diseases; Committee on Fetus and Newborn, Baker CJ, Byington CL, Polin RA. Policy statement—Recommendations for the prevention of perinatal group B streptococcal (GBS) disease. *Pediatrics* 2011; 128(3):611-616.
19. Committee on Infectious Diseases. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. *Pediatrics* 2011; 128(3):630-632.
20. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. *Pediatrics* 2011; 128(4):e1034-1045.
21. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. *Pediatrics* 2011; 128(4):803-804.

22. American Academy of Pediatrics Committee on Infectious Diseases. Poliovirus. *Pediatrics* 2011; 128(4):805-808.
23. Centers for Disease Control and Prevention; American Academy of Pediatrics Committee on Infectious Diseases. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). *Pediatrics* 2011; 128(4):809-812.
24. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. *Pediatrics* 2011; 128(4):813-825.
25. Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. *Pediatrics* 2011; 128(6):1213-1218.
26. Lessin HR, Edwards KM; Committee on Practice and Ambulatory Medicine; Committee on Infectious Diseases. Immunizing parents and other close family contacts in the pediatric office setting. *Pediatrics* 2012; 129(1):e247-253.
27. National Vaccine Advisory Committee. A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011. *Public Health Rep* 2012; 127 (Suppl 1):1-42.
28. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedules--United States, 2012. *Pediatrics* 2012; 129(2):385-386. Erratum in: *Pediatrics* 2012; 129(3):596-597. *Pediatrics* 2012; 129(5):993.
29. Committee on Infectious Diseases. HPV vaccine recommendations. *Pediatrics* 2012; 129(3):602-605.
30. Polin RA, Denson S, Brady MT; Committee on Fetus and Newborn; Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. *Pediatrics* 2012; 129(4):e1104-1109.
31. Polin RA, Denson S, Brady MT; Committee on Fetus and Newborn; Committee on Infectious Diseases. Strategies for prevention of health care-associated infections in the NICU. *Pediatrics* 2012; 129(4):e1085-1093.
32. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2012-2013. *Pediatrics* 2012; 130(4):780-792. doi: 10.1542/peds.2012-2308.

33. Schutze GE, Willoughby RE; Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. *Pediatrics* 2013; 131(1):196-200. doi: 10.1542/peds.2012-2992.
34. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule--United States, 2013. *Pediatrics* 2013; 131(2):397-398. doi: 10.1542/peds.2012-3706.
35. Kimberlin DW, Baley J; Committee on Infectious Diseases; Committee on Fetus and Newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. *Pediatrics* 2013; 131(2):383-386. doi: 10.1542/peds.2012-3217.
36. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2013-2014. *Pediatrics* 2013; 132(4):e1089-1094. doi: 10.1542/peds.2013-2377.
37. Committee on Infectious Diseases; Committee on Nutrition; American Academy of Pediatrics. Consumption of raw or unpasteurized milk and milk products by pregnant women and children. *Pediatrics* 2014; 133(1):175-179. doi: 10.1542/peds.2013-3502.
38. Committee on Infectious Diseases, American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule--United States, 2014. *Pediatrics* 2014; 133(2):357-363. doi: 10.1542/peds.2013-3965.
39. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics* 2014; 134(2):e620-638. doi: 10.1542/peds.2014-1666.
40. American Academy of Pediatrics Committee on Infectious Diseases. Updated recommendations on the use of meningococcal vaccines. *Pediatrics* 2014; 134(2):400-403. doi: 10.1542/peds.2014-1383.
41. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics* 2014; 134(2):415-420. doi: 10.1542/peds.2014-1665. Erratum in: *Pediatrics* 2014; 134(6):1221.
42. Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory

- Council. Pediatric anthrax clinical management. *Pediatrics* 2014; 133(5):e1411-1436. doi:10.1542/peds.2014-0563.
43. Committee on Infectious Diseases. Immunization for *Streptococcus pneumoniae* infections in high-risk children. *Pediatrics* 2014; 134(6):1230-1233. doi: 10.1542/peds.2014-2811.
 44. **Orenstein WA**; Committee on Infectious Diseases. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever. *Pediatrics* 2015; 135(1):196-202. doi: 10.1542/peds.2014-3163.
 45. The National Vaccine Advisory Committee. Reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014. *Public Health Rep* 2015; 130(1):10-42. PMC4245282.
 46. National Vaccine Advisory Committee. HHS National Vaccine Program and Global Immunization, NVAC Report and Recommendations. *Public Health Rep* 2014; 129(S3):1-85. Full Issue: All articles are available free through PMC.
 47. National Vaccine Advisory Committee. NVAC statement of support regarding efforts to better implement IIS-to-IIS data exchange across jurisdictions: Approved by the National Vaccine Advisory Committee on February 10, 2015. *Public Health Rep* 2015; 130(4):332-335. PMC4547572.
 48. National Vaccine Advisory Committee. Assessing the State of Vaccine Confidence in the United States: Recommendations from the National Vaccine Advisory Committee. Approved by the National Vaccine Advisory Committee on June 9, 2015. *Public Health Rep* 2015; 130(6):573-595. PMC4612166.
 49. National Vaccine Advisory Committee. A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015. *Public Health Rep* 2016; 131(1):11-16. PMC4716466.
 50. National Vaccine Advisory Committee. Overcoming barriers to low HPV vaccine uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015. *Public Health Rep* 2016; 131(1):17-25. PMC4716467.